Processing 00000000.tx.1: Mitogen-Activated Protein Kinase p38 Mediates Reduced Nerve Conduction Velocity in Experimental Diabetic Neuropathy Interactions With Aldose Reductase Sally A. 

Phrase: "Mitogen-Activated Protein Kinase p38"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1120843:mitogen-activated protein kinase p38 [Amino Acid, Peptide, or Protein,Enzyme]
   771   C0752312:Mitogen-Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   717   C1979930:Mitogen-activated protein [Amino Acid, Peptide, or Protein]

Phrase: "Mediates"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0086597:Mediate [Social Behavior]

Phrase: "Reduced Nerve Conduction Velocity in Experimental Diabetic Neuropathy Interactions"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   790   C0429381:Nerve conduction velocity [Finding]
   790   C2982003:Nerve Conduction Velocity [Diagnostic Procedure]
   764   C0027788:Nerve Conduction [Organ or Tissue Function]
   764   C0234084:Conduction velocity [Organ or Tissue Function]
   742   C0027740:Nerve [Tissue]
   742   C0027757:NERVE [Tissue]
   742   C0232217:Conduction [Organ or Tissue Function]
   742   C0439830:Velocity [Quantitative Concept]
   742   C0457405:Conduction [Natural Phenomenon or Process]
   742   C1280541:Nerve [Body Part, Organ, or Organ Component]
   742   C1547053:*Velocity [Quantitative Concept]

Phrase: "With Aldose Reductase Sally A."
Processing 00000000.tx.2: Price, Sithiporn Agthong, Alicia B. 

Phrase: "Price,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0080045:Price [Quantitative Concept]

Phrase: "Sithiporn Agthong,"

Phrase: "Alicia B."
Processing 00000000.tx.3: Middlemas, and David R. 

Phrase: "Middlemas,"

Phrase: "and"

Phrase: "David R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.4: Tomlinson From the Division of Neuroscience, School of Biological Sciences, University of Manchester, Manchester, U.K  ABSTRACT TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES  This study examined the role of p38 mitogen-activated protein (MAP) kinase in transducing high glucose into deficits in nerve conduction velocity (NCV) that are characteristic of diabetic neuropathy. 

Phrase: "Tomlinson From the Division of Neuroscience,"

Phrase: "School of Biological Sciences,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0036375:School [Manufactured Object,Organization]

Phrase: "University of Manchester,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0041740:University [Manufactured Object,Organization]

Phrase: "Manchester,"

Phrase: "U.K  ABSTRACT TOP ABSTRACT RESEARCH DESIGN"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   818   C0035171:Research Design [Research Activity]
   795   C0035168:research [Research Activity]
   795   C0242481:Research [Research Activity]
   795   C1707689:Design [Activity]
   795   C2983265:DESIGN [Intellectual Product]

Phrase: "AND"

Phrase: "METHODS RESULTS DISCUSSION"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "This study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]

Phrase: "examined"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332128:Examined [Finding]

Phrase: "the role of p38 mitogen-activated protein (MAP) kinase"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0035820:Role [Social Behavior]
   744   C1705810:Role [Conceptual Entity]
   703   C1456380:p38 Mitogen Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "in transducing high glucose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0860803:high glucose [Finding]
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "into deficits"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C2987487:deficits [Qualitative Concept]
   966 E C0162429:Deficit, NOS [Disease or Syndrome]

Phrase: "in nerve conduction velocity (NCV)"
Meta Candidates (Total=13; Excluded=2; Pruned=0; Remaining=11)
  1000   C0429381:Nerve conduction velocity [Finding]
  1000   C2982003:Nerve Conduction Velocity [Diagnostic Procedure]
   901   C0027788:Nerve Conduction [Organ or Tissue Function]
   901   C0234084:Conduction velocity [Organ or Tissue Function]
   827   C0027740:Nerve [Tissue]
   827   C0027757:NERVE [Tissue]
   827   C0232217:Conduction [Organ or Tissue Function]
   827   C0439830:Velocity [Quantitative Concept]
   827   C0457405:Conduction [Natural Phenomenon or Process]
   827   C1280541:Nerve [Body Part, Organ, or Organ Component]
   827   C1547053:*Velocity [Quantitative Concept]
   771 E C0599851:Neural [Functional Concept]
   755 E C0027769:nervy [Sign or Symptom]

Phrase: "that"

Phrase: "are"

Phrase: "characteristic of diabetic neuropathy."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1521970:Characteristic [Qualitative Concept]
Processing 00000000.tx.5: p38 activation and NCV were measured in streptozocin-induced diabetic rats treated with a p38 inhibitor, an aldose reductase inhibitor, and insulin. 

Phrase: "p38 activation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1879547:Activation [Activity]

Phrase: "and"

Phrase: "NCV"
Meta Candidates (Total=13; Excluded=2; Pruned=0; Remaining=11)
  1000   C0429381:Nerve conduction velocity [Finding]
  1000   C2982003:Nerve Conduction Velocity [Diagnostic Procedure]
   901   C0027788:Nerve Conduction [Organ or Tissue Function]
   901   C0234084:Conduction velocity [Organ or Tissue Function]
   827   C0027740:Nerve [Tissue]
   827   C0027757:NERVE [Tissue]
   827   C0232217:Conduction [Organ or Tissue Function]
   827   C0439830:Velocity [Quantitative Concept]
   827   C0457405:Conduction [Natural Phenomenon or Process]
   827   C1280541:Nerve [Body Part, Organ, or Organ Component]
   827   C1547053:*Velocity [Quantitative Concept]
   771 E C0599851:Neural [Functional Concept]
   755 E C0027769:nervy [Sign or Symptom]

Phrase: "were"

Phrase: "measured in streptozocin-induced diabetic rats"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   753   C0034693:rats [Mammal]
   753   C0034721:Rats [Mammal]
   753   C0038432:Streptozocin [Antibiotic,Carbohydrate]
   753   C0205263:Induced [Functional Concept]
   753   C0241863:DIABETIC [Finding]
   753   C0444706:Measured [Qualitative Concept]
   753   C3541902:MEASURED [Diagnostic Procedure]
   719 E C0079809:Measure [Quantitative Concept]
   719 E C0242485:Measure [Functional Concept]

Phrase: "treated with a p38 inhibitor,"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   806   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   760   C1522326:Treated [Functional Concept]
   760   C1999216:Inhibitor [Qualitative Concept]
   726 E C1292734:TREAT [Functional Concept]

Phrase: "an aldose reductase inhibitor,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C2348243:Aldose Reductase Inhibitor [Pharmacologic Substance]
   901   C0002003:Aldose Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   901   C1412322:ALDOSE REDUCTASE [Gene or Genome]
   827   C0030016:Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0682934:Aldose [Carbohydrate]
   827   C1999216:Inhibitor [Qualitative Concept]

Phrase: "and"

Phrase: "insulin."
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1579433:Insulin [Pharmacologic Substance]
   944 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.6: Dorsal root ganglia (DRG) from diabetic animals showed marked activation of p38 at 12 weeks of diabetes. 

Phrase: "Dorsal root ganglia (DRG) from diabetic animals"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
   833   C0017070:Dorsal Root Ganglia [Body Part, Organ, or Organ Component]
           Dorsal Root
   799 E C1761610:Dorsal root ganglion [Body Part, Organ, or Organ Component]
   790   C0205955:Dorsal root [Body Part, Organ, or Organ Component]
   773   C1186181:root ganglion [Body Part, Organ, or Organ Component]
   753   C0017067:Ganglia [Body Part, Organ, or Organ Component]
   753   C0040452:Root [Body Part, Organ, or Organ Component]
   753   C0205095:Dorsal [Spatial Concept]
   753   C0242726:Root [Plant]
   753   C1318154:Root [Body Part, Organ, or Organ Component]
   753   C1705917:Root [Idea or Concept]
   719 E C1258666:Ganglion, NOS [Acquired Abnormality,Disease or Syndrome]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "marked activation of p38"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1879547:Activation [Activity]

Phrase: "at 12 weeks"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439230:weeks [Temporal Concept]
   827 E C0332174:/week [Temporal Concept]

Phrase: "of diabetes."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]
Processing 00000000.tx.7: Insulin treatment for the last 4 of 12 weeks of diabetes normalized p38 activation. 

Phrase: "Insulin treatment for the last 4 of 12 weeks of diabetes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   756   C0745343:insulin treatment [Therapeutic or Preventive Procedure]
   738   C0039798:treatment [Functional Concept]
   738   C0087111:Treatment [Therapeutic or Preventive Procedure]
   738   C1522326:Treatment [Functional Concept]
   738   C1533734:Treatment [Therapeutic or Preventive Procedure]
   738   C1705169:Treatment [Conceptual Entity]
   738   C3538994:TREATMENT [Research Activity]

Phrase: "normalized"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882115:Normalized [Research Activity]

Phrase: "p38 activation."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1879547:Activation [Activity]
Processing 00000000.tx.8: Furthermore, activation was completely prevented by 12 weeks treatment with the aldose reductase inhibitor, fidarestat. 

Phrase: "Furthermore,"

Phrase: "activation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1879547:Activation [Activity]

Phrase: "was"

Phrase: "completely"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205197:Completely [Qualitative Concept]

Phrase: "prevented by 12 weeks treatment"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C0439230:weeks [Temporal Concept]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C3538994:TREATMENT [Research Activity]
   726   C0309872:PREVENT [Pharmacologic Substance]
   726 E C0332174:/week [Temporal Concept]

Phrase: "with the aldose reductase inhibitor,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C2348243:Aldose Reductase Inhibitor [Pharmacologic Substance]
   901   C0002003:Aldose Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   901   C1412322:ALDOSE REDUCTASE [Gene or Genome]
   827   C0030016:Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0682934:Aldose [Carbohydrate]
   827   C1999216:Inhibitor [Qualitative Concept]

Phrase: "fidarestat."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0905478:fidarestat [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.9: Immunocytochemistry localized activation of p38 to the nuclei of virtually all sensory neuronal phenotypes in the DRG, and activation was clear in diabetes, as was inhibition by fidarestat and by the p38 inhibitor SB 239063. 

Phrase: "Immunocytochemistry"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0242349:Immunocytochemistry [Laboratory Procedure]

Phrase: "localized"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0392752:Localized [Spatial Concept]

Phrase: "activation of p38"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1879547:Activation [Activity]

Phrase: "to the nuclei"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0007610:Nucleus [Cell Component]

Phrase: "of virtually"

Phrase: "all sensory neuronal phenotypes in the DRG,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   742   C0031437:Phenotypes [Organism Attribute]
   708 E C1285572:Phenotype [Laboratory Procedure]

Phrase: "and"

Phrase: "activation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1879547:Activation [Activity]

Phrase: "was"

Phrase: "clear in diabetes,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C2963144:Clear [Qualitative Concept]

Phrase: "as"

Phrase: "was"

Phrase: "inhibition by fidarestat"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   790   C0021467:Inhibition [Mental Process]
   790   C0021469:Inhibition [Molecular Function]
   790   C1628982:% inhibition [Quantitative Concept]
   790   C3463820:Inhibition [Activity]
   718 E C0311403:Inhibited [Qualitative Concept]

Phrase: "and by the p38 inhibitor SB 239063."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   778   C0913456:SB 239063 [Organic Chemical]
   748   C1515981:And [Idea or Concept]
   748   C1999216:Inhibitor [Qualitative Concept]
Processing 00000000.tx.10: In the ventral horn of the spinal cord, p38 was present in motoneuron cell bodies; 

Phrase: "In the ventral horn"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0019939:Horn [Body Part, Organ, or Organ Component]

Phrase: "of the spinal cord,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0037925:Spinal Cord [Body Part, Organ, or Organ Component]
  1000   C1278836:Spinal cord [Body Part, Organ, or Organ Component]
   861   C0521329:Spinal [Spatial Concept]
   861   C1550235:Cord [Body Part, Organ, or Organ Component]
   861   C1552938:cord [Quantitative Concept]
   861   C1706500:Cord [Manufactured Object]

Phrase: "p38"

Phrase: "was"

Phrase: "present in motoneuron cell bodies"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0150312:Present [Quantitative Concept]
   760   C0449450:Present [Idea or Concept]

Phrase: ";"
Processing 00000000.tx.11: and again, activation in diabetes and fidarestat inhibition was clear. 

Phrase: "and"

Phrase: "again,"

Phrase: "activation in diabetes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1879547:Activation [Activity]

Phrase: "and"

Phrase: "fidarestat inhibition"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   861   C0021467:Inhibition [Mental Process]
   861   C0021469:Inhibition [Molecular Function]
   861   C1628982:% inhibition [Quantitative Concept]
   861   C3463820:Inhibition [Activity]
   789 E C0311403:Inhibited [Qualitative Concept]

Phrase: "was"

Phrase: "clear."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2963144:Clear [Qualitative Concept]
Processing 00000000.tx.12: Treatment of diabetic animals with a specific inhibitor of p38 (SB 239063), fidarestat, or insulin also prevented reductions in both motor and sensory NCV. 

Phrase: "Treatment of diabetic animals"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C0039798:treatment [Functional Concept]
   770   C0087111:Treatment [Therapeutic or Preventive Procedure]
   770   C1522326:Treatment [Functional Concept]
   770   C1533734:Treatment [Therapeutic or Preventive Procedure]
   770   C1705169:Treatment [Conceptual Entity]
   770   C3538994:TREATMENT [Research Activity]

Phrase: "with a specific inhibitor"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1999216:Inhibitor [Qualitative Concept]

Phrase: "of p38"

Phrase: "(SB 239063"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0913456:SB 239063 [Organic Chemical]

Phrase: ")"

Phrase: ","

Phrase: "fidarestat,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0905478:fidarestat [Organic Chemical,Pharmacologic Substance]

Phrase: "or"

Phrase: "insulin also prevented reductions in both motor"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   748   C0301630:reductions [Natural Phenomenon or Process]
   748   C0441610:reductions [Therapeutic or Preventive Procedure]
   714 E C0392756:Reduction [Qualitative Concept]

Phrase: "and"

Phrase: "sensory NCV."
Meta Candidates (Total=16; Excluded=2; Pruned=0; Remaining=14)
  1000   C0457378:Sensory nerve conduction velocity [Finding]
   923   C0429381:Nerve conduction velocity [Finding]
   923   C2982003:Nerve Conduction Velocity [Diagnostic Procedure]
   861   C0027788:Nerve Conduction [Organ or Tissue Function]
   861   C0234084:Conduction velocity [Organ or Tissue Function]
   861   C0501385:Sensory nerve [Body Part, Organ, or Organ Component]
   812   C0027740:Nerve [Tissue]
   812   C0027757:NERVE [Tissue]
   812   C0232217:Conduction [Organ or Tissue Function]
   812   C0439830:Velocity [Quantitative Concept]
   812   C0445254:Sensory [Qualitative Concept]
   812   C0457405:Conduction [Natural Phenomenon or Process]
   812   C1280541:Nerve [Body Part, Organ, or Organ Component]
   812   C1547053:*Velocity [Quantitative Concept]
   756 E C0599851:Neural [Functional Concept]
   741 E C0027769:nervy [Sign or Symptom]
Processing 00000000.tx.13: These findings suggest that increased polyol pathway flux in diabetic animals leads to the activation of p38. 

Phrase: "These findings"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C2607943:findings [Functional Concept]
  1000   C2926606:Findings [Clinical Attribute]
  1000   C3539655:Findings [Intellectual Product]
   966 E C0037088:Finding [Sign or Symptom]
   966 E C0243095:Finding [Finding]
   966 E C2825141:Finding [Finding]

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that increased polyol pathway flux in diabetic animals"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C2348693:Flux [Natural Phenomenon or Process]

Phrase: "leads to the activation of p38."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   753   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   753   C0181586:leads [Medical Device]
   753   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   753   C1522538:Lead [Functional Concept]
   753   C1879547:Activation [Activity]
   753   C2348269:Lead [Element, Ion, or Isotope]
   753   C3275067:LEAD [Therapeutic or Preventive Procedure]
Processing 00000000.tx.14: This activation can mediate changes in gene transcription and cellular phenotype that are likely to underlie the NCV deficits. 

Phrase: "This activation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1879547:Activation [Activity]

Phrase: "can"

Phrase: "mediate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0086597:Mediate [Social Behavior]

Phrase: "changes in gene transcription"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   770   C0392747:changes [Functional Concept]
   770   C0443172:changes [Quantitative Concept]
   737 E C1705241:Change [Quantitative Concept]

Phrase: "and"

Phrase: "cellular phenotype"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0031437:Phenotype [Organism Attribute]
   861   C1285572:Phenotype [Laboratory Procedure]

Phrase: "that"

Phrase: "are"

Phrase: "likely to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0332148:Likely [Qualitative Concept]
   861   C0750492:Likely [Idea or Concept]

Phrase: "underlie"

Phrase: "the NCV deficits."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   812   C2987487:deficits [Qualitative Concept]
   779 E C0162429:Deficit, NOS [Disease or Syndrome]
   756   C0429381:Nerve conduction velocity [Finding]
   756   C2982003:Nerve Conduction Velocity [Diagnostic Procedure]
Processing 00000000.tx.15: Insulin and aldose reductase inhibitors can prevent excess polyol pathway flux, and hence these agents may prevent NCV deficits by preventing p38 MAP kinase activation. 

Phrase: "Insulin"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1579433:Insulin [Pharmacologic Substance]
   944 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "aldose reductase inhibitors"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   966   C2348243:Aldose Reductase Inhibitor [Pharmacologic Substance]
   901   C0002003:Aldose Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   901   C1412322:ALDOSE REDUCTASE [Gene or Genome]
   827   C0030016:Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0243077:inhibitors [Chemical Viewed Functionally]
   827   C0682934:Aldose [Carbohydrate]
   793 E C1999216:Inhibitor [Qualitative Concept]

Phrase: "can"

Phrase: "prevent"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0309872:PREVENT [Pharmacologic Substance]

Phrase: "excess polyol pathway flux,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C2348693:Flux [Natural Phenomenon or Process]

Phrase: "and"

Phrase: "hence"

Phrase: "these agents"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C0450442:Agent [Chemical Viewed Functionally]
   966   C1254351:Agent [Pharmacologic Substance]
   966   C1521826:Agent [Intellectual Product]

Phrase: "may"

Phrase: "prevent"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0309872:PREVENT [Pharmacologic Substance]

Phrase: "NCV deficits by preventing p38 MAP kinase activation."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   736   C2987487:deficits [Qualitative Concept]
   703 E C0162429:Deficit, NOS [Disease or Syndrome]
Processing 00000000.tx.16: Reduced nerve conduction velocity (NCV) is an established hallmark of diabetic neuropathy, occurring in diabetes in both patients (1) and diabetic laboratory animals (2). 

Phrase: "Reduced nerve conduction velocity"
Meta Candidates (Total=13; Excluded=2; Pruned=0; Remaining=11)
   923   C0429381:Nerve conduction velocity [Finding]
   923   C2982003:Nerve Conduction Velocity [Diagnostic Procedure]
   861   C0027788:Nerve Conduction [Organ or Tissue Function]
   861   C0234084:Conduction velocity [Organ or Tissue Function]
   812   C0027740:Nerve [Tissue]
   812   C0027757:NERVE [Tissue]
   812   C0232217:Conduction [Organ or Tissue Function]
   812   C0439830:Velocity [Quantitative Concept]
   812   C0457405:Conduction [Natural Phenomenon or Process]
   812   C1280541:Nerve [Body Part, Organ, or Organ Component]
   812   C1547053:*Velocity [Quantitative Concept]
   756 E C0599851:Neural [Functional Concept]
   741 E C0027769:nervy [Sign or Symptom]

Phrase: "(NCV"
Meta Candidates (Total=13; Excluded=2; Pruned=0; Remaining=11)
  1000   C0429381:Nerve conduction velocity [Finding]
  1000   C2982003:Nerve Conduction Velocity [Diagnostic Procedure]
   901   C0027788:Nerve Conduction [Organ or Tissue Function]
   901   C0234084:Conduction velocity [Organ or Tissue Function]
   827   C0027740:Nerve [Tissue]
   827   C0027757:NERVE [Tissue]
   827   C0232217:Conduction [Organ or Tissue Function]
   827   C0439830:Velocity [Quantitative Concept]
   827   C0457405:Conduction [Natural Phenomenon or Process]
   827   C1280541:Nerve [Body Part, Organ, or Organ Component]
   827   C1547053:*Velocity [Quantitative Concept]
   771 E C0599851:Neural [Functional Concept]
   755 E C0027769:nervy [Sign or Symptom]

Phrase: ")"

Phrase: "is"

Phrase: "an established hallmark of diabetic neuropathy,"

Phrase: "occurring in diabetes"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0011847:Diabetes [Disease or Syndrome]
   790   C0011849:Diabetes [Disease or Syndrome]
   756   C1709305:Occur [Activity]
   756   C2745955:OCCUR [Temporal Concept]

Phrase: "in both patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "(1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: ")"

Phrase: "and"

Phrase: "diabetic laboratory animals"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0003064:Animals, Laboratory [Animal]
   827   C0003062:Animals [Animal]
   827   C0022877:Laboratory [Manufactured Object,Organization]
   827   C3244292:laboratory [Functional Concept]

Phrase: "(2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: ")."
Processing 00000000.tx.17: Since the earliest demonstration (3) that aldose reductase inhibitors prevented slowing of motor NCV (MNCV) in rats with experimental diabetes, it has become a well-defined end point for the evaluation of this class of drugs. 

Phrase: "Since"

Phrase: "the earliest demonstration"

Phrase: "(3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: ")"

Phrase: "that aldose reductase inhibitors"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   966   C2348243:Aldose Reductase Inhibitor [Pharmacologic Substance]
   901   C0002003:Aldose Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   901   C1412322:ALDOSE REDUCTASE [Gene or Genome]
   827   C0030016:Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0243077:inhibitors [Chemical Viewed Functionally]
   827   C0682934:Aldose [Carbohydrate]
   793 E C1999216:Inhibitor [Qualitative Concept]

Phrase: "prevented"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0309872:PREVENT [Pharmacologic Substance]

Phrase: "slowing of motor NCV (NCV)"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
   882   C0457379:Motor nerve conduction velocity [Finding]
   833   C0429381:Nerve conduction velocity [Finding]
   833   C2982003:Nerve Conduction Velocity [Diagnostic Procedure]
   790   C0027788:Nerve Conduction [Organ or Tissue Function]
   790   C0234084:Conduction velocity [Organ or Tissue Function]
   790   C0501384:Motor nerve [Body Part, Organ, or Organ Component]
   753   C0027740:Nerve [Tissue]
   753   C0027757:NERVE [Tissue]
   753   C0232217:Conduction [Organ or Tissue Function]
   753   C0439830:Velocity [Quantitative Concept]
   753   C0439834:slowing [Qualitative Concept]
   753   C0457405:Conduction [Natural Phenomenon or Process]
   753   C1280541:Nerve [Body Part, Organ, or Organ Component]
   753   C1513492:Motor [Functional Concept]
   753   C1547053:*Velocity [Quantitative Concept]
   753   C1705994:Motor [Manufactured Object]

Phrase: "in rats"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0034693:rats [Mammal]
  1000   C0034721:Rats [Mammal]

Phrase: "with experimental diabetes,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "it"

Phrase: "has"

Phrase: "become"

Phrase: "a well-defined end point for the evaluation of this class"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   756   C2349179:End Point [Qualitative Concept]
   756   C2826544:ENDPOINT [Quantitative Concept]
   754   C2924612:A point [Body Location or Region]
   738   C0444930:End [Spatial Concept]
   738   C1552961:Point [Quantitative Concept]
   738   C2347617:point [Quantitative Concept]
   738   C2746065:End [Temporal Concept]

Phrase: "of drugs."
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
  1000   C0013227:Drugs [Pharmacologic Substance]
   966 E C1254351:Drug [Pharmacologic Substance]
   928 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   928 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   900 E C0456386:Medicament [Pharmacologic Substance]
Processing 00000000.tx.18: Conduction changes have also been the most responsive component of neuropathic diabetic defects in the clinic (4,5). 

Phrase: "Conduction changes"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0392747:changes [Functional Concept]
   861   C0443172:changes [Quantitative Concept]
   827 E C1705241:Change [Quantitative Concept]

Phrase: "have"

Phrase: "also"

Phrase: "been"

Phrase: "the most responsive component of neuropathic diabetic defects"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0449432:Component [Manufactured Object]
   744   C1705248:Component [Conceptual Entity]

Phrase: "in the clinic"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0002424:Clinic [Health Care Related Organization,Manufactured Object]
  1000   C0442592:Clinic [Health Care Related Organization,Manufactured Object]
   928 E C0205210:Clinical [Qualitative Concept]

Phrase: "(4,"

Phrase: "5"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.19: Despite this, we have no proven link between exaggerated flux through the sorbitol pathway and the molecular basis of the conduction velocity deficit. 

Phrase: "Despite this,"

Phrase: "we"

Phrase: "have"

Phrase: "no proven link between exaggerated flux"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1517892:Link [Intellectual Product]
   753   C1704666:Link [Intellectual Product]

Phrase: "through the sorbitol pathway"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1704259:Pathway [Molecular Function]
   861   C1705987:Pathway [Conceptual Entity]

Phrase: "and"

Phrase: "the molecular basis of the conduction velocity deficit."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C1853126:MOLECULAR BASIS [Idea or Concept]
   744   C1527178:Basis [Functional Concept]
   744   C1874451:Basis [Pharmacologic Substance]
Processing 00000000.tx.20: The Diabetes Control and Complications Trial (6) has focused our attention on elevated glucose as a primary cause of diabetes complications, thus we assume that excessive glucose causes biochemical derangements that ultimately develop into diabetes complications. 

Phrase: "The Diabetes Control and Complications Trial"
Meta Candidates (Total=13; Excluded=2; Pruned=0; Remaining=11)
   875   C0342257:Diabetes Complications [Pathologic Function]
   804   C0008976:Trial [Research Activity]
   804   C0009566:Complications [Pathologic Function]
   804   C0011847:Diabetes [Disease or Syndrome]
   804   C0011849:Diabetes [Disease or Syndrome]
   804   C0243148:control [Qualitative Concept]
   804   C1171258:complications [Pathologic Function]
   804   C1550141:Control [Substance]
   804   C1882979:Control [Conceptual Entity]
   804   C2587213:Control [Functional Concept]
   804   C3274648:Control [Qualitative Concept]
   771 E C2362589:Complication [Idea or Concept]
   721 E C0231242:Complicated [Functional Concept]

Phrase: "(6"

Phrase: ")"

Phrase: "has"

Phrase: "focused"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205234:Focused [Spatial Concept]
  1000   C1285542:focused [Functional Concept]

Phrase: "our attention on elevated glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0004268:Attention [Mental Process]

Phrase: "as a primary cause"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0015127:cause [Functional Concept]
   861   C0205225:Primary [Qualitative Concept]
   861   C0439631:Primary [Therapeutic or Preventive Procedure]
   861   C1524003:Cause [Conceptual Entity]

Phrase: "of diabetes complications,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0342257:Diabetes Complications [Pathologic Function]
   861   C0009566:Complications [Pathologic Function]
   861   C1171258:complications [Pathologic Function]
   827 E C2362589:Complication [Idea or Concept]
   777 E C0231242:Complicated [Functional Concept]

Phrase: "thus"

Phrase: "we"

Phrase: "assume"

Phrase: "that excessive glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "causes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0015127:cause [Functional Concept]
  1000   C1314792:Causes [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "biochemical derangements"

Phrase: "that ultimately"

Phrase: "develop into diabetes complications."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   833   C0342257:Diabetes Complications [Pathologic Function]
   770   C0009566:Complications [Pathologic Function]
   770   C0011847:Diabetes [Disease or Syndrome]
   770   C0011849:Diabetes [Disease or Syndrome]
   770   C1171258:complications [Pathologic Function]
   737 E C2362589:Complication [Idea or Concept]
Processing 00000000.tx.21: We have recently implicated the mitogen-activated protein (MAP) kinase p38 as a de facto glucose transducer in promoting some of the changes in neuronal phenotype caused by raised glucose. 

Phrase: "We"

Phrase: "have"

Phrase: "recently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332185:Recently [Temporal Concept]

Phrase: "implicated"

Phrase: "the mitogen-activated protein"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1979930:Mitogen-activated protein [Amino Acid, Peptide, or Protein]
   827   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(MAP) kinase p38 as a de facto glucose transducer"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   820   C1120843:mitogen-activated protein kinase p38 [Amino Acid, Peptide, or Protein,Enzyme]
           p38 Protein Kinase
   813 E C1456380:p38 Mitogen Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "in promoting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033414:Promoting [Activity]

Phrase: "some of the changes"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   770   C0205392:Some [Quantitative Concept]
   770   C0392747:changes [Functional Concept]
   770   C0443172:changes [Quantitative Concept]
   770   C3540770:Some [Intellectual Product]
   737 E C1705241:Change [Quantitative Concept]

Phrase: "in neuronal phenotype"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0031437:Phenotype [Organism Attribute]
   861   C1285572:Phenotype [Laboratory Procedure]

Phrase: "caused by raised glucose."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   770   C0442818:Raised [Quantitative Concept]
   737   C0015127:cause [Functional Concept]
   737   C1524003:Cause [Conceptual Entity]
Processing 00000000.tx.22: We showed consistent activation of p38 in neurons cultured with raised glucose in nerve from diabetic rats and in sural nerve specimens from diabetic patients (7). 

Phrase: "We"

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "consistent activation of p38"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1879547:Activation [Activity]

Phrase: "in neurons"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0027882:Neurons [Cell]
   916 E C0521390:Neuronal [Immunologic Factor]

Phrase: "cultured with raised glucose"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   770   C0442818:Raised [Quantitative Concept]
   737   C0010453:Culture [Idea or Concept]
   737   C0220814:culture [Functional Concept]
   737   C0430400:Culture [Laboratory Procedure]
   737   C2242979:Culture [Laboratory Procedure]

Phrase: "in nerve"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0027740:Nerve [Tissue]
  1000   C0027757:NERVE [Tissue]
  1000   C1280541:Nerve [Body Part, Organ, or Organ Component]
   944 E C0599851:Neural [Functional Concept]
   928 E C0027769:nervy [Sign or Symptom]

Phrase: "from diabetic rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0241863:DIABETIC [Finding]

Phrase: "and in sural nerve specimens"
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
   806   C0038879:Sural Nerve [Body Part, Organ, or Organ Component]
   806   C1278864:Sural nerve [Body Part, Organ, or Organ Component]
   760   C0027740:Nerve [Tissue]
   760   C0027757:NERVE [Tissue]
   760   C0370003:specimens [Substance]
   760   C0626053:sural [Pharmacologic Substance]
   760   C1280541:Nerve [Body Part, Organ, or Organ Component]
   760   C1515981:And [Idea or Concept]
   726 E C2347026:Specimen [Conceptual Entity]
   704 E C0599851:Neural [Functional Concept]

Phrase: "from diabetic patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "(7"

Phrase: ")."
Processing 00000000.tx.23: The present study was designed to test the hypothesis that nerve conduction deficits form a functional component of the downstream effects of persistent p38 activation in diabetic rats. 

Phrase: "The present study"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0150312:Present [Quantitative Concept]
   861   C0449450:Present [Idea or Concept]
   861   C0557651:Study [Manufactured Object]
   861   C2603343:Study [Research Activity]

Phrase: "was"

Phrase: "designed"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1707689:Design [Activity]
   966   C2983265:DESIGN [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "test"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0022885:Test [Laboratory Procedure]
  1000   C0039593:Test [Functional Concept]
  1000   C0392366:test [Intellectual Product]

Phrase: "the hypothesis"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1512571:Hypothesis [Idea or Concept]

Phrase: "that nerve conduction deficits"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C2987487:deficits [Qualitative Concept]
   793 E C0162429:Deficit, NOS [Disease or Syndrome]
   734   C0027788:Nerve Conduction [Organ or Tissue Function]

Phrase: "form"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0348078:Form [Qualitative Concept]
  1000   C0376315:Form [Manufactured Object]
  1000   C1522492:Form [Functional Concept]

Phrase: "a functional component of the downstream effects of persistent p38 activation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   756   C1179435:Functional Component [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   738   C0449432:Component [Manufactured Object]
   738   C1705248:Component [Conceptual Entity]

Phrase: "in diabetic rats."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0241863:DIABETIC [Finding]
Processing 00000000.tx.24: To do this, the second-generation p38 inhibitor SB 239063 was used because this specifically inhibits p38 and - isoforms, the main isoforms expressed in neuronal tissue (8), and has no effect on other MAP, tyrosine, or lipid kinases (9). 

Phrase: "To do"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1883351:To [Qualitative Concept]

Phrase: "this,"

Phrase: "the second-generation p38 inhibitor SB 239063"
Meta Candidates (Total=13; Excluded=4; Pruned=0; Remaining=9)
   827   C0913456:SB 239063 [Organic Chemical]
   799   C0079411:Generation [Temporal Concept]
   799   C0205436:Second [Quantitative Concept]
   799   C0457385:Second [Temporal Concept]
   799   C0565930:/second [Quantitative Concept]
   799   C1561503:second [Idea or Concept]
   799   C1705190:Second [Qualitative Concept]
   799   C1999216:Inhibitor [Qualitative Concept]
   799   C3146294:Generation [Activity]
   727 E C0027627:secondary [Neoplastic Process]
   727 E C0175668:Secondary [Temporal Concept]
   706 E C1414672:Genesis [Gene or Genome]
   706 E C2984892:Genesis [Gene or Genome]

Phrase: "was"

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "because"

Phrase: "this specifically"

Phrase: "inhibits"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   944   C0018790:arrested [Disease or Syndrome]
   944   C0237477:Arrest [Temporal Concept]
   944   C0392351:arrest [Governmental or Regulatory Activity]
   944   C0521111:Retarded [Qualitative Concept]
   916 E C0311403:Inhibited [Qualitative Concept]
   916 E C3463820:Inhibiting [Activity]

Phrase: "p38"

Phrase: "and -"

Phrase: "isoforms,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0597298:Isoforms [Amino Acid, Peptide, or Protein]

Phrase: "the main isoforms"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0597298:Isoforms [Amino Acid, Peptide, or Protein]

Phrase: "expressed in neuronal tissue"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0040300:Tissue [Tissue]
   770   C0521390:Neuronal [Immunologic Factor]
   770   C1547928:Tissue [Intellectual Product]

Phrase: "(8"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "has"

Phrase: "no effect on other MAP,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   778   C1301751:No effect [Qualitative Concept]
   748   C1280500:Effect [Qualitative Concept]
   748   C2348382:Effect [Qualitative Concept]

Phrase: "tyrosine,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041485:Tyrosine [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "or"

Phrase: "lipid kinases"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0031727:Kinases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "(9"

Phrase: ")."
Processing 00000000.tx.25: Since nerve conduction defects also respond to aldose reductase inhibitors, we also tested the possibility that the sorbitol pathway is involved in the activation of p38 by diabetes by testing the effect of aldose reductase inhibition on p38 activation and NCV in peripheral nerve.  

Phrase: "Since"

Phrase: "nerve conduction defects also"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0264886:Conduction defects [Disease or Syndrome]
   812   C0243067:defects [Functional Concept]
   779 E C1457869:Defect [Functional Concept]
   779 E C1861101:DEFECT [Disease or Syndrome]

Phrase: "respond to aldose reductase inhibitors,"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   828   C2348243:Aldose Reductase Inhibitor [Pharmacologic Substance]
   806   C0002003:Aldose Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   806   C1412322:ALDOSE REDUCTASE [Gene or Genome]
   760   C0030016:Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   760   C0243077:inhibitors [Chemical Viewed Functionally]
   760   C0682934:Aldose [Carbohydrate]
   726 E C1999216:Inhibitor [Qualitative Concept]

Phrase: "we also"

Phrase: "tested"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0392366:tested [Intellectual Product]
   966 E C0022885:Test [Laboratory Procedure]
   966 E C0039593:Test [Functional Concept]

Phrase: "the possibility"

Phrase: "that"

Phrase: "the sorbitol pathway"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1704259:Pathway [Molecular Function]
   861   C1705987:Pathway [Conceptual Entity]

Phrase: "is"

Phrase: "involved in the activation of p38"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1314939:Involved [Functional Concept]
   753   C1879547:Activation [Activity]

Phrase: "by diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]

Phrase: "by testing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0039593:Testing [Functional Concept]
  1000   C0392366:testing [Intellectual Product]

Phrase: "the effect of aldose reductase inhibition"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1280500:Effect [Qualitative Concept]
   753   C2348382:Effect [Qualitative Concept]

Phrase: "on p38 activation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1879547:Activation [Activity]

Phrase: "and"

Phrase: "NCV in peripheral nerve."
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   833   C0429381:Nerve conduction velocity [Finding]
   833   C2982003:Nerve Conduction Velocity [Diagnostic Procedure]
   790   C0027788:Nerve Conduction [Organ or Tissue Function]
   790   C0234084:Conduction velocity [Organ or Tissue Function]
   753   C0027740:Nerve [Tissue]
   753   C0027757:NERVE [Tissue]
   753   C0232217:Conduction [Organ or Tissue Function]
   753   C0439830:Velocity [Quantitative Concept]
   753   C0457405:Conduction [Natural Phenomenon or Process]
   753   C1280541:Nerve [Body Part, Organ, or Organ Component]
   753   C1547053:*Velocity [Quantitative Concept]
   742   C0031119:Peripheral Nerves [Body Part, Organ, or Organ Component]
Processing 00000000.tx.26: RESEARCH DESIGN AND METHODS TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES  This study comprised several self-contained experiments (i.e., each with its own nondiabetic and diabetic control groups). 

Phrase: "RESEARCH DESIGN"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0035171:Research Design [Research Activity]
   861   C0035168:research [Research Activity]
   861   C0242481:Research [Research Activity]
   861   C1707689:Design [Activity]
   861   C2983265:DESIGN [Intellectual Product]

Phrase: "AND"

Phrase: "METHODS TOP ABSTRACT RESEARCH DESIGN"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   875   C0086912:methods research [Research Activity]
   840   C0035171:Research Design [Research Activity]
   804   C0035168:research [Research Activity]
   804   C0242481:Research [Research Activity]
   804   C1707689:Design [Activity]
   804   C2983265:DESIGN [Intellectual Product]

Phrase: "AND"

Phrase: "METHODS RESULTS DISCUSSION"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "This study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]

Phrase: "comprised"

Phrase: "several self-contained experiments"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   812   C0681814:Experiments [Research Activity]
   779 E C1706386:Experiment [Conceptual Entity]
   729 E C1517586:Experimental [Qualitative Concept]

Phrase: "(i.e.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0683454:I-E [Diagnostic Procedure,Intellectual Product]
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "each with its own nondiabetic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1457900:Each [Quantitative Concept]

Phrase: "and"

Phrase: "diabetic control groups"
Meta Candidates (Total=13; Excluded=0; Pruned=0; Remaining=13)
   901   C0009932:Control Groups [Group]
   827   C0243148:control [Qualitative Concept]
   827   C0441833:Group [Idea or Concept]
   827   C0687744:group [Population Group]
   827   C1257890:Group [Population Group]
   827   C1550141:Control [Substance]
   827   C1552516:Group [Health Care Related Organization]
   827   C1552839:groups [Idea or Concept]
   827   C1705428:Group [Conceptual Entity]
   827   C1705429:Group [Population Group]
   827   C1882979:Control [Conceptual Entity]
   827   C2587213:Control [Functional Concept]
   827   C3274648:Control [Qualitative Concept]

Phrase: ")."
Processing 00000000.tx.27: One study tested the effect of treatment with an aldose reductase inhibitor on the expression and state of activation of p38 MAP kinase. 

Phrase: "One study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0557651:Study [Manufactured Object]
   861   C2603343:Study [Research Activity]

Phrase: "tested"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0392366:tested [Intellectual Product]
   966 E C0022885:Test [Laboratory Procedure]
   966 E C0039593:Test [Functional Concept]

Phrase: "the effect of treatment"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   819   C1518681:Treatment Effect [Finding]
   770   C1280500:Effect [Qualitative Concept]
   770   C2348382:Effect [Qualitative Concept]

Phrase: "with an aldose reductase inhibitor"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C2348243:Aldose Reductase Inhibitor [Pharmacologic Substance]
   901   C0002003:Aldose Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   901   C1412322:ALDOSE REDUCTASE [Gene or Genome]
   827   C0030016:Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0682934:Aldose [Carbohydrate]
   827   C1999216:Inhibitor [Qualitative Concept]

Phrase: "on the expression"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "state of activation of p38 MAP kinase."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   742   C1301808:State [Geographic Area]
   742   C1442792:State [Functional Concept]
   742   C3148680:State [Geographic Area]
Processing 00000000.tx.28: A second study examined the effect of glycemic control with insulin. 

Phrase: "A second study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0557651:Study [Manufactured Object]
   861   C2603343:Study [Research Activity]

Phrase: "examined"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332128:Examined [Finding]

Phrase: "the effect of glycemic control"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "with insulin."
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1579433:Insulin [Pharmacologic Substance]
   944 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.29: A third experiment examined the effect of a specific inhibitor of p38 MAP kinase on MNCV and sensory NCV (SNCV). 

Phrase: "A third experiment"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0681814:Experiment [Research Activity]
   861   C1706386:Experiment [Conceptual Entity]
   789 E C1517586:Experimental [Qualitative Concept]

Phrase: "examined"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332128:Examined [Finding]

Phrase: "the effect of a specific inhibitor of p38 MAP kinase"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   736   C1280500:Effect [Qualitative Concept]
   736   C2348382:Effect [Qualitative Concept]

Phrase: "on MNCV"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2982003:NCV [Diagnostic Procedure]

Phrase: "and"

Phrase: "sensory NCV (SNCV)."
Meta Candidates (Total=16; Excluded=2; Pruned=0; Remaining=14)
  1000   C0457378:Sensory nerve conduction velocity [Finding]
   923   C0429381:Nerve conduction velocity [Finding]
   923   C2982003:Nerve Conduction Velocity [Diagnostic Procedure]
   861   C0027788:Nerve Conduction [Organ or Tissue Function]
   861   C0234084:Conduction velocity [Organ or Tissue Function]
   861   C0501385:Sensory nerve [Body Part, Organ, or Organ Component]
   812   C0027740:Nerve [Tissue]
   812   C0027757:NERVE [Tissue]
   812   C0232217:Conduction [Organ or Tissue Function]
   812   C0439830:Velocity [Quantitative Concept]
   812   C0445254:Sensory [Qualitative Concept]
   812   C0457405:Conduction [Natural Phenomenon or Process]
   812   C1280541:Nerve [Body Part, Organ, or Organ Component]
   812   C1547053:*Velocity [Quantitative Concept]
   756 E C0599851:Neural [Functional Concept]
   741 E C0027769:nervy [Sign or Symptom]
Processing 00000000.tx.30: Animals and diabetes. 

Phrase: "Animals"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0003062:Animals [Animal]

Phrase: "and"

Phrase: "diabetes."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]
Processing 00000000.tx.31: All studies used male Wistar rats with starting weights in the range of 280 to 400 g. 

Phrase: "All"

Phrase: "studies"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557651:Study [Manufactured Object]
  1000   C0947630:studies [Laboratory Procedure]
  1000   C2603343:Study [Research Activity]

Phrase: "used male Wistar rats with starting weights"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   778   C0034716:Rats, Wistar [Mammal]
   748   C0034693:rats [Mammal]
   748   C0034721:Rats [Mammal]
   748   C2700262:Wistar [Mammal]

Phrase: "in the range"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1514721:Range [Quantitative Concept]
  1000   C2348147:Range [Quantitative Concept]
  1000   C3542016:Range [Intellectual Product]

Phrase: "of 280"

Phrase: "to 400 g."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.32: Diabetes was induced by an intraperitoneal injection of streptozocin (STZ; Sigma, St. Louis, MO) freshly dissolved in normal saline at a dose of 55 mg/;kg, administered the morning after an overnight fast. 

Phrase: "Diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]

Phrase: "was"

Phrase: "induced by an intraperitoneal injection of streptozocin"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   778   C0021493:Intraperitoneal injection [Therapeutic or Preventive Procedure]
   748   C0021485:injection [Therapeutic or Preventive Procedure]
   748   C0038432:Streptozocin [Antibiotic,Carbohydrate]
   748   C0205263:Induced [Functional Concept]
   748   C0442120:Intraperitoneal [Spatial Concept]
   748   C1272883:Injection [Biomedical or Dental Material]
   748   C1533685:Injection [Therapeutic or Preventive Procedure]
   748   C1828121:Injection [Functional Concept]

Phrase: "(STZ"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0038432:STZ [Antibiotic,Carbohydrate]
  1000   C1539862:STZ [Gene or Genome]

Phrase: "; Sigma,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1719918:Sigma [Intellectual Product]

Phrase: "St. Louis,"

Phrase: "MO) freshly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3538743:MO [Idea or Concept]

Phrase: "dissolved in normal saline"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   833   C0445115:Normal saline [Inorganic Chemical,Pharmacologic Substance]
   770   C0036082:Saline [Substance]
   770   C0205307:Normal [Qualitative Concept]
   770   C0439166:% normal [Quantitative Concept]
   770   C2347086:% Normal [Quantitative Concept]
   737   C1549535:Dissolve [Functional Concept]

Phrase: "at a dose"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0178602:Dose [Quantitative Concept]
  1000   C0869039:Dose [Quantitative Concept]
  1000   C1114758:Dose # [Clinical Attribute]

Phrase: "of 55 mg/;kg,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   901   C0439272:mg kg [Quantitative Concept]
   827   C0022718:KG [Geographic Area]
   827   C0439209:kg [Quantitative Concept]
   827   C0439269:mg% [Quantitative Concept]
   827   C1960952:mg % [Quantitative Concept]
   827   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "administered"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1521801:Administered [Functional Concept]
   966 E C1621583:Administer [Functional Concept]

Phrase: "the morning after an overnight fast."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0554816:Morning after [Temporal Concept]
   753   C0332170:Morning [Temporal Concept]
Processing 00000000.tx.33: Three days later, glucose was measured by reflectance photometry on tail vein blood, and any STZ-administered rats with blood glucose <15 mmol/;l were rejected from the study. 

Phrase: "Three days later,"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   827   C0439228:days [Temporal Concept]
   793 E C0332173:/day [Temporal Concept]
   793 E C0439505:/day [Temporal Concept]

Phrase: "glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "was"

Phrase: "measured by reflectance photometry"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   770   C0031752:Photometry [Laboratory Procedure]
   770   C0444706:Measured [Qualitative Concept]
   770   C3541902:MEASURED [Diagnostic Procedure]
   737 E C0079809:Measure [Quantitative Concept]
   737 E C0242485:Measure [Functional Concept]

Phrase: "on tail vein blood,"
Meta Candidates (Total=11; Excluded=7; Pruned=0; Remaining=4)
   827   C0005767:Blood [Tissue]
   827   C0005768:blood [Body Substance]
   827   C0229664:Blood [Body Substance]
   755 E C0333275:Bloody [Qualitative Concept]
   743 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   743 E C0392895:Bloods [Population Group]
   743 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   743 E C1511228:VESSEL, BLOOD [Tissue]
   734   C2985205:Tail Vein [Body Part, Organ, or Organ Component]
   727 E C1558950:VASCULAR [Finding]
   727 E C1801960:Vascular [Qualitative Concept]

Phrase: "and"

Phrase: "any STZ-administered rats with blood glucose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0034693:rats [Mammal]
   748   C0034721:Rats [Mammal]

Phrase: "<15 mmol/;l"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   901   C1532563:mmol/L [Quantitative Concept]

Phrase: "were"

Phrase: "rejected from the study."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   770   C0557651:Study [Manufactured Object]
   770   C1548437:Rejected [Idea or Concept]
   770   C2603343:Study [Research Activity]
   737 E C2700401:Reject [Activity]
Processing 00000000.tx.34: Animals were then group housed with full access to food and water for durations of 12 weeks, and treatments were given as defined below. 

Phrase: "Animals"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0003062:Animals [Animal]

Phrase: "were"

Phrase: "then group"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0441833:Group [Idea or Concept]
   861   C0687744:group [Population Group]
   861   C1257890:Group [Population Group]
   861   C1552516:Group [Health Care Related Organization]
   861   C1705428:Group [Conceptual Entity]
   861   C1705429:Group [Population Group]

Phrase: "housed with full access"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   770   C0020056:Housed [Manufactured Object]
   770   C0443225:Full [Qualitative Concept]
   770   C0444454:Access [Spatial Concept]
   770   C1554204:access [Idea or Concept]
   737 E C0442519:house [Conceptual Entity]
   737 E C2003847:House [Manufactured Object]

Phrase: "to food"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016452:Food [Food]

Phrase: "and"

Phrase: "water for durations of 12 weeks,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0043047:Water [Inorganic Chemical,Pharmacologic Substance]
   753   C0599638:WATER [Substance]
   753   C1550678:Water [Inorganic Chemical]

Phrase: "and"

Phrase: "treatments"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
  1000   C0087111:Treatments [Therapeutic or Preventive Procedure]
   966 E C0039798:treatment [Functional Concept]
   966 E C1522326:Treatment [Functional Concept]
   966 E C1533734:Treatment [Therapeutic or Preventive Procedure]
   966 E C1705169:Treatment [Conceptual Entity]
   966 E C3538994:TREATMENT [Research Activity]

Phrase: "were"

Phrase: "given"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C1442162:GIVEN [Conceptual Entity]
  1000   C1550718:given [Idea or Concept]
  1000   C3244317:given [Intellectual Product]
   966 E C1947971:Give [Functional Concept]

Phrase: "as"

Phrase: "defined below."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C1704788:Defined [Conceptual Entity]
   833   C3539106:Defined [Intellectual Product]
Processing 00000000.tx.35: Treatments. 

Phrase: "Treatments."
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
  1000   C0087111:Treatments [Therapeutic or Preventive Procedure]
   966 E C0039798:treatment [Functional Concept]
   966 E C1522326:Treatment [Functional Concept]
   966 E C1533734:Treatment [Therapeutic or Preventive Procedure]
   966 E C1705169:Treatment [Conceptual Entity]
   966 E C3538994:TREATMENT [Research Activity]
Processing 00000000.tx.36: Aldose reductase inhibition was achieved using fidarestat. 

Phrase: "Aldose reductase inhibition"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   827   C0021467:Inhibition [Mental Process]
   827   C0021469:Inhibition [Molecular Function]
   827   C1628982:% inhibition [Quantitative Concept]
   827   C3463820:Inhibition [Activity]
   755 E C0311403:Inhibited [Qualitative Concept]
   734   C0002003:Aldose Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   734   C1412322:ALDOSE REDUCTASE [Gene or Genome]

Phrase: "was"

Phrase: "achieved"

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "fidarestat."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0905478:fidarestat [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.37: We measured daily food consumption at between 80 and 100 g/;rat; 

Phrase: "We"

Phrase: "measured"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0444706:Measured [Qualitative Concept]
  1000   C3541902:MEASURED [Diagnostic Procedure]
   966 E C0079809:Measure [Quantitative Concept]
   966 E C0242485:Measure [Functional Concept]

Phrase: "daily food consumption at"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C2983605:Food Consumption [Activity]
   770   C0009830:Consumption [Activity]
   770   C1947907:Consumption [Physiologic Function]

Phrase: "between 80"

Phrase: "and"

Phrase: "100 g/;rat"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0034693:Rat, NOS [Mammal]
   827   C0034721:Rat [Mammal]

Phrase: ";"
Processing 00000000.tx.38: hence, 240300 g/;kg body wt. 

Phrase: "hence,"

Phrase: "240300 g/;kg body wt."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C2700323:WT [Fish]
Processing 00000000.tx.39: Rats were housed in groups of three, and sufficient fidarestat to provide a dose of 2 mg/;kg was added to 200 g diet, which was made into a stiff slurry with water. 

Phrase: "Rats"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0034693:rats [Mammal]
  1000   C0034721:Rats [Mammal]

Phrase: "were"

Phrase: "housed in groups of three,"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   760   C0020056:Housed [Manufactured Object]
   760   C0205449:Three [Quantitative Concept]
   760   C0441833:Group [Idea or Concept]
   760   C0687744:group [Population Group]
   760   C1257890:Group [Population Group]
   760   C1552516:Group [Health Care Related Organization]
   760   C1552839:groups [Idea or Concept]
   760   C1705428:Group [Conceptual Entity]
   760   C1705429:Group [Population Group]
   726 E C0442519:house [Conceptual Entity]
   726 E C2003847:House [Manufactured Object]

Phrase: "and"

Phrase: "sufficient fidarestat to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0905478:fidarestat [Organic Chemical,Pharmacologic Substance]

Phrase: "provide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provide [Activity]

Phrase: "a dose of 2 mg/;kg"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0178602:Dose [Quantitative Concept]
   753   C0869039:Dose [Quantitative Concept]
   753   C1114758:Dose # [Clinical Attribute]

Phrase: "was"

Phrase: "added to 200 g diet,"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   760   C0012155:Diet [Food]
   760   C0439267:g% [Quantitative Concept]
   760   C1442959:Diet [Organism Function]
   760   C1519433:DIET [Therapeutic or Preventive Procedure]
   760   C1524062:Added [Functional Concept]
   760   C2983588:DIET [Food]
   726 E C1883712:Add [Functional Concept]

Phrase: "which"

Phrase: "was"

Phrase: "made into a stiff slurry"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0221170:Stiff [Sign or Symptom]
   760   C1883043:Slurry [Substance]
   726   C1881534:Make [Functional Concept]

Phrase: "with water."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0043047:Water [Inorganic Chemical,Pharmacologic Substance]
  1000   C0599638:WATER [Substance]
  1000   C1550678:Water [Inorganic Chemical]
   928 E C0443350:Watery [Qualitative Concept]
Processing 00000000.tx.40: Thus, 200 g medicated diet was provided daily, plus an excess of normal diet. 

Phrase: "Thus,"

Phrase: "200 g medicated diet"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   812   C0012155:Diet [Food]
   812   C1442959:Diet [Organism Function]
   812   C1519433:DIET [Therapeutic or Preventive Procedure]
   812   C2983588:DIET [Food]
   741 E C2699635:DIETARY [Functional Concept]

Phrase: "was"

Phrase: "provided"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provided [Activity]

Phrase: "daily,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332173:Daily [Temporal Concept]

Phrase: "plus"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332287:Plus [Qualitative Concept]

Phrase: "an excess of normal diet."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   762   C0814150:dietary excess [Finding]
   760   C1979886:Excess [Qualitative Concept]
Processing 00000000.tx.41: Rats always preferred the slurry and consumed the entire amount each day, thereby guaranteeing adequate dosing over the three animals. 

Phrase: "Rats always"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]

Phrase: "preferred"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0558295:Preferred [Idea or Concept]
  1000   C1548789:Preferred [Qualitative Concept]
  1000   C3543840:Preferred [Qualitative Concept]

Phrase: "the slurry"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883043:Slurry [Substance]

Phrase: "and"

Phrase: "consumed"

Phrase: "the entire"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439751:Entire [Quantitative Concept]
  1000   C0444667:Entire [Quantitative Concept]

Phrase: "amount"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1265611:Amount [Quantitative Concept]

Phrase: "each day,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0332173:/day [Temporal Concept]
  1000   C0439228:day [Temporal Concept]
  1000   C0439505:/day [Temporal Concept]

Phrase: "thereby"

Phrase: "guaranteeing"

Phrase: "adequate dosing over the three animals."
Processing 00000000.tx.42: Because weight loss was evenly spread, we judged the amount consumed to be roughly equal between "cage mates." 

Phrase: "Because"

Phrase: "weight loss"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0043096:WEIGHTLOSS [Finding]
  1000   C2911645:Weight loss [Finding]
   861   C0005910:weight [Organism Attribute]
   861   C0043100:Weight [Quantitative Concept]
   861   C1305866:weight [Diagnostic Procedure]
   861   C1517945:Loss [Quantitative Concept]
   861   C1705104:Weight [Idea or Concept]

Phrase: "was"

Phrase: "evenly"

Phrase: "spread"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332261:Spread [Qualitative Concept]
  1000   C1947932:Spread [Activity]

Phrase: ","

Phrase: "we"

Phrase: "judged"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0221191:Judge [Professional or Occupational Group]

Phrase: "the amount"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1265611:Amount [Quantitative Concept]

Phrase: "consumed"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "roughly equal between ""cage mates."""
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0205163:Equal [Qualitative Concept]
   760   C1549782:Equal [Idea or Concept]
Processing 00000000.tx.43: The p38 inhibitor SB 239063 was given at a dose of 20 mg  kg1  day1 by gavage of an aqueous suspension. 

Phrase: "The p38 inhibitor SB 239063"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0913456:SB 239063 [Organic Chemical]
   812   C1999216:Inhibitor [Qualitative Concept]

Phrase: "was"

Phrase: "given at a dose of 20 mg  kg1  day1"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   742   C0178602:Dose [Quantitative Concept]
   742   C0439269:mg% [Quantitative Concept]
   742   C0869039:Dose [Quantitative Concept]
   742   C1114758:Dose # [Clinical Attribute]
   742   C1442162:GIVEN [Conceptual Entity]
   742   C1550718:given [Idea or Concept]
   742   C1960952:mg % [Quantitative Concept]
   742   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]
   742   C3244317:given [Intellectual Product]
   708 E C1947971:Give [Functional Concept]

Phrase: "by gavage"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041281:Gavage [Therapeutic or Preventive Procedure]

Phrase: "of an aqueous suspension."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0038960:Suspension [Biomedical or Dental Material]
   861   C0599956:Aqueous [Qualitative Concept]
   861   C1382107:Suspension [Substance]
   861   C1705537:Suspension [Functional Concept]
Processing 00000000.tx.44: Treatment was begun immediately after confirmation of diabetes (day 3 after STZ administration) and was maintained until the end of the protocol. 

Phrase: "Treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "was"

Phrase: "begun"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0439659:Begin [Temporal Concept]

Phrase: "immediately"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205548:Immediately [Temporal Concept]

Phrase: "after"

Phrase: "confirmation of diabetes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   882   C0521091:Confirmation of [Qualitative Concept]
           confirmation
   790   C0750484:Confirmation [Idea or Concept]

Phrase: "(day 3 after STZ administration"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   760   C0001554:Administration [Occupational Activity]
   760   C0038432:STZ [Antibiotic,Carbohydrate]
   760   C0332173:/day [Temporal Concept]
   760   C0439228:day [Temporal Concept]
   760   C0439505:/day [Temporal Concept]
   760   C1533734:Administration [Therapeutic or Preventive Procedure]
   760   C1539862:STZ [Gene or Genome]

Phrase: ")"

Phrase: "and"

Phrase: "was"

Phrase: "maintained until the end of the protocol."
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   804   C0444496:End of protocol [Temporal Concept]
   748   C0442711:Protocol [Intellectual Product]
   748   C0444930:End [Spatial Concept]
   748   C1314677:Maintained [Functional Concept]
   748   C1507394:Protocol [Intellectual Product]
   748   C1522729:Protocol [Intellectual Product]
   748   C2348563:Protocol [Intellectual Product]
   748   C2746065:End [Temporal Concept]
   714 E C0024501:Maintain [Activity]
Processing 00000000.tx.45: Insulin treatment (given via two subcutaneous Linplants, see [10] for details) was started after 8 weeks untreated diabetes and maintained for the final 4 weeks. 

Phrase: "Insulin treatment"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0745343:insulin treatment [Therapeutic or Preventive Procedure]
   861   C0039798:treatment [Functional Concept]
   861   C0087111:Treatment [Therapeutic or Preventive Procedure]
   861   C1522326:Treatment [Functional Concept]
   861   C1533734:Treatment [Therapeutic or Preventive Procedure]
   861   C1705169:Treatment [Conceptual Entity]
   861   C3538994:TREATMENT [Research Activity]

Phrase: "("

Phrase: "given via two subcutaneous Linplants,"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   760   C0205448:Two [Quantitative Concept]
   760   C0443315:subcutaneous [Spatial Concept]
   760   C1442162:GIVEN [Conceptual Entity]
   760   C1550718:given [Idea or Concept]
   760   C3244317:given [Intellectual Product]
   726 E C1947971:Give [Functional Concept]

Phrase: "see [10"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0042789:see [Organism Function]
   861   C1947903:See [Activity]

Phrase: "]"

Phrase: "for details"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1522508:Details [Qualitative Concept]
   966 E C1561567:detail [Functional Concept]

Phrase: ")"

Phrase: "was"

Phrase: "started after 8 weeks untreated diabetes"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   753   C0011847:Diabetes [Disease or Syndrome]
   753   C0011849:Diabetes [Disease or Syndrome]
   753   C0332155:untreated [Finding]
   753   C0439230:weeks [Temporal Concept]
   753   C1272689:Started [Qualitative Concept]
   719 E C0332174:/week [Temporal Concept]
   719 E C0439659:Start [Temporal Concept]

Phrase: "and"

Phrase: "maintained for the final 4 weeks."
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   753   C0205088:Final [Temporal Concept]
   753   C0439230:weeks [Temporal Concept]
   753   C1314677:Maintained [Functional Concept]
   753   C1546485:Final [Idea or Concept]
   719 E C0024501:Maintain [Activity]
   719 E C0332174:/week [Temporal Concept]
Processing 00000000.tx.46: Tissues and measurements. 

Phrase: "Tissues"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0040300:Tissues [Tissue]
   966 E C1547928:Tissue [Intellectual Product]

Phrase: "and"

Phrase: "measurements."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0242485:measurements [Functional Concept]
Processing 00000000.tx.47: At the end of the designated protocol, rats were anesthetized (isoflurane in oxygen) and MNCV and SNCV were measured exactly as described elsewhere (11). 

Phrase: "At the end"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0444930:End [Spatial Concept]
  1000   C2746065:End [Temporal Concept]
   944 E C0205088:Terminal [Temporal Concept]
   944 E C1705314:Terminal [Manufactured Object]
   944 E C1705315:Terminal [Spatial Concept]

Phrase: "of the designated protocol,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0442711:Protocol [Intellectual Product]
   861   C1507394:Protocol [Intellectual Product]
   861   C1522729:Protocol [Intellectual Product]
   861   C2348563:Protocol [Intellectual Product]

Phrase: "rats"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0034693:rats [Mammal]
  1000   C0034721:Rats [Mammal]

Phrase: "were"

Phrase: "anesthetized"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1720436:Anesthetized [Finding]

Phrase: "(isoflurane in oxygen"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0022180:Isoflurane [Organic Chemical,Pharmacologic Substance]

Phrase: ")"

Phrase: "and"

Phrase: "MNCV"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2982003:NCV [Diagnostic Procedure]

Phrase: "and"

Phrase: "SNCV"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2982003:NCV [Diagnostic Procedure]

Phrase: "were"

Phrase: "measured"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0444706:Measured [Qualitative Concept]
  1000   C3541902:MEASURED [Diagnostic Procedure]
   966 E C0079809:Measure [Quantitative Concept]
   966 E C0242485:Measure [Functional Concept]

Phrase: "exactly"

Phrase: "as"

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "elsewhere"

Phrase: "(11"

Phrase: ")."
Processing 00000000.tx.48: The animals were then exsanguinated from the right ventricle under anesthetic, and tissues were dissected and placed in tubes on dry ice for subsequent assay. 

Phrase: "The animals"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0003062:Animals [Animal]

Phrase: "were"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "exsanguinated from the right ventricle"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C0225883:Right Ventricle [Body Part, Organ, or Organ Component]
   806   C1269891:Right ventricle [Body Part, Organ, or Organ Component]
   760   C0018827:Ventricle [Body Part, Organ, or Organ Component]
   760   C0205090:Right [Spatial Concept]
   760   C0232101:Exsanguinated [Finding]
   760   C2355627:Ventricle [Body Part, Organ, or Organ Component]

Phrase: "under anesthetic,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0002932:Anaesthetic [Pharmacologic Substance]

Phrase: "and"

Phrase: "tissues"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0040300:Tissues [Tissue]
   966 E C1547928:Tissue [Intellectual Product]

Phrase: "were"

Phrase: "dissected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205239:dissected [Functional Concept]

Phrase: "and"

Phrase: "placed in tubes"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   790   C0175730:tubes [Medical Device]
   790   C1547937:Tubes [Intellectual Product]
   790   C1704474:Tubes [Quantitative Concept]
   756   C0442504:Place [Spatial Concept]
   756 E C1561954:tube [Conceptual Entity]
   756 E C1704730:TUBE [Medical Device]
   756   C1704765:Place [Functional Concept]
   756   C1882509:Place [Activity]
   756   C3496241:place [Disease or Syndrome]

Phrase: "on dry ice"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0013239:Dry Ice [Inorganic Chemical]
   861   C0011682:Dry [Natural Phenomenon or Process]
   861   C0020746:Ice [Inorganic Chemical]
   861   C0205222:Dry [Qualitative Concept]
   861   C1512080:Dry [Qualitative Concept]

Phrase: "for subsequent assay."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0005507:Assay [Laboratory Procedure]
   861   C0243073:assay [Qualitative Concept]
   861   C1510438:Assay [Laboratory Procedure]
Processing 00000000.tx.49: In experiments involving fidarestat, one sciatic nerve was removed from each rat for measurement of glucose, fructose, and sorbitol by capillary gas chromatography of trimethylsilyl derivatives exactly as described elsewhere (12). 

Phrase: "In experiments"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0681814:Experiments [Research Activity]
   966 E C1706386:Experiment [Conceptual Entity]
   916 E C1517586:Experimental [Qualitative Concept]

Phrase: "involving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1314939:Involving [Functional Concept]

Phrase: "fidarestat,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0905478:fidarestat [Organic Chemical,Pharmacologic Substance]

Phrase: "one sciatic nerve"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   901   C0036394:Sciatic Nerve [Body Part, Organ, or Organ Component]
   901   C1278851:Sciatic nerve [Body Part, Organ, or Organ Component]
   827   C0027740:Nerve [Tissue]
   827   C0027757:NERVE [Tissue]
   827   C1280541:Nerve [Body Part, Organ, or Organ Component]
   771 E C0599851:Neural [Functional Concept]
   755 E C0027769:nervy [Sign or Symptom]

Phrase: "was"

Phrase: "removed from each rat"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   770   C0034693:Rat, NOS [Mammal]
   770   C0034721:Rat [Mammal]
   770   C0849355:Removed [Qualitative Concept]
   737 E C1883720:Remove [Activity]
   737 E C3244314:remove [Functional Concept]

Phrase: "for measurement"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0242485:Measurement [Functional Concept]

Phrase: "of glucose,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "fructose,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016745:Fructose [Carbohydrate,Pharmacologic Substance]

Phrase: "and"

Phrase: "sorbitol by capillary gas chromatography of trimethylsilyl derivatives exactly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0037688:Sorbitol [Carbohydrate,Pharmacologic Substance]

Phrase: "as"

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "elsewhere"

Phrase: "(12"

Phrase: ")."
Processing 00000000.tx.50: In all experiments with treatments, the L4 and L5 dorsal root ganglia (DRG) were removed for SDS-PAGE and Western blotting, again exactly as described elsewhere (7). 

Phrase: "In all experiments"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0681814:Experiments [Research Activity]
   966 E C1706386:Experiment [Conceptual Entity]
   916 E C1517586:Experimental [Qualitative Concept]

Phrase: "with treatments,"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
  1000   C0087111:Treatments [Therapeutic or Preventive Procedure]
   966 E C0039798:treatment [Functional Concept]
   966 E C1522326:Treatment [Functional Concept]
   966 E C1533734:Treatment [Therapeutic or Preventive Procedure]
   966 E C1705169:Treatment [Conceptual Entity]
   966 E C3538994:TREATMENT [Research Activity]

Phrase: "the L4"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1419676:L4 [Gene or Genome]

Phrase: "and"

Phrase: "L5 dorsal root ganglia"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
   923   C0017070:Dorsal Root Ganglia [Body Part, Organ, or Organ Component]
           Dorsal Root
   890 E C1761610:Dorsal root ganglion [Body Part, Organ, or Organ Component]
   861   C0205955:Dorsal root [Body Part, Organ, or Organ Component]
   844   C1186181:root ganglion [Body Part, Organ, or Organ Component]
   812   C0017067:Ganglia [Body Part, Organ, or Organ Component]
   812   C0040452:Root [Body Part, Organ, or Organ Component]
   812   C0205095:Dorsal [Spatial Concept]
   812   C0242726:Root [Plant]
   812   C1318154:Root [Body Part, Organ, or Organ Component]
   812   C1705917:Root [Idea or Concept]
   779 E C1258666:Ganglion, NOS [Acquired Abnormality,Disease or Syndrome]

Phrase: "(DRG"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
  1000   C0017070:Dorsal Root Ganglia [Body Part, Organ, or Organ Component]
           Dorsal Root
   966 E C1761610:Dorsal root ganglion [Body Part, Organ, or Organ Component]
   901   C0205955:Dorsal root [Body Part, Organ, or Organ Component]
   884   C1186181:root ganglion [Body Part, Organ, or Organ Component]
   827   C0017067:Ganglia [Body Part, Organ, or Organ Component]
   827   C0040452:Root [Body Part, Organ, or Organ Component]
   827   C0205095:Dorsal [Spatial Concept]
   827   C0242726:Root [Plant]
   827   C1318154:Root [Body Part, Organ, or Organ Component]
   827   C1705917:Root [Idea or Concept]
   793 E C1258666:Ganglion, NOS [Acquired Abnormality,Disease or Syndrome]

Phrase: ")"

Phrase: "were"

Phrase: "removed for SDS-PAGE"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   833   C0600209:SDS-PAGE [Laboratory Procedure,Research Activity]
   770   C0849355:Removed [Qualitative Concept]
   770   C1704732:Page [Intellectual Product]
   737 E C1883720:Remove [Activity]
   737 E C3244314:remove [Functional Concept]

Phrase: "and"

Phrase: "Western blotting,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0005863:Western Blotting [Laboratory Procedure,Molecular Biology Research Technique]
   983 E C0949466:Western Blot [Laboratory Procedure]
   861   C1705493:Western [Spatial Concept]

Phrase: "again exactly"

Phrase: "as"

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "elsewhere"

Phrase: "(7"

Phrase: ")."
Processing 00000000.tx.51: Blots were exposed to either an antibody directed at a nonphosphorylated epitope of p38 MAP kinase to measure total protein (rabbit polyclonal at a dilution of 1:2,000; 

Phrase: "Blots"

Phrase: "were"

Phrase: "exposed to either"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   882   C0332157:Exposed to [Clinical Attribute]
           Exposed

Phrase: "an antibody"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
  1000   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "directed at a nonphosphorylated epitope of p38 MAP kinase to"
Meta Candidates (Total=17; Excluded=2; Pruned=0; Remaining=15)
   810   C1456380:p38 Mitogen Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   804 E C1120843:mitogen-activated protein kinase p38 [Amino Acid, Peptide, or Protein,Enzyme]
           p38 Protein Kinase
   790   C0752312:Mitogen-Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   770   C1979930:Mitogen-activated protein [Amino Acid, Peptide, or Protein]
   767   C0010531:Protein Kinase A [Amino Acid, Peptide, or Protein,Enzyme]
   753   C0033640:PROTEIN KINASE [Amino Acid, Peptide, or Protein,Enzyme]
   751   C0038164:Protein A [Amino Acid, Peptide, or Protein,Immunologic Factor,Indicator, Reagent, or Diagnostic Aid]
   736   C0003316:Epitope [Immunologic Factor]
   736   C0018284:Mitogen [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   736   C0026249:Mitogen [Pharmacologic Substance]
   736   C0031727:Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   736   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   736   C1879547:Activated [Activity]
   703   C0439851:Direct [Qualitative Concept]
   703 E C1515877:Activate [Functional Concept]
   703   C1947931:Direct [Qualitative Concept]

Phrase: "measure"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0079809:Measure [Quantitative Concept]
  1000   C0242485:Measure [Functional Concept]

Phrase: "total protein"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0555903:Total protein [Laboratory Procedure]
  1000   C1261360:total protein [Laboratory or Test Result]
   861   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0439175:% total [Quantitative Concept]
   861   C0439810:Total [Qualitative Concept]

Phrase: "(rabbit"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0034493:Rabbit [Mammal]

Phrase: "polyclonal at a dilution of 1"

Phrase: ":"

Phrase: "2,000"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0740116:+2 [Quantitative Concept]
   861   C2827735:2+ [Quantitative Concept]
   861   C2981700:2+ [Classification]

Phrase: ";"
Processing 00000000.tx.52: New England Biolabs, Beverly, MA) or a phosphospecific antibody to measure activation of p38 (rabbit polyclonal at a dilution of 1:4,000; 

Phrase: "New England Biolabs,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   734   C0027965:New England [Geographic Area]

Phrase: "Beverly,"

Phrase: "MA)"

Phrase: "or"

Phrase: "a phosphospecific antibody to"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C1257988:Phosphospecific Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   827   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "measure"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0079809:Measure [Quantitative Concept]
  1000   C0242485:Measure [Functional Concept]

Phrase: "activation of p38"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1879547:Activation [Activity]

Phrase: "(rabbit"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0034493:Rabbit [Mammal]

Phrase: "polyclonal at a dilution of 1"

Phrase: ":"

Phrase: "4,000"

Phrase: ";"
Processing 00000000.tx.53: Biosource, Camarillo, CA). 

Phrase: "Biosource,"

Phrase: "Camarillo,"

Phrase: "CA)."
Processing 00000000.tx.54: Gels were then scanned and immunoreactivity for p38 bands estimated using proprietary densitometry software (Molecular Analyst). 

Phrase: "Gels"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0017243:Gels [Biomedical or Dental Material]
   966 E C1382104:Gel [Substance]

Phrase: "were"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "scanned"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0441633:scanned [Diagnostic Procedure]
   966 E C0034606:Scan [Diagnostic Procedure]
   966 E C2826292:SCAN [Finding]

Phrase: "and"

Phrase: "immunoreactivity for p38 bands"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0597879:immunoreactivity [Molecular Function]

Phrase: "estimated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750572:Estimated [Quantitative Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "proprietary densitometry software"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0037585:Software [Intellectual Product,Manufactured Object]

Phrase: "(Molecular Analyst"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0870132:analyst [Professional or Occupational Group]

Phrase: ")."
Processing 00000000.tx.55: All gels comprised 20 lanes, and in every gel there were 10 lanes from control samples (10 different rats). 

Phrase: "All gels"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0017243:Gels [Biomedical or Dental Material]
   966 E C1382104:Gel [Substance]

Phrase: "comprised"

Phrase: "20 lanes,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1708639:Lane [Spatial Concept]

Phrase: "and in every gel there"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0017243:Gel [Biomedical or Dental Material]
   760   C1382104:Gel [Substance]
   760   C1515981:And [Idea or Concept]

Phrase: "were"

Phrase: "10 lanes from control samples"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   726   C1708639:Lane [Spatial Concept]

Phrase: "(10 different rats"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0034693:rats [Mammal]
   827   C0034721:Rats [Mammal]

Phrase: ")."
Processing 00000000.tx.56: Thus, within each gel, each diabetic sample (either untreated or treated, depending on the experiment) was normalized to the mean value for all controls in the same gel. 

Phrase: "Thus,"

Phrase: "within each gel,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0017243:Gel [Biomedical or Dental Material]
  1000   C1382104:Gel [Substance]

Phrase: "each diabetic sample"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0370003:Sample [Substance]
   861   C2347026:Sample [Conceptual Entity]

Phrase: "(either untreated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0332155:untreated [Finding]

Phrase: "or"

Phrase: "treated,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0332293:treated [Therapeutic or Preventive Procedure]
  1000   C1522326:Treated [Functional Concept]
   966 E C1292734:TREAT [Functional Concept]

Phrase: "depending on the experiment"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0681814:Experiment [Research Activity]
   770   C1706386:Experiment [Conceptual Entity]
   737   C0725813:depend [Medical Device]

Phrase: ")"

Phrase: "was"

Phrase: "normalized to the mean value"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0444504:Mean [Quantitative Concept]
   760   C1522609:Value [Quantitative Concept]
   760   C1882115:Normalized [Research Activity]
   760   C2347634:Mean [Quantitative Concept]
   760   C2348143:Mean [Quantitative Concept]

Phrase: "for all"

Phrase: "controls in the same gel."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   760   C0017243:Gel [Biomedical or Dental Material]
   760   C0243148:control [Qualitative Concept]
   760   C0445247:Same [Qualitative Concept]
   760   C1382104:Gel [Substance]
   760   C1550141:Control [Substance]
   760   C1882979:Control [Conceptual Entity]
   760   C2587213:Control [Functional Concept]
   760   C3274648:Control [Qualitative Concept]
Processing 00000000.tx.57: That done, phosphospecific p38 immunoreactivity was normalized to total p38 protein for the same tissue sample. 

Phrase: "That"

Phrase: "done"

Phrase: ","

Phrase: "phosphospecific p38 immunoreactivity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597879:immunoreactivity [Molecular Function]

Phrase: "was"

Phrase: "normalized to total p38 protein"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   797   C0439177:Protein.total [Quantitative Concept]
   797   C0555903:Total protein [Laboratory Procedure]
   797   C1261360:total protein [Laboratory or Test Result]
   760   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   760   C0439175:% total [Quantitative Concept]
   760   C0439810:Total [Qualitative Concept]
   760   C1882115:Normalized [Research Activity]

Phrase: "for the same tissue sample."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C1292533:Tissue Sample [Tissue]
   827   C0370003:Sample [Substance]
   827   C2347026:Sample [Conceptual Entity]
Processing 00000000.tx.58: This enabled an estimate of activation of p38 independent of any changes in expression; 

Phrase: "This enabled"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0562342:Enabled [Mental Process]
   966 E C1171285:enable [Mental Process]

Phrase: "an estimate of activation of p38"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0750572:Estimate [Quantitative Concept]

Phrase: "independent of any"

Phrase: "changes in expression"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0185117:Expression [Therapeutic or Preventive Procedure]
   790   C0392747:Change [Functional Concept]
   790   C0443172:change [Quantitative Concept]
   790   C1705241:Change [Quantitative Concept]

Phrase: ";"
Processing 00000000.tx.59: in fact, no systematic changes in p38 total immunoreactivity were seen, but the procedure was maintained as a fail-safe. 

Phrase: "in fact,"

Phrase: "no systematic changes in p38 total immunoreactivity"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   757   C0442739:No change [Finding]
   757   C1548568:No change [Intellectual Product]
   748   C0392747:changes [Functional Concept]
   748   C0443172:changes [Quantitative Concept]
   714 E C1705241:Change [Quantitative Concept]

Phrase: "were"

Phrase: "seen"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0205397:Seen [Qualitative Concept]
   966 E C0042789:see [Organism Function]
   966 E C1947903:See [Activity]

Phrase: ","

Phrase: "but"

Phrase: "the procedure"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0184661:Procedure [Diagnostic Procedure,Therapeutic or Preventive Procedure]
  1000   C1948041:Procedure [Therapeutic or Preventive Procedure]
  1000   C2700391:Procedure [Activity]
  1000   C3274430:PROCEDURE [Health Care Activity]
  1000   C3538935:Procedure [Idea or Concept]
  1000   C3539779:Procedure [Intellectual Product]

Phrase: "was"

Phrase: "maintained as a fail-safe."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   760   C0231175:fail [Functional Concept]
   760   C1314677:Maintained [Functional Concept]
   726 E C0024501:Maintain [Activity]
Processing 00000000.tx.60: In the fidarestat study, 10 rats from each group were fixed by arterial perfusion (4% paraformaldehyde in PBS) under anesthetic and sections prepared for immunocytochemistry as described elsewhere (13). 

Phrase: "In the fidarestat study,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0557651:Study [Manufactured Object]
   861   C2603343:Study [Research Activity]

Phrase: "10 rats from each group"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0034693:rats [Mammal]
   760   C0034721:Rats [Mammal]

Phrase: "were"

Phrase: "fixed by arterial perfusion"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   833   C0398345:Arterial perfusion [Therapeutic or Preventive Procedure]
   770   C0003842:Arterial [Body Part, Organ, or Organ Component]
   770   C0031001:Perfusion [Therapeutic or Preventive Procedure]
   770   C0221464:Arterial [Spatial Concept]
   770   C0231441:Fixed [Finding]
   770   C0443218:Fixed [Qualitative Concept]
   770   C2827483:Fixed [Body Substance]

Phrase: "(4% paraformaldehyde in PBS)"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0070066:Paraformaldehyde [Biomedical or Dental Material,Organic Chemical,Pharmacologic Substance]

Phrase: "under anesthetic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0002932:Anaesthetic [Pharmacologic Substance]

Phrase: "and"

Phrase: "sections"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   966   C0205155:Section [Spatial Concept]
   966   C1293097:Section, NOS [Therapeutic or Preventive Procedure]
   966   C1522472:Section [Substance]
   966   C1552923:Section [Quantitative Concept]
   966   C1705191:Section [Physical Object]

Phrase: "prepared for immunocytochemistry"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0242349:Immunocytochemistry [Laboratory Procedure]
   756   C1521827:Prepare [Functional Concept]

Phrase: "as"

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "elsewhere"

Phrase: "(13"

Phrase: ")."
Processing 00000000.tx.61: Sections of L4 or L5 DRG and of L1 spinal cord were stained for p38 immunoreactivity (total protein, rabbit polyclonal antibody at 1:200 dilution; 

Phrase: "Sections of L4"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   756   C0205155:Section [Spatial Concept]
   756   C1293097:Section, NOS [Therapeutic or Preventive Procedure]
   756   C1522472:Section [Substance]
   756   C1552923:Section [Quantitative Concept]
   756   C1705191:Section [Physical Object]

Phrase: "or"

Phrase: "L5 DRG"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
   923   C0017070:Dorsal Root Ganglia [Body Part, Organ, or Organ Component]
           Dorsal Root
   890 E C1761610:Dorsal root ganglion [Body Part, Organ, or Organ Component]
   861   C0205955:Dorsal root [Body Part, Organ, or Organ Component]
   844   C1186181:root ganglion [Body Part, Organ, or Organ Component]
   812   C0017067:Ganglia [Body Part, Organ, or Organ Component]
   812   C0040452:Root [Body Part, Organ, or Organ Component]
   812   C0205095:Dorsal [Spatial Concept]
   812   C0242726:Root [Plant]
   812   C1318154:Root [Body Part, Organ, or Organ Component]
   812   C1705917:Root [Idea or Concept]
   779 E C1258666:Ganglion, NOS [Acquired Abnormality,Disease or Syndrome]

Phrase: "and of L1 spinal cord"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   806   C0037925:Spinal Cord [Body Part, Organ, or Organ Component]
   806   C1278836:Spinal cord [Body Part, Organ, or Organ Component]
   760   C0441918:L1 [Finding]
   760   C0521329:Spinal [Spatial Concept]
   760   C1179698:L1 [Body Location or Region]
   760   C1416177:L1 [Gene or Genome]
   760   C1515981:And [Idea or Concept]
   760   C1550235:Cord [Body Part, Organ, or Organ Component]
   760   C1552938:cord [Quantitative Concept]
   760   C1706500:Cord [Manufactured Object]

Phrase: "were"

Phrase: "stained for p38 immunoreactivity"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   770   C0597879:immunoreactivity [Molecular Function]
   770   C2986582:Stained [Qualitative Concept]
   737 E C0038128:Stain [Indicator, Reagent, or Diagnostic Aid]

Phrase: "(total protein,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0555903:Total protein [Laboratory Procedure]
  1000   C1261360:total protein [Laboratory or Test Result]
   861   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0439175:% total [Quantitative Concept]
   861   C0439810:Total [Qualitative Concept]

Phrase: "rabbit polyclonal antibody at 1"

Phrase: ":"

Phrase: "200 dilution"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0079240:Dilution [Laboratory Procedure]
   861   C1948037:Dilution [Functional Concept]

Phrase: ";"
Processing 00000000.tx.62: Santa Cruz Biotechnology, Santa Cruz, CA; 

Phrase: "Santa Cruz Biotechnology,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0005574:Biotechnology [Biomedical Occupation or Discipline]

Phrase: "Santa Cruz,"

Phrase: "CA"

Phrase: ";"
Processing 00000000.tx.63: and phospho-protein, rabbit polyclonal at 1:250 dilution; 

Phrase: "and"

Phrase: "phospho-protein,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "rabbit polyclonal at 1"

Phrase: ":"

Phrase: "250 dilution"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0079240:Dilution [Laboratory Procedure]
   861   C1948037:Dilution [Functional Concept]

Phrase: ";"
Processing 00000000.tx.64: Biosource). 

Phrase: "Biosource"

Phrase: ")."
Processing 00000000.tx.65: Analysis. 

Phrase: "Analysis."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0002778:Analysis [Laboratory Procedure]
  1000   C0936012:Analysis [Research Activity]
  1000   C1524024:analysis [Functional Concept]
Processing 00000000.tx.66: All comparisons were made within each self-contained experiment (see Table 1 for an example). 

Phrase: "All comparisons"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1707455:Comparison [Activity]

Phrase: "were"

Phrase: "made within each self-contained experiment"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   753   C0036588:Self [Idea or Concept]
   753   C0332256:contained [Functional Concept]
   753   C0681814:Experiment [Research Activity]
   753   C1551994:self [Intellectual Product]
   753   C1706386:Experiment [Conceptual Entity]
   753   C2700400:Contained [Activity]
   753   C3244295:Self [Intellectual Product]
   719   C1881534:Make [Functional Concept]

Phrase: "("

Phrase: "see"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0042789:see [Organism Function]
  1000   C1947903:See [Activity]

Phrase: "Table 1 for an example"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0039224:Table [Manufactured Object]
   760   C1706073:Table [Medical Device]
   760   C1706074:Table [Intellectual Product]
   760   C1707959:Example [Conceptual Entity]

Phrase: ")."
Processing 00000000.tx.67: Group means were compared using one-way ANOVA, and, where the F ratio is indicated, individual means were compared using Scheffes range tests. 

Phrase: "Group means"
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
   861   C0441833:Group [Idea or Concept]
   861   C0687744:group [Population Group]
   861   C1257890:Group [Population Group]
   861   C1552516:Group [Health Care Related Organization]
   861   C1704970:Means [Conceptual Entity]
   861   C1705428:Group [Conceptual Entity]
   861   C1705429:Group [Population Group]
   827 E C0444504:Mean [Quantitative Concept]
   827 E C2347634:Mean [Quantitative Concept]
   827 E C2348143:Mean [Quantitative Concept]

Phrase: "were"

Phrase: "compared"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707455:Compared [Activity]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "one-way ANOVA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1709320:One-way ANOVA [Quantitative Concept]

Phrase: "and"

Phrase: ","

Phrase: "where"

Phrase: "the F ratio"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0456603:Ratio [Quantitative Concept]
   861   C1547037:Ratio [Intellectual Product]

Phrase: "is"

Phrase: "indicated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1444656:Indicated [Finding]

Phrase: ","

Phrase: "individual means"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C1704970:Means [Conceptual Entity]
   827 E C0444504:Mean [Quantitative Concept]
   827 E C2347634:Mean [Quantitative Concept]
   827 E C2348143:Mean [Quantitative Concept]

Phrase: "were"

Phrase: "compared"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707455:Compared [Activity]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "Scheffes range tests."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0022885:Tests [Laboratory Procedure]
   827   C0392366:Tests [Intellectual Product]
   793 E C0039593:Test [Functional Concept]
Processing 00000000.tx.68: View this table: [in this window] [in a new window]  TABLE 1 Changes in body weight, plasma glucose, and nerve polyol pathway metabolites (where measured) with all treatments   RESULTS TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES  Effects of treatments on body weight and diabetes. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  TABLE 1 Changes in body weight,"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   820   C0005911:Body Weight Changes [Finding]
           weight changes
   753   C0392747:changes [Functional Concept]
   753   C0443172:changes [Quantitative Concept]
   719 E C1705241:Change [Quantitative Concept]

Phrase: "plasma glucose,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0202042:Plasma glucose [Laboratory Procedure]
  1000   C0455280:plasma glucose [Laboratory or Test Result]
   861   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   861   C0032105:Plasma [Body Substance]
   861   C1550098:Plasma, NOS (not otherwise specified) [Body Substance]

Phrase: "and"

Phrase: "nerve polyol pathway metabolites"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0870883:Metabolites [Biologically Active Substance]
   812   C2698672:METABOLITES [Regulation or Law]

Phrase: "(where"

Phrase: "measured"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0444706:Measured [Qualitative Concept]
  1000   C3541902:MEASURED [Diagnostic Procedure]
   966 E C0079809:Measure [Quantitative Concept]
   966 E C0242485:Measure [Functional Concept]

Phrase: ")"

Phrase: "with all treatments   RESULTS TOP ABSTRACT RESEARCH DESIGN"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   859   C0282334:treatment research [Research Activity]
   827   C0035171:Research Design [Research Activity]
   799   C0035168:research [Research Activity]
   799   C0242481:Research [Research Activity]
   799   C1707689:Design [Activity]
   799   C2983265:DESIGN [Intellectual Product]

Phrase: "AND"

Phrase: "METHODS RESULTS DISCUSSION"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Effects of treatments"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   824   C1518681:Treatment Effect [Finding]
   790   C1280500:effects [Qualitative Concept]
   756 E C2348382:Effect [Qualitative Concept]

Phrase: "on body weight"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
  1000   C0005910:Body Weight [Organism Attribute]
           weight
  1000   C1305866:body weight [Diagnostic Procedure]
           weight
   861   C0043100:Weight [Quantitative Concept]
   861   C0242821:body [Human]
   861   C0460148:Body [Anatomical Structure]
   861   C1268086:Body [Anatomical Structure]
   861   C1705104:Weight [Idea or Concept]
   777 E C1995017:Bodies [Cell Component]

Phrase: "and"

Phrase: "diabetes."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]
Processing 00000000.tx.69: All data are in Table 1. 

Phrase: "All data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "are in Table 1."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0039224:Table [Manufactured Object]
   770   C1551058:Are [Quantitative Concept]
   770   C1706073:Table [Medical Device]
   770   C1706074:Table [Intellectual Product]
Processing 00000000.tx.70: Neither the aldose reductase inhibitor nor the p38 inhibitor affected body weight or glycemia; 

Phrase: "Neither"

Phrase: "the aldose reductase inhibitor"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C2348243:Aldose Reductase Inhibitor [Pharmacologic Substance]
   901   C0002003:Aldose Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   901   C1412322:ALDOSE REDUCTASE [Gene or Genome]
   827   C0030016:Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0682934:Aldose [Carbohydrate]
   827   C1999216:Inhibitor [Qualitative Concept]

Phrase: "nor"

Phrase: "the p38 inhibitor"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1999216:Inhibitor [Qualitative Concept]

Phrase: "affected"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0392760:Affected [Functional Concept]
  1000   C1314939:Affected [Functional Concept]
   966 E C0001721:Affect [Mental Process]

Phrase: "body weight"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
  1000   C0005910:Body Weight [Organism Attribute]
           weight
  1000   C1305866:body weight [Diagnostic Procedure]
           weight
   861   C0043100:Weight [Quantitative Concept]
   861   C0242821:body [Human]
   861   C0460148:Body [Anatomical Structure]
   861   C1268086:Body [Anatomical Structure]
   861   C1705104:Weight [Idea or Concept]
   777 E C1995017:Bodies [Cell Component]

Phrase: "or"

Phrase: "glycemia"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005802:glycemia [Carbohydrate]

Phrase: ";"
Processing 00000000.tx.71: thus any neurological changes seen with these cannot be attributed to attenuation of diabetes severity. 

Phrase: "thus"

Phrase: "any neurological changes"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0392747:changes [Functional Concept]
   861   C0443172:changes [Quantitative Concept]
   827 E C1705241:Change [Quantitative Concept]

Phrase: "seen with these"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   790   C0205397:Seen [Qualitative Concept]
   756 E C0042789:see [Organism Function]
   756 E C1947903:See [Activity]

Phrase: "cannot"

Phrase: "be"

Phrase: "attributed to attenuation of diabetes severity."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   753   C0011847:Diabetes [Disease or Syndrome]
   753   C0011849:Diabetes [Disease or Syndrome]
   753   C0439793:Severity [Qualitative Concept]
   753   C0599946:Attenuation [Activity]
   753   C2983285:Severity [Intellectual Product]
   719   C0449234:Attribute [Idea or Concept]
   719   C1704772:Attribute [Conceptual Entity]
   719   C1882133:Attribute [Qualitative Concept]
Processing 00000000.tx.72: However, the insulin implant normalized morning glycemia and allowed the animals to gain weight dramatically, obtaining similar weights to the nondiabetic controls. 

Phrase: "However,"

Phrase: "the insulin implant normalized morning glycemia"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0005802:glycemia [Carbohydrate]

Phrase: "and"

Phrase: "allowed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0683607:allowed [Social Behavior]

Phrase: "the animals to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0003062:Animals [Animal]

Phrase: "gain"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C1517378:Gain [Quantitative Concept]
   944 E C0205217:Increased [Quantitative Concept]
   944 E C0439661:Acquired [Temporal Concept]
   944 E C0442805:Increase [Functional Concept]
   944 E C0442808:Increasing [Functional Concept]
   944 E C1301820:Obtain [Functional Concept]
   944 E C1706701:Acquire [Activity]
   944 E C3245488:acquired [Intellectual Product]

Phrase: "weight dramatically,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0005910:weight [Organism Attribute]
   861   C0043100:Weight [Quantitative Concept]
   861   C1305866:weight [Diagnostic Procedure]
   861   C1705104:Weight [Idea or Concept]

Phrase: "obtaining"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
   966   C1301820:Obtain [Functional Concept]
   966   C1706701:Obtain [Activity]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0205217:Increased [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442805:Increase [Functional Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "similar weights to the nondiabetic controls."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   753   C0043100:Weights [Quantitative Concept]
   750   C0920298:Weight control [Therapeutic or Preventive Procedure]
   719 E C0005910:weight [Organism Attribute]
   719 E C1305866:weight [Diagnostic Procedure]
   719 E C1705104:Weight [Idea or Concept]
Processing 00000000.tx.73: Effects of treatments on biochemical and functional variables. 

Phrase: "Effects of treatments"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   824   C1518681:Treatment Effect [Finding]
   790   C1280500:effects [Qualitative Concept]
   756 E C2348382:Effect [Qualitative Concept]

Phrase: "on biochemical"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205474:Biochemical [Functional Concept]

Phrase: "and"

Phrase: "functional variables."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439828:variables [Qualitative Concept]
Processing 00000000.tx.74: Fidarestat significantly reduced flux through the sorbitol pathway (Table 1). 

Phrase: "Fidarestat significantly reduced flux through the sorbitol pathway"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C2348693:Flux [Natural Phenomenon or Process]

Phrase: "(Table 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.75: Indeed, the levels of both sorbitol and fructose were normalized by fidarestat at 2.0 mg/;kg. 

Phrase: "Indeed,"

Phrase: "the levels of both sorbitol"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   760   C0441889:Levels [Qualitative Concept]
   726 E C0456079:Level [Classification]
   726 E C1547707:Level [Geographic Area]
   726 E C2946261:Level [Pharmacologic Substance]

Phrase: "and"

Phrase: "fructose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016745:Fructose [Carbohydrate,Pharmacologic Substance]

Phrase: "were"

Phrase: "normalized by fidarestat at 2.0 mg/;kg."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   770   C0439272:mg kg [Quantitative Concept]
   767   C2346927:Mg+2 [Element, Ion, or Isotope,Pharmacologic Substance]
           Mg++
   744   C0022718:KG [Geographic Area]
   744   C0439209:kg [Quantitative Concept]
   744   C0439269:mg% [Quantitative Concept]
   744   C0905478:fidarestat [Organic Chemical,Pharmacologic Substance]
   744   C1882115:Normalized [Research Activity]
   744   C1960952:mg % [Quantitative Concept]
Processing 00000000.tx.76: The profound inhibition of flux through the pathway by fidarestat was associated with a significant increase in nerve glucose. 

Phrase: "The profound inhibition of flux"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0021467:Inhibition [Mental Process]
   760   C0021469:Inhibition [Molecular Function]
   760   C1628982:% inhibition [Quantitative Concept]
   760   C3463820:Inhibition [Activity]

Phrase: "through the pathway"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1704259:Pathway [Molecular Function]
  1000   C1705987:Pathway [Conceptual Entity]

Phrase: "by fidarestat"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0905478:fidarestat [Organic Chemical,Pharmacologic Substance]

Phrase: "was"

Phrase: "associated with a significant increase"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   806   C0332281:Associated with [Qualitative Concept]
           Associated
   760   C0237881:significant [Quantitative Concept]
   760   C0442805:Increase [Functional Concept]
   760   C0750502:Significant [Idea or Concept]
   760   C1546944:Significant [Qualitative Concept]
   726 E C0750490:Associate [Idea or Concept]
   726 E C1706221:Associate [Professional or Occupational Group]

Phrase: "in nerve glucose."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
Processing 00000000.tx.77: p38 MAP kinase was markedly activated in Western blots made from lumbar DRG from diabetic rats, without any significant change in the amount of protein expression. 

Phrase: "p38 MAP kinase"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
  1000   C1456380:p38 Mitogen Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   979 E C1120843:p38 Mitogen-Activated Protein Kinases [Amino Acid, Peptide, or Protein,Enzyme]
           p38 Protein Kinase
   937   C0752312:Mitogen-Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   884   C1979930:Mitogen-activated protein [Amino Acid, Peptide, or Protein]
   840   C0033640:PROTEIN KINASE [Amino Acid, Peptide, or Protein,Enzyme]
   804   C0018284:Mitogen [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0026249:Mitogen [Pharmacologic Substance]
   804   C0031727:Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   804   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C1879547:Activated [Activity]
   771 E C1515877:Activate [Functional Concept]

Phrase: "was"

Phrase: "markedly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0522501:Markedly [Qualitative Concept]

Phrase: "activated in Western blots"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   833   C0949466:Western Blots [Laboratory Procedure]
   799 E C0005863:Western Blot [Laboratory Procedure,Molecular Biology Research Technique]
   770   C1705493:Western [Spatial Concept]
   770   C1879547:Activated [Activity]
   737 E C1515877:Activate [Functional Concept]

Phrase: "made from lumbar DRG"
Meta Candidates (Total=17; Excluded=2; Pruned=0; Remaining=15)
   866   C0457468:Lumbar dorsal root ganglion [Body Part, Organ, or Organ Component]
   833   C0017070:Dorsal Root Ganglia [Body Part, Organ, or Organ Component]
           Dorsal Root
   799 E C1761610:Dorsal root ganglion [Body Part, Organ, or Organ Component]
   790   C0205955:Dorsal root [Body Part, Organ, or Organ Component]
   783   C0229020:Lumbar ganglia [Body Part, Organ, or Organ Component]
   783   C1281807:Lumbar ganglia [Body Part, Organ, or Organ Component]
   773   C1186181:root ganglion [Body Part, Organ, or Organ Component]
   753   C0017067:Ganglia [Body Part, Organ, or Organ Component]
   753   C0024090:Lumbar [Body Location or Region]
   753   C0040452:Root [Body Part, Organ, or Organ Component]
   753   C0205095:Dorsal [Spatial Concept]
   753   C0242726:Root [Plant]
   753   C1318154:Root [Body Part, Organ, or Organ Component]
   753   C1705917:Root [Idea or Concept]
   719 E C1258666:Ganglion, NOS [Acquired Abnormality,Disease or Syndrome]
   719   C1881534:Make [Functional Concept]

Phrase: "from diabetic rats,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0241863:DIABETIC [Finding]

Phrase: "without any significant change"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0392747:Change [Functional Concept]
   861   C0443172:change [Quantitative Concept]
   861   C1705241:Change [Quantitative Concept]

Phrase: "in the amount"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1265611:Amount [Quantitative Concept]

Phrase: "of protein expression."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1171362:protein expression [Genetic Function]
   861   C0185117:Expression [Therapeutic or Preventive Procedure]
Processing 00000000.tx.78: This was consistent throughout all treatment experiments (all data in Fig. 1). 

Phrase: "This"

Phrase: "was"

Phrase: "consistent throughout all treatment experiments"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0332290:Consistent [Idea or Concept]

Phrase: "("

Phrase: "all data in Fig. 1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1511726:Data [Idea or Concept]
   760   C3245479:data [Medical Device]

Phrase: ")."
Processing 00000000.tx.79: Treatment with fidarestat reduced p38 activation below that of controls, and this effect was also seen by immunocytochemistry (see below). 

Phrase: "Treatment with fidarestat reduced p38 activation"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   753   C0039798:treatment [Functional Concept]
   753   C0087111:Treatment [Therapeutic or Preventive Procedure]
   753   C1522326:Treatment [Functional Concept]
   753   C1533734:Treatment [Therapeutic or Preventive Procedure]
   753   C1705169:Treatment [Conceptual Entity]
   753   C3538994:TREATMENT [Research Activity]

Phrase: "below that"

Phrase: "of controls,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   966   C0243148:control [Qualitative Concept]
   966   C1550141:Control [Substance]
   966   C1882979:Control [Conceptual Entity]
   966   C2587213:Control [Functional Concept]
   966   C3274648:Control [Qualitative Concept]

Phrase: "and"

Phrase: "this effect"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1280500:Effect [Qualitative Concept]
  1000   C2348382:Effect [Qualitative Concept]

Phrase: "was"

Phrase: "also"

Phrase: "seen by immunocytochemistry"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C0205397:Seen [Qualitative Concept]
   790   C0242349:Immunocytochemistry [Laboratory Procedure]
   756 E C0042789:see [Organism Function]
   756 E C1947903:See [Activity]

Phrase: "("

Phrase: "see below"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C0042789:see [Organism Function]
   833   C1947903:See [Activity]

Phrase: ")."
Processing 00000000.tx.80: Insulin treatment for the final 4 weeks of the protocol also normalized the activation of p38, as did treatment with SB 239063 (Fig. 1). 

Phrase: "Insulin treatment for the final 4 weeks of the protocol also"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   756   C0745343:insulin treatment [Therapeutic or Preventive Procedure]
   754   C0040808:Treatment Protocol [Therapeutic or Preventive Procedure]
   738   C0039798:treatment [Functional Concept]
   738   C0087111:Treatment [Therapeutic or Preventive Procedure]
   738   C1522326:Treatment [Functional Concept]
   738   C1533734:Treatment [Therapeutic or Preventive Procedure]
   738   C1705169:Treatment [Conceptual Entity]
   738   C3538994:TREATMENT [Research Activity]

Phrase: "normalized"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882115:Normalized [Research Activity]

Phrase: "the activation of p38,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1879547:Activation [Activity]

Phrase: "as"

Phrase: "did"

Phrase: "treatment with SB 239063"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C0039798:treatment [Functional Concept]
   770   C0087111:Treatment [Therapeutic or Preventive Procedure]
   770   C1522326:Treatment [Functional Concept]
   770   C1533734:Treatment [Therapeutic or Preventive Procedure]
   770   C1705169:Treatment [Conceptual Entity]
   770   C3538994:TREATMENT [Research Activity]

Phrase: "(Fig. 1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.81: This was evident in Western blots from DRG, and because the MAP kinase may have had effects on the nerve axons in relation to its effect on nerve conduction, we also found inhibition of the enzyme in blots made from the sciatic nerve (Fig. 2). 

Phrase: "This"

Phrase: "was"

Phrase: "evident in Western blots"

Phrase: "from DRG,"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
  1000   C0017070:Dorsal Root Ganglia [Body Part, Organ, or Organ Component]
           Dorsal Root
   966 E C1761610:Dorsal root ganglion [Body Part, Organ, or Organ Component]
   901   C0205955:Dorsal root [Body Part, Organ, or Organ Component]
   884   C1186181:root ganglion [Body Part, Organ, or Organ Component]
   827   C0017067:Ganglia [Body Part, Organ, or Organ Component]
   827   C0040452:Root [Body Part, Organ, or Organ Component]
   827   C0205095:Dorsal [Spatial Concept]
   827   C0242726:Root [Plant]
   827   C1318154:Root [Body Part, Organ, or Organ Component]
   827   C1705917:Root [Idea or Concept]
   793 E C1258666:Ganglion, NOS [Acquired Abnormality,Disease or Syndrome]

Phrase: "and"

Phrase: "because"

Phrase: "the MAP kinase"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
  1000   C0752312:Mitogen-Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   923   C1979930:Mitogen-activated protein [Amino Acid, Peptide, or Protein]
   861   C0033640:PROTEIN KINASE [Amino Acid, Peptide, or Protein,Enzyme]
   812   C0018284:Mitogen [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   812   C0026249:Mitogen [Pharmacologic Substance]
   812   C0031727:Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   812   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   812   C1879547:Activated [Activity]
   779 E C1515877:Activate [Functional Concept]

Phrase: "may"

Phrase: "have"

Phrase: "had"

Phrase: "effects on the nerve axons"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C1280500:effects [Qualitative Concept]
   726 E C2348382:Effect [Qualitative Concept]

Phrase: "in relation to its effect"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1280500:Effect [Qualitative Concept]
  1000   C2348382:Effect [Qualitative Concept]

Phrase: "on nerve conduction,"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C0027788:Nerve Conduction [Organ or Tissue Function]
   861   C0027740:Nerve [Tissue]
   861   C0027757:NERVE [Tissue]
   861   C0232217:Conduction [Organ or Tissue Function]
   861   C0457405:Conduction [Natural Phenomenon or Process]
   861   C1280541:Nerve [Body Part, Organ, or Organ Component]
   805 E C0599851:Neural [Functional Concept]
   789 E C0027769:nervy [Sign or Symptom]

Phrase: "we also found inhibition of the enzyme"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   774   C0877008:enzyme inhibition [Disease or Syndrome]
   774   C1524081:Enzyme Inhibition [Physiologic Function]
   748   C0021467:Inhibition [Mental Process]
   748   C0021469:Inhibition [Molecular Function]
   748   C1628982:% inhibition [Quantitative Concept]
   748   C3463820:Inhibition [Activity]

Phrase: "in blots"

Phrase: "made from the sciatic nerve"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   806   C0036394:Sciatic Nerve [Body Part, Organ, or Organ Component]
   806   C1278851:Sciatic nerve [Body Part, Organ, or Organ Component]
   760   C0027740:Nerve [Tissue]
   760   C0027757:NERVE [Tissue]
   760   C1280541:Nerve [Body Part, Organ, or Organ Component]
   726   C1881534:Make [Functional Concept]
   704 E C0599851:Neural [Functional Concept]

Phrase: "(Fig. 2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.82: In all cases, treatment resulted in a level of active p38 similar to the physiological levels of active p38 displayed by control animals. 

Phrase: "In all cases,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0868928:Cases [Functional Concept]
  1000   C1533148:Cases [Quantitative Concept]
   966 E C1706255:CASE [Medical Device]
   966 E C1706256:Case [Conceptual Entity]

Phrase: "treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "resulted in a level of active p38"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   748   C0205177:Active [Functional Concept]
   748   C0441889:Level [Qualitative Concept]
   748   C0456079:Level [Classification]
   748   C1547707:Level [Geographic Area]
   748   C2946261:Level [Pharmacologic Substance]
   714   C1274040:Result [Functional Concept]
   714   C1546471:Result [Idea or Concept]
   714   C2825142:Result [Finding]

Phrase: "similar to the physiological levels of active p38"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C2348205:Similar [Qualitative Concept]

Phrase: "displayed by control animals."
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   799   C1511501:Control Animal [Animal]
   770   C0003062:Animals [Animal]
   770   C0243148:control [Qualitative Concept]
   770   C0870432:displayed [Functional Concept]
   770   C1550141:Control [Substance]
   770   C1882979:Control [Conceptual Entity]
   770   C2587213:Control [Functional Concept]
   770   C3274648:Control [Qualitative Concept]
   737 E C1705417:Display [Manufactured Object]
Processing 00000000.tx.83: The dose of SB 239063 was slightly lower than the dose that has been demonstrated (14) to display complete inhibition of p38. 

Phrase: "The dose of SB 239063"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0178602:Dose [Quantitative Concept]
   760   C0869039:Dose [Quantitative Concept]
   760   C1114758:Dose # [Clinical Attribute]

Phrase: "was"

Phrase: "slightly lower than the dose"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0441994:Lower [Spatial Concept]
   760   C1548802:Lower [Body Location or Region]
   760   C2003888:Lower [Activity]

Phrase: "that"

Phrase: "has"

Phrase: "been"

Phrase: "demonstrated"

Phrase: "(14"

Phrase: ")"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "display"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705417:Display [Manufactured Object]

Phrase: "complete inhibition of p38."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0021467:Inhibition [Mental Process]
   770   C0021469:Inhibition [Molecular Function]
   770   C1628982:% inhibition [Quantitative Concept]
   770   C3463820:Inhibition [Activity]
Processing 00000000.tx.84: Alternatively, the phosphospecific p38 antibody recognizes the -isoform of p38, which is not inhibited by SB 239063. 

Phrase: "Alternatively,"

Phrase: "the phosphospecific p38 antibody"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   913   C1257988:Phosphospecific Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   827   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "recognizes"

Phrase: "the -isoform of p38,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0597298:Isoform [Amino Acid, Peptide, or Protein]

Phrase: "which"

Phrase: "is"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "inhibited by SB 239063."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C0913456:SB 239063 [Organic Chemical]
   770   C0311403:Inhibited [Qualitative Concept]
Processing 00000000.tx.85: Ganglia from these SB 239063treated rats were also subjected to Western blotting for extracellular signalrelated kinase and c-Jun NH2-terminal kinase to monitor specificity of the enzyme against the other MAP kinases, both of which are reproducibly activated by STZ-induced diabetes (7). 

Phrase: "Ganglia from these SB 239063treated rats"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C0017067:Ganglia [Body Part, Organ, or Organ Component]
   719 E C1258666:Ganglion, NOS [Acquired Abnormality,Disease or Syndrome]

Phrase: "were"

Phrase: "also"

Phrase: "subjected to Western blotting"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   833   C0005863:Western Blotting [Laboratory Procedure,Molecular Biology Research Technique]
   816 E C0949466:Western Blot [Laboratory Procedure]
   770   C1705493:Western [Spatial Concept]
   737   C0681850:Subject [Group]
   737   C1550501:{Subject} [Idea or Concept]
   737   C1706203:Subject [Idea or Concept]
   737   C2349001:Subject [Human]
   737   C2697811:Subject [Functional Concept]

Phrase: "for extracellular signalrelated kinase"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0031727:Kinase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "and"

Phrase: "c-Jun NH2-terminal kinase to"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   901   C0248813:jun-NH2-Terminal Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   885   C0872123:c JUN kinase [Amino Acid, Peptide, or Protein,Enzyme]
   858   C0872053:JUN kinase [Amino Acid, Peptide, or Protein,Enzyme]
   858   C1334482:Jun kinase [Gene or Genome]
   858   C1367019:Jun Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   799   C0031727:Kinase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "monitor"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0030695:monitor [Health Care Activity]
  1000   C0150369:monitor [Health Care Activity]
  1000   C0181904:Monitor [Medical Device]
  1000   C0596972:Monitor [Medical Device]
  1000   C1521743:Monitor [Professional or Occupational Group]
  1000   C1704646:Monitor [Manufactured Object]

Phrase: "specificity of the enzyme"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   819   C0678612:enzyme specificity [Natural Phenomenon or Process]
   770   C0037791:Specificity [Quantitative Concept]
   770   C1511884:Specificity [Quantitative Concept]

Phrase: "against the"

Phrase: "other MAP kinases,"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
  1000   C0752312:Mitogen-Activated Protein Kinases [Amino Acid, Peptide, or Protein,Enzyme]
   923   C1979930:Mitogen-activated protein [Amino Acid, Peptide, or Protein]
   861   C0033640:Protein Kinases [Amino Acid, Peptide, or Protein,Enzyme]
   812   C0018284:Mitogen [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   812   C0026249:Mitogen [Pharmacologic Substance]
   812   C0031727:Kinases [Amino Acid, Peptide, or Protein,Enzyme]
   812   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   812   C1879547:Activated [Activity]
   779 E C1515877:Activate [Functional Concept]

Phrase: "both of which"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0238767:Both [Spatial Concept]
   790   C1706086:Both [Qualitative Concept]

Phrase: "are"

Phrase: "reproducibly"

Phrase: "activated by STZ-induced diabetes"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   760   C0011847:Diabetes [Disease or Syndrome]
   760   C0011849:Diabetes [Disease or Syndrome]
   760   C0038432:STZ [Antibiotic,Carbohydrate]
   760   C0205263:Induced [Functional Concept]
   760   C1539862:STZ [Gene or Genome]
   760   C1879547:Activated [Activity]
   726 E C1515877:Activate [Functional Concept]

Phrase: "(7"

Phrase: ")."
Processing 00000000.tx.86: The inhibitor was without effect. 

Phrase: "The inhibitor"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999216:Inhibitor [Qualitative Concept]

Phrase: "was without effect."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C0043194:WAS [Disease or Syndrome]
   790   C0258432:WAS [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   790   C1280500:Effect [Qualitative Concept]
   790   C1421478:WAS [Gene or Genome]
   790   C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.87: View larger version (46K): [in this window] [in a new window]  FIG. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(46K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  FIG."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.88: 1. 

Phrase: "1."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]
Processing 00000000.tx.89: Bar charts from three experiments showing the effects of treatment of diabetic rats with the aldose reductase inhibitor, fidarestat (2 mg  kg1  day1 per os), with insulin (subcutaneous implants), and the specific inhibitor of p38 MAP kinase, SB 239063 (20 mg  kg1  day1 per os) on diabetes-induced activation of p38. 

Phrase: "Bar charts from three experiments"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0684240:Charts [Intellectual Product]
   726 E C0007963:chart [Medical Device]

Phrase: "showing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "the effects of treatment of diabetic rats"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   757   C1518681:Treatment Effect [Finding]
   748   C1280500:effects [Qualitative Concept]
   714 E C2348382:Effect [Qualitative Concept]

Phrase: "with the aldose reductase inhibitor,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C2348243:Aldose Reductase Inhibitor [Pharmacologic Substance]
   901   C0002003:Aldose Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   901   C1412322:ALDOSE REDUCTASE [Gene or Genome]
   827   C0030016:Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0682934:Aldose [Carbohydrate]
   827   C1999216:Inhibitor [Qualitative Concept]

Phrase: "fidarestat"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0905478:fidarestat [Organic Chemical,Pharmacologic Substance]

Phrase: "(2 mg  kg1  day1 per os"

Phrase: ")"

Phrase: ","

Phrase: "with insulin"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1579433:Insulin [Pharmacologic Substance]
   944 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "(subcutaneous implants"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0021102:Implants [Medical Device]
   861   C2926601:Implants [Clinical Attribute]
   827 E C0021107:implant [Therapeutic or Preventive Procedure]
   827 E C0332837:Implant [Injury or Poisoning]
   827 E C1711357:Implant [Functional Concept]

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "the specific inhibitor of p38 MAP kinase,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   838   C1513344:Mitogen-Activated Protein Kinase Inhibitor [Pharmacologic Substance]
   784   C1449702:Protein kinase inhibitor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   762   C1171350:Kinase Inhibitor [Pharmacologic Substance]
   762   C3537023:kinase inhibitor [Molecular Function]
   762   C3537035:kinase inhibitor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   742   C1999216:Inhibitor [Qualitative Concept]

Phrase: "SB 239063"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0913456:SB 239063 [Organic Chemical]

Phrase: "(20 mg  kg1  day1 per os"

Phrase: ")"

Phrase: "on diabetes-induced activation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1879547:Activation [Activity]

Phrase: "of p38."
Processing 00000000.tx.90: Open columns () show control rats, filled columns () show untreated diabetic rats, and shaded columns (, , or ) show animals treated with insulin, fidarestat, and SB239063, respectively. 

Phrase: "Open columns"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1185738:Column [Body Part, Organ, or Organ Component]
   827   C1706132:Column [Idea or Concept]

Phrase: "("

Phrase: ")"

Phrase: "show"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "control rats,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]

Phrase: "filled columns"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1185738:Column [Body Part, Organ, or Organ Component]
   827   C1706132:Column [Idea or Concept]

Phrase: "("

Phrase: ")"

Phrase: "show"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "untreated diabetic rats,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0034693:rats [Mammal]
   827   C0034721:Rats [Mammal]
   827   C0241863:DIABETIC [Finding]

Phrase: "and"

Phrase: "shaded columns"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1185738:Column [Body Part, Organ, or Organ Component]
   827   C1706132:Column [Idea or Concept]

Phrase: "(,"

Phrase: ", or )"

Phrase: "show"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "animals"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0003062:Animals [Animal]

Phrase: "treated with insulin,"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   882   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   790   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   790   C1522326:Treated [Functional Concept]
   790   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   790   C1579433:Insulin [Pharmacologic Substance]
   756 E C1292734:TREAT [Functional Concept]
   734 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   706 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "fidarestat,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0905478:fidarestat [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "SB239063,"

Phrase: "respectively."
Processing 00000000.tx.91: Error bars show 1 SD. 

Phrase: "Error bars"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1707156:BARS [Gene or Genome]
   861   C3274014:BARS [Intellectual Product]
   861   C3541345:BARS [Intellectual Product]

Phrase: "show"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "1 SD."
Processing 00000000.tx.92: In all cases, the effect of diabetes against controls was significant (P < 0.01), as were the effects of fidarestat, insulin, and SB 239063 against their untreated diabetic groups (P < 0.01). 

Phrase: "In all cases,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0868928:Cases [Functional Concept]
  1000   C1533148:Cases [Quantitative Concept]
   966 E C1706255:CASE [Medical Device]
   966 E C1706256:Case [Conceptual Entity]

Phrase: "the effect of diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1280500:Effect [Qualitative Concept]
   770   C2348382:Effect [Qualitative Concept]

Phrase: "against controls"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   966   C0243148:control [Qualitative Concept]
   966   C1550141:Control [Substance]
   966   C1882979:Control [Conceptual Entity]
   966   C2587213:Control [Functional Concept]
   966   C3274648:Control [Qualitative Concept]

Phrase: "was"

Phrase: "significant"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0237881:significant [Quantitative Concept]
  1000   C0750502:Significant [Idea or Concept]
  1000   C1546944:Significant [Qualitative Concept]

Phrase: "(P < 0.01"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: ")"

Phrase: ","

Phrase: "as"

Phrase: "were"

Phrase: "the effects of fidarestat,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C1280500:effects [Qualitative Concept]
   737 E C2348382:Effect [Qualitative Concept]

Phrase: "insulin,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1579433:Insulin [Pharmacologic Substance]
   944 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "SB 239063 against their untreated diabetic groups"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   778   C0913456:SB 239063 [Organic Chemical]
   748   C0241863:DIABETIC [Finding]
   748   C0332155:untreated [Finding]
   748   C0441833:Group [Idea or Concept]
   748   C0687744:group [Population Group]
   748   C1257890:Group [Population Group]
   748   C1552516:Group [Health Care Related Organization]
   748   C1552839:groups [Idea or Concept]
   748   C1705428:Group [Conceptual Entity]
   748   C1705429:Group [Population Group]

Phrase: "(P < 0.01"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: ")."
Processing 00000000.tx.93: Below are shown sample gels from the fidarestat study. 

Phrase: "Below"

Phrase: "are"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "sample"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0370003:Sample [Substance]
  1000   C2347026:Sample [Conceptual Entity]

Phrase: "gels from the fidarestat study."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0017243:Gels [Biomedical or Dental Material]
   726 E C1382104:Gel [Substance]
Processing 00000000.tx.94: The same samples are shown in the upper pair of gels (immunostained for phosphorylated p38) as in the lower pair (immunostained for total p38). 

Phrase: "The same samples"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0370003:Sample [Substance]
   827   C2347026:Sample [Conceptual Entity]

Phrase: "are"

Phrase: "shown in the upper pair of gels"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   748   C0017243:Gels [Biomedical or Dental Material]
   748   C1282910:Upper [Spatial Concept]
   748   C1709450:Pair [Qualitative Concept]
   714 E C1382104:Gel [Substance]
   714   C1547282:Show [Intellectual Product]

Phrase: "("

Phrase: "immunostained for phosphorylated p38"

Phrase: ")"

Phrase: "as in the lower pair"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0441994:Lower [Spatial Concept]
   760   C1548802:Lower [Body Location or Region]
   760   C1709450:Pair [Qualitative Concept]
   760   C2003888:Lower [Activity]

Phrase: "("

Phrase: "immunostained for total p38"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0439175:% total [Quantitative Concept]
   770   C0439810:Total [Qualitative Concept]

Phrase: ")."
Processing 00000000.tx.95: C, control rats; 

Phrase: "C,"

Phrase: "control rats"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]

Phrase: ";"
Processing 00000000.tx.96: DF, fidarestat-treated diabetic rats; 

Phrase: "DF,"

Phrase: "fidarestat-treated diabetic rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0034693:rats [Mammal]
   812   C0034721:Rats [Mammal]
   812   C0241863:DIABETIC [Finding]

Phrase: ";"
Processing 00000000.tx.97: UD, untreated diabetic rats.  

Phrase: "UD,"

Phrase: "untreated diabetic rats."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0034693:rats [Mammal]
   827   C0034721:Rats [Mammal]
   827   C0241863:DIABETIC [Finding]
Processing 00000000.tx.98: View larger version (33K): [in this window] [in a new window]  FIG. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(33K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  FIG."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.99: 2. 

Phrase: "2."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]
Processing 00000000.tx.100: Western blots showing p38 MAPK activation in the sciatic nerve. 

Phrase: "Western blots"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0949466:Western Blots [Laboratory Procedure]
   966 E C0005863:Western Blot [Laboratory Procedure,Molecular Biology Research Technique]
   861   C1705493:Western [Spatial Concept]

Phrase: "showing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "p38 MAPK activation in the sciatic nerve."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   778   C1155551:MAPK activation [Molecular Function]
   748   C1879547:Activation [Activity]
Processing 00000000.tx.101: In nerve from diabetic rats, the level of activation relative to controls (P < 0.01) was similar to that seen in DRG (Fig. 1) and, as with DRG, was blocked completely (P < 0.01) by treatment with the inhibitor SB 239063. 

Phrase: "In nerve"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0027740:Nerve [Tissue]
  1000   C0027757:NERVE [Tissue]
  1000   C1280541:Nerve [Body Part, Organ, or Organ Component]
   944 E C0599851:Neural [Functional Concept]
   928 E C0027769:nervy [Sign or Symptom]

Phrase: "from diabetic rats,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0241863:DIABETIC [Finding]

Phrase: "the level of activation"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0441889:Level [Qualitative Concept]
   770   C0456079:Level [Classification]
   770   C1547707:Level [Geographic Area]
   770   C2946261:Level [Pharmacologic Substance]

Phrase: "relative to controls"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0080103:Relative [Family Group]
   790   C0205345:Relative [Qualitative Concept]
   790   C1547039:*Relative [Quantitative Concept]

Phrase: "(P < 0.01"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: ")"

Phrase: "was"

Phrase: "similar to that"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C2348205:Similar [Qualitative Concept]

Phrase: "seen in DRG"
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
   862   C0017070:Dorsal Root Ganglia [Body Part, Organ, or Organ Component]
           Dorsal Root
   828 E C1761610:Dorsal root ganglion [Body Part, Organ, or Organ Component]
   806   C0205955:Dorsal root [Body Part, Organ, or Organ Component]
   790   C1186181:root ganglion [Body Part, Organ, or Organ Component]
   760   C0017067:Ganglia [Body Part, Organ, or Organ Component]
   760   C0040452:Root [Body Part, Organ, or Organ Component]
   760   C0205095:Dorsal [Spatial Concept]
   760   C0205397:Seen [Qualitative Concept]
   760   C0242726:Root [Plant]
   760   C1318154:Root [Body Part, Organ, or Organ Component]
   760   C1705917:Root [Idea or Concept]
   726 E C0042789:see [Organism Function]
   726 E C1258666:Ganglion, NOS [Acquired Abnormality,Disease or Syndrome]
   726 E C1947903:See [Activity]

Phrase: "(Fig. 1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")"

Phrase: "and"

Phrase: ","

Phrase: "as with DRG,"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
   862   C0017070:Dorsal Root Ganglia [Body Part, Organ, or Organ Component]
           Dorsal Root
   828 E C1761610:Dorsal root ganglion [Body Part, Organ, or Organ Component]
   806   C0205955:Dorsal root [Body Part, Organ, or Organ Component]
   790   C1186181:root ganglion [Body Part, Organ, or Organ Component]
   760   C0017067:Ganglia [Body Part, Organ, or Organ Component]
   760   C0040452:Root [Body Part, Organ, or Organ Component]
   760   C0205095:Dorsal [Spatial Concept]
   760   C0242726:Root [Plant]
   760   C1318154:Root [Body Part, Organ, or Organ Component]
   760   C1705917:Root [Idea or Concept]
   726 E C1258666:Ganglion, NOS [Acquired Abnormality,Disease or Syndrome]

Phrase: "was"

Phrase: "blocked"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0028778:Blocked [Pathologic Function]
  1000   C0332206:Blocked [Functional Concept]
  1000   C2983591:BLOCKED [Research Activity]
   966 E C1533157:Block [Substance]
   966 E C1706084:Block [Geographic Area]
   966 E C2828370:Block [Quantitative Concept]

Phrase: "completely"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205197:Completely [Qualitative Concept]

Phrase: "(P < 0.01"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: ")"

Phrase: "by treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "with the inhibitor SB 239063."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0913456:SB 239063 [Organic Chemical]
   827   C1999216:Inhibitor [Qualitative Concept]
Processing 00000000.tx.102: C, control rats; 

Phrase: "C,"

Phrase: "control rats"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]

Phrase: ";"
Processing 00000000.tx.103: D, diabetic rats; 

Phrase: "D,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0073187:D NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "diabetic rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0241863:DIABETIC [Finding]

Phrase: ";"
Processing 00000000.tx.104: DI, diabetic rats treated with the p38 inhibitor SB239063.  

Phrase: "DI,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C3538902:DI [Gene or Genome]
  1000   C3541881:DI [Idea or Concept]

Phrase: "diabetic rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0241863:DIABETIC [Finding]

Phrase: "treated with the p38 inhibitor SB239063."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   790   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   753   C1522326:Treated [Functional Concept]
   753   C1999216:Inhibitor [Qualitative Concept]
   719 E C1292734:TREAT [Functional Concept]
Processing 00000000.tx.105: Immunocytochemistry on DRG and spinal cord sections was carried out in 10 control, 10 untreated diabetic, 10 fidarestat-treated diabetic, and 5 SB 239063treated diabetic rats using the phosphospecific p38 antibody. 

Phrase: "Immunocytochemistry on DRG"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0242349:Immunocytochemistry [Laboratory Procedure]

Phrase: "and"

Phrase: "spinal cord sections"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   793   C0205155:Section [Spatial Concept]
   793   C1293097:Section, NOS [Therapeutic or Preventive Procedure]
   793   C1522472:Section [Substance]
   793   C1552923:Section [Quantitative Concept]
   793   C1705191:Section [Physical Object]
   734   C0037925:Spinal Cord [Body Part, Organ, or Organ Component]
   734   C1278836:Spinal cord [Body Part, Organ, or Organ Component]

Phrase: "was"

Phrase: "carried"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0206243:carried [Activity]
  1000   C0699809:carried [Finding]

Phrase: "out in 10 control,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   770   C0243148:control [Qualitative Concept]
   770   C0439787:Out [Spatial Concept]
   770   C0849355:Out [Qualitative Concept]
   770   C1550141:Control [Substance]
   770   C1882979:Control [Conceptual Entity]
   770   C2587213:Control [Functional Concept]
   770   C3274648:Control [Qualitative Concept]

Phrase: "10 untreated diabetic, 10 fidarestat-treated diabetic,"

Phrase: "and"

Phrase: "5 SB 239063treated diabetic rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   804   C0034693:rats [Mammal]
   804   C0034721:Rats [Mammal]
   804   C0241863:DIABETIC [Finding]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the phosphospecific p38 antibody."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   913   C1257988:Phosphospecific Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   827   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
Processing 00000000.tx.106: These results confirmed those obtained by Western blotting, and typical micrographs from animals from each of these groups are shown in Fig. 

Phrase: "These results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "confirmed"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0521093:confirmed [Qualitative Concept]
  1000   C0750484:Confirmed [Idea or Concept]
   966 E C1456348:Confirm [Qualitative Concept]

Phrase: "those"

Phrase: "obtained by Western blotting,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   833   C0005863:Western Blotting [Laboratory Procedure,Molecular Biology Research Technique]
   816 E C0949466:Western Blot [Laboratory Procedure]
   770   C1301820:Obtained [Functional Concept]
   770   C1705493:Western [Spatial Concept]
   737 E C1706701:Obtain [Activity]

Phrase: "and"

Phrase: "typical micrographs from animals"

Phrase: "from each"

Phrase: "of these groups"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0441833:Group [Idea or Concept]
  1000   C0687744:group [Population Group]
  1000   C1257890:Group [Population Group]
  1000   C1552516:Group [Health Care Related Organization]
  1000   C1552839:groups [Idea or Concept]
  1000   C1705428:Group [Conceptual Entity]
  1000   C1705429:Group [Population Group]

Phrase: "are"

Phrase: "shown in Fig."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0349966:Fig [Food]
   790   C1337208:FIG [Food]
   756   C1547282:Show [Intellectual Product]
Processing 00000000.tx.107: 3. 

Phrase: "3."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]
Processing 00000000.tx.108: Sections exposed to secondary antibody without prior exposure to the phosho-p38 antiserum showed no immunoreactivity (Fig. 3E). 

Phrase: "Sections"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   966   C0205155:Section [Spatial Concept]
   966   C1293097:Section, NOS [Therapeutic or Preventive Procedure]
   966   C1522472:Section [Substance]
   966   C1552923:Section [Quantitative Concept]
   966   C1705191:Section [Physical Object]

Phrase: "exposed to secondary antibody"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   833   C0332157:Exposed to [Clinical Attribute]
           Exposed
   819   C0175668:Secondary to [Temporal Concept]
           Secondary
   770   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   770   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   770   C0027627:secondary [Neoplastic Process]
   770   C0205436:Secondary [Quantitative Concept]

Phrase: "without prior exposure"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0274281:Exposure, NOS [Injury or Poisoning]
   861   C0332157:Exposure [Clinical Attribute]

Phrase: "to the phosho-p38 antiserum"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0020960:Antiserum [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "no immunoreactivity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0597879:immunoreactivity [Molecular Function]

Phrase: "(Fig. 3E"

Phrase: ")."
Processing 00000000.tx.109: Ganglia from control rats showed patchy immunofluorescence from the phospho-p38 antibody. 

Phrase: "Ganglia from control rats"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0017067:Ganglia [Body Part, Organ, or Organ Component]
   737 E C1258666:Ganglion, NOS [Acquired Abnormality,Disease or Syndrome]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "patchy immunofluorescence from the phospho-p38 antibody."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0016318:Immunofluorescence [Laboratory Procedure]
   748   C0079603:Immunofluorescence [Laboratory Procedure]
Processing 00000000.tx.110: This was not clearly related to any identifiable neuronal phenotype, such that examples of both large and small cell-body nuclei showed punctate fluorescence of varying intensities. 

Phrase: "This"

Phrase: "was"

Phrase: "not clearly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1518422:Not [Functional Concept]

Phrase: "related to any identifiable neuronal phenotype,"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   753   C0031437:Phenotype [Organism Attribute]
   753   C0205396:Identifiable [Qualitative Concept]
   753   C0439849:Related [Qualitative Concept]
   753   C0445223:Related [Finding]
   753   C0521390:Neuronal [Immunologic Factor]
   753   C1285572:Phenotype [Laboratory Procedure]
   753   C1705683:Identifiable [Conceptual Entity]
   719 E C0163712:Relate [Organic Chemical]

Phrase: "such"

Phrase: "that examples of both large"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   726   C1707959:Example [Conceptual Entity]

Phrase: "and"

Phrase: "small cell-body nuclei"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   875   C0007610:Cell Nuclei [Cell Component]
           Nucleus

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "punctate fluorescence of varying intensities."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0016315:Fluorescence [Natural Phenomenon or Process]
Processing 00000000.tx.111: In striking contrast, ganglia from diabetic rats displayed intense fluorescence in virtually all neuronal nuclei, indicating a strong activation of p38. 

Phrase: "In striking contrast,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1979874:Contrast [Qualitative Concept]

Phrase: "ganglia from diabetic rats"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0017067:Ganglia [Body Part, Organ, or Organ Component]
   737 E C1258666:Ganglion, NOS [Acquired Abnormality,Disease or Syndrome]

Phrase: "displayed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0870432:displayed [Functional Concept]
   966 E C1705417:Display [Manufactured Object]

Phrase: "intense fluorescence in virtually"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0016315:Fluorescence [Natural Phenomenon or Process]

Phrase: "all neuronal nuclei,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C3146324:neuronal nuclei [Gene or Genome]
   827   C0007610:Nucleus [Cell Component]

Phrase: "indicating"

Phrase: "a strong activation of p38."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1879547:Activation [Activity]
Processing 00000000.tx.112: There was also a diffuse fluorescence in the cytoplasm of many cells. 

Phrase: "There"

Phrase: "was"

Phrase: "also"

Phrase: "a diffuse fluorescence in the cytoplasm of many cells."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0016315:Fluorescence [Natural Phenomenon or Process]
Processing 00000000.tx.113: This predominantly nuclear localization is consistent with the notion that activated p38 is translocated to the nucleus, where it can have profound effects on gene transcription. 

Phrase: "This predominantly nuclear localization"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0475264:Localisation [Functional Concept]
   827   C1744691:localisation [Biologic Function]

Phrase: "is"

Phrase: "consistent with the notion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C0332290:Consistent with [Idea or Concept]
           Consistent

Phrase: "that activated p38"

Phrase: "is"

Phrase: "translocated to the nucleus,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0007610:Nucleus [Cell Component]

Phrase: "where"

Phrase: "it"

Phrase: "can"

Phrase: "have"

Phrase: "profound effects on gene transcription."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C1280500:effects [Qualitative Concept]
   726 E C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.114: The diabetes-induced activation was clearly prevented by fidarestat, demonstrated by the distinct reduction in fluorescence so that the general level of fluorescence in neuronal nuclei appeared to be lower than that of controls (Fig. 3). 

Phrase: "The diabetes-induced activation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1879547:Activation [Activity]

Phrase: "was"

Phrase: "clearly"

Phrase: "prevented by fidarestat,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0905478:fidarestat [Organic Chemical,Pharmacologic Substance]
   756   C0309872:PREVENT [Pharmacologic Substance]

Phrase: "demonstrated by the distinct reduction"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0301630:Reduction [Natural Phenomenon or Process]
   760   C0392756:Reduction [Qualitative Concept]
   760   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "in fluorescence"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0016315:Fluorescence [Natural Phenomenon or Process]
   928 E C0303920:Fluorescent [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "so"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0037640:SO [Geographic Area]

Phrase: "that"

Phrase: "the general level of fluorescence"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0441889:Level [Qualitative Concept]
   760   C0456079:Level [Classification]
   760   C1547707:Level [Geographic Area]
   760   C2946261:Level [Pharmacologic Substance]

Phrase: "in neuronal nuclei"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C3146324:neuronal nuclei [Gene or Genome]
   827   C0007610:Nucleus [Cell Component]

Phrase: "appeared"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0700364:APPEAR [Qualitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "lower than that of controls"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0441994:Lower [Spatial Concept]
   760   C1548802:Lower [Body Location or Region]
   760   C2003888:Lower [Activity]

Phrase: "(Fig. 3"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.115: Nuclear fluorescence in DRG cells was also prevented by treatment with SB 239063. 

Phrase: "Nuclear fluorescence in DRG cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0016315:Fluorescence [Natural Phenomenon or Process]

Phrase: "was"

Phrase: "also"

Phrase: "prevented by treatment"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   790   C0039798:treatment [Functional Concept]
   790   C0087111:Treatment [Therapeutic or Preventive Procedure]
   790   C1522326:Treatment [Functional Concept]
   790   C1533734:Treatment [Therapeutic or Preventive Procedure]
   790   C1705169:Treatment [Conceptual Entity]
   790   C3538994:TREATMENT [Research Activity]
   756   C0309872:PREVENT [Pharmacologic Substance]

Phrase: "with SB 239063."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0913456:SB 239063 [Organic Chemical]
Processing 00000000.tx.116: In the L1 spinal cord, diabetes promoted p38 MAP kinase activation in motoneuron cell bodies, which was identified by colocalization of choline acetyltransferase (ChAT) (Fig. 3). 

Phrase: "In the L1 spinal cord,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   901   C0037925:Spinal Cord [Body Part, Organ, or Organ Component]
   901   C1278836:Spinal cord [Body Part, Organ, or Organ Component]
   827   C0521329:Spinal [Spatial Concept]
   827   C1550235:Cord [Body Part, Organ, or Organ Component]
   827   C1552938:cord [Quantitative Concept]
   827   C1706500:Cord [Manufactured Object]

Phrase: "diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]

Phrase: "promoted"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0033414:Promote [Activity]

Phrase: "p38 MAP kinase activation in motoneuron cell bodies,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   782   C1819041:protein kinase activation [Cell Function]
   757   C0599177:protein activation [Genetic Function]
   757   C1326120:cell activation [Cell Function]
   739   C1879547:Activation [Activity]

Phrase: "which"

Phrase: "was"

Phrase: "identified by colocalization of choline acetyltransferase (ChAT)"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   790   C0008407:Choline Acetyltransferase [Amino Acid, Peptide, or Protein,Enzyme]
   790   C1413376:CHOLINE ACETYLTRANSFERASE [Gene or Genome]
   753   C0001068:Acetyltransferase [Amino Acid, Peptide, or Protein,Enzyme]
   753   C0001390:Acetyltransferase [Amino Acid, Peptide, or Protein,Enzyme]
   753   C0008405:Choline [Biologically Active Substance,Organic Chemical,Pharmacologic Substance]
   753   C0205396:Identified [Qualitative Concept]
   753   C1550043:Identified [Finding]
   753   C1551388:Identified [Functional Concept]

Phrase: "(Fig. 3"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.117: There was also intense p38 activation in small cells, which might be microglia, and diffuse activation in neuronal and nonneuronal cells of the gray matter. 

Phrase: "There"

Phrase: "was"

Phrase: "also intense p38 activation in small cells,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   774   C1326120:activation cells [Cell Function]
   748   C1879547:Activation [Activity]

Phrase: "which"

Phrase: "might"

Phrase: "be"

Phrase: "microglia,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0206116:Microglia [Cell]
   928 E C0521398:Microglial [Body Location or Region]

Phrase: "and"

Phrase: "diffuse activation in neuronal"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1879547:Activation [Activity]

Phrase: "and"

Phrase: "nonneuronal cells of the gray matter."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   773   C0027836:Non-neuronal cell [Cell]
   753   C0007634:Cells [Cell]
   753   C3282337:Cells [Cell]
   719 E C1269647:Cell [Cell]
   719 E C1704653:Cell [Medical Device]
   719 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.118: All of this activation was inhibited by fidarestat. 

Phrase: "All of this activation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0444868:All [Quantitative Concept]
   770   C1879547:Activation [Activity]
   770   C3539085:All [Idea or Concept]

Phrase: "was"

Phrase: "inhibited by fidarestat."
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
   790   C0311403:Inhibited [Qualitative Concept]
   790   C0905478:fidarestat [Organic Chemical,Pharmacologic Substance]
   718 E C0018790:arrested [Disease or Syndrome]
   718 E C0237477:Arrest [Temporal Concept]
   718 E C0392351:arrest [Governmental or Regulatory Activity]
   718 E C0521111:Retarded [Qualitative Concept]
Processing 00000000.tx.119: It was also noted that ChAT staining was reduced in motoneuron cell bodies of diabetic rats (Fig. 3). 

Phrase: "It"

Phrase: "was"

Phrase: "also"

Phrase: "noted"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1316572:Note [Clinical Attribute]
   966   C1317574:Note [Intellectual Product]
   966   C1369612:Note [Clinical Attribute]

Phrase: "that ChAT staining"

Phrase: "was"

Phrase: "reduced in motoneuron cell bodies of diabetic rats"
Meta Candidates (Total=15; Excluded=3; Pruned=0; Remaining=12)
   767   C0599444:bodies cell [Cell Component]
   744   C0007634:Cell [Cell]
   744   C0026609:Motoneuron [Cell]
   744   C0034693:rats [Mammal]
   744   C0034721:Rats [Mammal]
   744   C0241863:DIABETIC [Finding]
   744   C0242821:bodies [Human]
   744   C0392756:Reduced [Qualitative Concept]
   744   C1269647:Cell [Cell]
   744   C1704653:Cell [Medical Device]
   744   C1948049:Cell [Spatial Concept]
   744   C1995017:Bodies [Cell Component]
   737 E C2752549:cell body [Cell Component]
   711 E C0460148:Body [Anatomical Structure]
   711 E C1268086:Body [Anatomical Structure]

Phrase: "(Fig. 3"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.120: Again, this was prevented by fidarestat. 

Phrase: "Again,"

Phrase: "this"

Phrase: "was"

Phrase: "prevented by fidarestat."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0905478:fidarestat [Organic Chemical,Pharmacologic Substance]
   756   C0309872:PREVENT [Pharmacologic Substance]
Processing 00000000.tx.121: View larger version (122K): [in this window] [in a new window]  FIG. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(122K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  FIG."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.122: 3. 

Phrase: "3."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]
Processing 00000000.tx.123: Micrographs from different rats showing immunoreactivity attributed to phospo-p38 (yellow-green) in L1 spinal cord and L4 DRG. 

Phrase: "Micrographs from different rats"

Phrase: "showing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "immunoreactivity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0597879:immunoreactivity [Molecular Function]

Phrase: "attributed to phospo-p38"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   737   C0449234:Attribute [Idea or Concept]
   737   C1704772:Attribute [Conceptual Entity]
   737   C1882133:Attribute [Qualitative Concept]

Phrase: "(yellow-green"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1269775:Yellow green [Classification]
   861   C0221205:Yellow [Qualitative Concept]
   861   C0332583:Green [Qualitative Concept]

Phrase: ")"

Phrase: "in L1 spinal cord"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   901   C0037925:Spinal Cord [Body Part, Organ, or Organ Component]
   901   C1278836:Spinal cord [Body Part, Organ, or Organ Component]
   827   C0521329:Spinal [Spatial Concept]
   827   C1550235:Cord [Body Part, Organ, or Organ Component]
   827   C1552938:cord [Quantitative Concept]
   827   C1706500:Cord [Manufactured Object]

Phrase: "and"

Phrase: "L4 DRG."
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
   923   C0017070:Dorsal Root Ganglia [Body Part, Organ, or Organ Component]
           Dorsal Root
   890 E C1761610:Dorsal root ganglion [Body Part, Organ, or Organ Component]
   861   C0205955:Dorsal root [Body Part, Organ, or Organ Component]
   844   C1186181:root ganglion [Body Part, Organ, or Organ Component]
   812   C0017067:Ganglia [Body Part, Organ, or Organ Component]
   812   C0040452:Root [Body Part, Organ, or Organ Component]
   812   C0205095:Dorsal [Spatial Concept]
   812   C0242726:Root [Plant]
   812   C1318154:Root [Body Part, Organ, or Organ Component]
   812   C1705917:Root [Idea or Concept]
   779 E C1258666:Ganglion, NOS [Acquired Abnormality,Disease or Syndrome]
Processing 00000000.tx.124: Experimental conditions are grouped vertically, as denoted by headings, and the tissue/;nature of micrographs horizontally (rows AC), except for the bottom micrographs, which show the appearance of DRG cells in rats treated with the p38 MAPK inhibitor SB 239063 (D) and a section from DRG of a diabetic rat exposed to the secondary antibody, but not to the primary (anti-p38 phos) antibody (E). 

Phrase: "Experimental conditions"
Meta Candidates (Total=13; Excluded=9; Pruned=0; Remaining=4)
   861   C1517586:Experimental [Qualitative Concept]
   827   C0012634:condition [Disease or Syndrome]
   827   C0348080:Condition [Qualitative Concept]
   827   C1705253:Condition [Conceptual Entity]
   805 E C0040607:Training [Educational Activity]
   805 E C0220931:Training [Educational Activity]
   805 E C0336809:Train [Manufactured Object]
   805 E C1552514:Train [Manufactured Object]
   805 E C2673163:training [Qualitative Concept]
   777 E C0009647:Conditioned [Mental Process]
   777 E C1701901:Conditional [Qualitative Concept]
   777 E C1963686:Conditional [Functional Concept]
   755 E C1519605:Conditionality [Conceptual Entity]

Phrase: "are"

Phrase: "grouped"
Meta Candidates (Total=7; Excluded=6; Pruned=0; Remaining=1)
  1000   C0439745:Grouped [Spatial Concept]
   966 E C0441833:Group [Idea or Concept]
   966 E C0687744:group [Population Group]
   966 E C1257890:Group [Population Group]
   966 E C1552516:Group [Health Care Related Organization]
   966 E C1705428:Group [Conceptual Entity]
   966 E C1705429:Group [Population Group]

Phrase: "vertically,"

Phrase: "as"

Phrase: "denoted by headings,"

Phrase: "and"

Phrase: "the tissue/"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0040300:Tissue [Tissue]
  1000   C1547928:Tissue [Intellectual Product]

Phrase: ";nature of micrographs horizontally"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0349590:Nature [Idea or Concept]
   770   C1262865:Nature [Functional Concept]

Phrase: "(rows AC"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1412573:AC [Gene or Genome]
   861   C2350443:AC [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3539770:AC [Gene or Genome]

Phrase: ")"

Phrase: ","

Phrase: "except for the bottom micrographs,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   755   C0240341:Micrographia [Finding]
   755   C0596928:micrography [Laboratory Procedure]

Phrase: "which"

Phrase: "show"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "the appearance of DRG cells"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0233426:Appearance [Organism Attribute]
   748   C0700364:Appearance [Qualitative Concept]

Phrase: "in rats"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0034693:rats [Mammal]
  1000   C0034721:Rats [Mammal]

Phrase: "treated with the p38 MAPK inhibitor SB 239063"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   770   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   770   C0913456:SB 239063 [Organic Chemical]
   770   C1120843:MAPK, p38 [Amino Acid, Peptide, or Protein,Enzyme]
   744   C1522326:Treated [Functional Concept]
   744   C1999216:Inhibitor [Qualitative Concept]
   711 E C1292734:TREAT [Functional Concept]

Phrase: "("

Phrase: "D)"

Phrase: "and"

Phrase: "a section from DRG of a diabetic rat"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   739   C0205155:Section [Spatial Concept]
   739   C1293097:Section, NOS [Therapeutic or Preventive Procedure]
   739   C1522472:Section [Substance]
   739   C1552923:Section [Quantitative Concept]
   739   C1705191:Section [Physical Object]

Phrase: "exposed to the secondary antibody,"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   806   C0332157:Exposed to [Clinical Attribute]
           Exposed
   797   C0175668:Secondary to [Temporal Concept]
           Secondary
   760   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   760   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   760   C0027627:secondary [Neoplastic Process]
   760   C0205436:Secondary [Quantitative Concept]

Phrase: "but"

Phrase: "not to the primary"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0205225:Primary [Qualitative Concept]
   770   C0439631:Primary [Therapeutic or Preventive Procedure]
   770   C1518422:Not [Functional Concept]

Phrase: "(anti-p38 phos"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0523826:PHOS [Laboratory Procedure]
   827   C1676384:Phos [Eukaryote]

Phrase: ")"

Phrase: "antibody"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
  1000   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "(E"

Phrase: ")."
Processing 00000000.tx.125: A: Low-power micrographs of the gray matter of the cord. 

Phrase: "A"

Phrase: ":"

Phrase: "Low-power micrographs of the gray matter of the cord."
Processing 00000000.tx.126: B: Higher-power micrographs of the ventral horn. 

Phrase: "B"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: ":"

Phrase: "Higher-power micrographs of the ventral horn."
Processing 00000000.tx.127: C: DRG are shown. 

Phrase: "C"

Phrase: ":"

Phrase: "DRG"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
  1000   C0017070:Dorsal Root Ganglia [Body Part, Organ, or Organ Component]
           Dorsal Root
   966 E C1761610:Dorsal root ganglion [Body Part, Organ, or Organ Component]
   901   C0205955:Dorsal root [Body Part, Organ, or Organ Component]
   884   C1186181:root ganglion [Body Part, Organ, or Organ Component]
   827   C0017067:Ganglia [Body Part, Organ, or Organ Component]
   827   C0040452:Root [Body Part, Organ, or Organ Component]
   827   C0205095:Dorsal [Spatial Concept]
   827   C0242726:Root [Plant]
   827   C1318154:Root [Body Part, Organ, or Organ Component]
   827   C1705917:Root [Idea or Concept]
   793 E C1258666:Ganglion, NOS [Acquired Abnormality,Disease or Syndrome]

Phrase: "are"

Phrase: "shown."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]
Processing 00000000.tx.128: In the cord, there was general activation of p38 MAP kinase by diabetes in all cells (A and B). 

Phrase: "In the cord,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1550235:Cord [Body Part, Organ, or Organ Component]
  1000   C1552938:cord [Quantitative Concept]
  1000   C1706500:Cord [Manufactured Object]

Phrase: "there"

Phrase: "was"

Phrase: "general activation of p38 MAP kinase"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   793   C1819041:protein kinase activation [Cell Function]
   767   C0599177:protein activation [Genetic Function]
   744   C1879547:Activation [Activity]
   703   C1456380:p38 Mitogen Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "by diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]

Phrase: "in all cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "(A"

Phrase: "and"

Phrase: "B"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.129: At higher power, activity was clear in the nuclei of motoneurons (MN), identified by staining for ChAT (orange). 

Phrase: "At higher power,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0032863:Power [Human-caused Phenomenon or Process]

Phrase: "activity"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0205177:Activity [Functional Concept]
  1000   C0439167:% activity [Quantitative Concept]
  1000   C0441655:Activity [Activity]
  1000   C1561536:*Activity [Idea or Concept]

Phrase: "was"

Phrase: "clear in the nuclei of motoneurons (MN),"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C2963144:Clear [Qualitative Concept]

Phrase: "identified by staining"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C0205396:Identified [Qualitative Concept]
   790   C0487602:Staining [Laboratory Procedure]
   790   C1550043:Identified [Finding]
   790   C1551388:Identified [Functional Concept]
   790   C1704680:Staining [Finding]

Phrase: "for ChAT"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   840   C0008407:Choline Acetyltransferase [Amino Acid, Peptide, or Protein,Enzyme]
   840   C1413376:CHOLINE ACETYLTRANSFERASE [Gene or Genome]
   804   C0001068:Acetyltransferase [Amino Acid, Peptide, or Protein,Enzyme]
   804   C0001390:Acetyltransferase [Amino Acid, Peptide, or Protein,Enzyme]
   804   C0008405:Choline [Biologically Active Substance,Organic Chemical,Pharmacologic Substance]
   804   C0521125:For [Qualitative Concept]

Phrase: "(orange"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0440277:Orange [Food]
  1000   C0475654:orange [Food]
  1000   C1313858:Orange [Qualitative Concept]

Phrase: ")."
Processing 00000000.tx.130: Treatment with fidarestat reduced the p38 activation in nerve cells. 

Phrase: "Treatment with fidarestat"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0039798:treatment [Functional Concept]
   790   C0087111:Treatment [Therapeutic or Preventive Procedure]
   790   C1522326:Treatment [Functional Concept]
   790   C1533734:Treatment [Therapeutic or Preventive Procedure]
   790   C1705169:Treatment [Conceptual Entity]
   790   C3538994:TREATMENT [Research Activity]

Phrase: "reduced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0392756:Reduced [Qualitative Concept]

Phrase: "the p38 activation in nerve cells."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   783   C1326120:activation cells [Cell Function]
   753   C1879547:Activation [Activity]
Processing 00000000.tx.131: In diabetes, ChAT staining was clearly reduced, and this was partly reversed by fidarestat. 

Phrase: "In diabetes,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]

Phrase: "ChAT staining"

Phrase: "was"

Phrase: "clearly"

Phrase: "reduced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0392756:Reduced [Qualitative Concept]

Phrase: ","

Phrase: "and"

Phrase: "this"

Phrase: "was"

Phrase: "partly"

Phrase: "reversed by fidarestat."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0905478:fidarestat [Organic Chemical,Pharmacologic Substance]
   756   C1555029:Reverse [Idea or Concept]
Processing 00000000.tx.132: In the DRG of control animals (row C), many nuclei showed modest immunoreactivity: in untreated diabetic rats virtually all nuclei show strong staining, whereas in fidarestat-treated diabetic rats, staining is virtually absent. 

Phrase: "In the DRG"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
  1000   C0017070:Dorsal Root Ganglia [Body Part, Organ, or Organ Component]
           Dorsal Root
   966 E C1761610:Dorsal root ganglion [Body Part, Organ, or Organ Component]
   901   C0205955:Dorsal root [Body Part, Organ, or Organ Component]
   884   C1186181:root ganglion [Body Part, Organ, or Organ Component]
   827   C0017067:Ganglia [Body Part, Organ, or Organ Component]
   827   C0040452:Root [Body Part, Organ, or Organ Component]
   827   C0205095:Dorsal [Spatial Concept]
   827   C0242726:Root [Plant]
   827   C1318154:Root [Body Part, Organ, or Organ Component]
   827   C1705917:Root [Idea or Concept]
   793 E C1258666:Ganglion, NOS [Acquired Abnormality,Disease or Syndrome]

Phrase: "of control animals"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   966   C1511501:Control Animal [Animal]
   861   C0003062:Animals [Animal]
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]

Phrase: "(row"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552846:Row [Idea or Concept]

Phrase: "C),"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "many nuclei"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0007610:Nucleus [Cell Component]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "modest immunoreactivity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0597879:immunoreactivity [Molecular Function]

Phrase: ":"

Phrase: "in untreated diabetic rats virtually"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0034693:rats [Mammal]
   812   C0034721:Rats [Mammal]
   812   C0241863:DIABETIC [Finding]

Phrase: "all nuclei"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0007610:Nucleus [Cell Component]

Phrase: "show"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "strong staining,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0487602:Staining [Laboratory Procedure]
   861   C1704680:Staining [Finding]

Phrase: "whereas in fidarestat-treated diabetic rats,"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   753   C0034693:rats [Mammal]
   753   C0034721:Rats [Mammal]
   753   C0241863:DIABETIC [Finding]
   753   C0332293:treated [Therapeutic or Preventive Procedure]
   753   C0905478:fidarestat [Organic Chemical,Pharmacologic Substance]
   753   C1522326:Treated [Functional Concept]
   719 E C1292734:TREAT [Functional Concept]

Phrase: "staining"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0487602:Staining [Laboratory Procedure]
  1000   C1704680:Staining [Finding]
   966 E C0038128:Stain [Indicator, Reagent, or Diagnostic Aid]

Phrase: "is"

Phrase: "virtually absent."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0332197:Absent [Quantitative Concept]
   861   C2699517:ABSENT [Finding]
   789 E C0424530:Absences [Finding]
   789 E C1689985:Absence [Anatomical Abnormality]
Processing 00000000.tx.133: The marker bar represents 100 m for row A and 50 m for rows B and C and for micrographs D and E.  

Phrase: "The marker bar"

Phrase: "represents"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "100 m for row A"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   760   C0441923:M+ [Intellectual Product]

Phrase: "and"

Phrase: "50 m for rows B"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   760   C0441923:M+ [Intellectual Product]

Phrase: "and"

Phrase: "C"

Phrase: "and for micrographs D"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1515981:And [Idea or Concept]

Phrase: "and"

Phrase: "E."
Processing 00000000.tx.134: To determine whether this inhibition of p38 signaling had functionally relevant consequences in diabetic rats, the MNCV and SNCV were measured. 

Phrase: "To"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "determine"

Phrase: "whether"

Phrase: "this inhibition of p38 signaling"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0021467:Inhibition [Mental Process]
   760   C0021469:Inhibition [Molecular Function]
   760   C1628982:% inhibition [Quantitative Concept]
   760   C3463820:Inhibition [Activity]

Phrase: "had"

Phrase: "functionally relevant consequences in diabetic rats,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0686907:consequences [Functional Concept]

Phrase: "the MNCV"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2982003:NCV [Diagnostic Procedure]

Phrase: "and"

Phrase: "SNCV"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2982003:NCV [Diagnostic Procedure]

Phrase: "were"

Phrase: "measured."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0444706:Measured [Qualitative Concept]
  1000   C3541902:MEASURED [Diagnostic Procedure]
   966 E C0079809:Measure [Quantitative Concept]
   966 E C0242485:Measure [Functional Concept]
Processing 00000000.tx.135: Diabetic rats displayed a significant reduction in both MNCV and SNCV compared with control animals (P < 0.01) (Table 2). 

Phrase: "Diabetic rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0241863:DIABETIC [Finding]

Phrase: "displayed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0870432:displayed [Functional Concept]
   966 E C1705417:Display [Manufactured Object]

Phrase: "a significant reduction in both MNCV"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0301630:Reduction [Natural Phenomenon or Process]
   748   C0392756:Reduction [Qualitative Concept]
   748   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "SNCV"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2982003:NCV [Diagnostic Procedure]

Phrase: "compared with control animals"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   799   C1511501:Control Animal [Animal]
   770   C0003062:Animals [Animal]
   770   C0243148:control [Qualitative Concept]
   770   C1550141:Control [Substance]
   770   C1707455:Compared [Activity]
   770   C1882979:Control [Conceptual Entity]
   770   C2587213:Control [Functional Concept]
   770   C3274648:Control [Qualitative Concept]

Phrase: "(P < 0.01"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: ")"

Phrase: "(Table 2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.136: This deficit was completely prevented by treatment with SB 239063 and fidarestat, such that the conduction velocities were not significantly different from those of the nondiabetic control groups. 

Phrase: "This deficit"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0162429:Deficit, NOS [Disease or Syndrome]
  1000   C2987487:Deficit [Qualitative Concept]

Phrase: "was"

Phrase: "completely"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205197:Completely [Qualitative Concept]

Phrase: "prevented by treatment"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   790   C0039798:treatment [Functional Concept]
   790   C0087111:Treatment [Therapeutic or Preventive Procedure]
   790   C1522326:Treatment [Functional Concept]
   790   C1533734:Treatment [Therapeutic or Preventive Procedure]
   790   C1705169:Treatment [Conceptual Entity]
   790   C3538994:TREATMENT [Research Activity]
   756   C0309872:PREVENT [Pharmacologic Substance]

Phrase: "with SB 239063"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0913456:SB 239063 [Organic Chemical]

Phrase: "and"

Phrase: "fidarestat,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0905478:fidarestat [Organic Chemical,Pharmacologic Substance]

Phrase: "such"

Phrase: "that"

Phrase: "the conduction velocities"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0234084:conduction velocities [Organ or Tissue Function]
   861   C0439830:Velocities [Quantitative Concept]
   827 E C1547053:*Velocity [Quantitative Concept]

Phrase: "were"

Phrase: "not significantly different from those of the nondiabetic control groups."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C1705242:Different [Qualitative Concept]
Processing 00000000.tx.137: Insulin-treated diabetic rats also had similar conduction velocities to control animals, indicating that the 4 weeks treatment completely reversed the deficits that developed over the previous 8 weeks of untreated diabetes. 

Phrase: "Insulin-treated diabetic rats also"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   804   C0034693:rats [Mammal]
   804   C0034721:Rats [Mammal]
   804   C0241863:DIABETIC [Finding]

Phrase: "had"

Phrase: "similar conduction velocities to control animals,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   799   C0003062:Animals [Animal]
   799   C0243148:control [Qualitative Concept]
   799   C1550141:Control [Substance]
   799   C1882979:Control [Conceptual Entity]
   799   C2587213:Control [Functional Concept]
   799   C3274648:Control [Qualitative Concept]
   793   C1511501:Control Animal [Animal]

Phrase: "indicating"

Phrase: "that"

Phrase: "the 4 weeks treatment completely"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   812   C0039798:treatment [Functional Concept]
   812   C0087111:Treatment [Therapeutic or Preventive Procedure]
   812   C1522326:Treatment [Functional Concept]
   812   C1533734:Treatment [Therapeutic or Preventive Procedure]
   812   C1705169:Treatment [Conceptual Entity]
   812   C3538994:TREATMENT [Research Activity]

Phrase: "reversed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1555029:Reverse [Idea or Concept]

Phrase: "the deficits"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C2987487:deficits [Qualitative Concept]
   966 E C0162429:Deficit, NOS [Disease or Syndrome]

Phrase: "that"

Phrase: "developed over the previous 8 weeks of untreated diabetes."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   742   C0011847:Diabetes [Disease or Syndrome]
   742   C0011849:Diabetes [Disease or Syndrome]
   742   C0205156:Previous [Temporal Concept]
   742   C0332155:untreated [Finding]
   742   C0439230:weeks [Temporal Concept]
   742   C1552607:previous [Temporal Concept]
   708 E C0332174:/week [Temporal Concept]
Processing 00000000.tx.138: View this table: [in this window] [in a new window]  TABLE 2 Nerve conduction data in meters per second: effects of insulin or fidarestat or the p38 MAP kinase inhibitor, SB239063   DISCUSSION TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES  This study shows clear activation of MAP kinase p38 in neurons of the lumbar DRG of diabetic rats. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  TABLE 2 Nerve conduction data in meters"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   774   C1706074:Data Table [Intellectual Product]
   748   C1511726:Data [Idea or Concept]
   748   C3245479:data [Medical Device]

Phrase: "per second"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
  1000   C0205436:Second [Quantitative Concept]
  1000   C0457385:Second [Temporal Concept]
  1000   C0565930:/second [Quantitative Concept]
  1000   C1561503:second [Idea or Concept]
  1000   C1705190:Second [Qualitative Concept]
   928 E C0027627:secondary [Neoplastic Process]
   928 E C0175668:Secondary [Temporal Concept]

Phrase: ":"

Phrase: "effects of insulin"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C1280500:effects [Qualitative Concept]
   756 E C2348382:Effect [Qualitative Concept]

Phrase: "or"

Phrase: "fidarestat"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0905478:fidarestat [Organic Chemical,Pharmacologic Substance]

Phrase: "or"

Phrase: "the p38 MAP kinase inhibitor,"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   947   C1513344:Mitogen-Activated Protein Kinase Inhibitor [Pharmacologic Substance]
   861   C1449702:Protein kinase inhibitor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   827   C1171350:Kinase Inhibitor [Pharmacologic Substance]
   827   C3537023:kinase inhibitor [Molecular Function]
   827   C3537035:kinase inhibitor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   799   C1999216:Inhibitor [Qualitative Concept]
   780   C1456380:p38 Mitogen Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   760 E C1120843:p38 Mitogen-Activated Protein Kinases [Amino Acid, Peptide, or Protein,Enzyme]
           p38 Protein Kinase
   734   C0752312:Mitogen-Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "SB239063   DISCUSSION TOP ABSTRACT RESEARCH DESIGN"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0035171:Research Design [Research Activity]
   799   C0035168:research [Research Activity]
   799   C0242481:Research [Research Activity]
   799   C1707689:Design [Activity]
   799   C2983265:DESIGN [Intellectual Product]

Phrase: "AND"

Phrase: "METHODS RESULTS DISCUSSION"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "This study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]

Phrase: "shows"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "clear activation of MAP kinase p38"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   793   C1819041:protein kinase activation [Cell Function]
   767   C0599177:protein activation [Genetic Function]
   744   C1879547:Activation [Activity]
   703   C1120843:mitogen-activated protein kinase p38 [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "in neurons"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0027882:Neurons [Cell]
   916 E C0521390:Neuronal [Immunologic Factor]

Phrase: "of the lumbar DRG"
Meta Candidates (Total=15; Excluded=2; Pruned=0; Remaining=13)
   983   C0457468:Lumbar dorsal root ganglion [Body Part, Organ, or Organ Component]
   923   C0017070:Dorsal Root Ganglia [Body Part, Organ, or Organ Component]
           Dorsal Root
   902   C0229020:Lumbar ganglia [Body Part, Organ, or Organ Component]
   902   C1281807:Lumbar ganglia [Body Part, Organ, or Organ Component]
   890 E C1761610:Dorsal root ganglion [Body Part, Organ, or Organ Component]
   861   C0205955:Dorsal root [Body Part, Organ, or Organ Component]
   844   C1186181:root ganglion [Body Part, Organ, or Organ Component]
   812   C0017067:Ganglia [Body Part, Organ, or Organ Component]
   812   C0040452:Root [Body Part, Organ, or Organ Component]
   812   C0205095:Dorsal [Spatial Concept]
   812   C0242726:Root [Plant]
   812   C1318154:Root [Body Part, Organ, or Organ Component]
   812   C1705917:Root [Idea or Concept]
   779 E C1258666:Ganglion, NOS [Acquired Abnormality,Disease or Syndrome]

Phrase: "of diabetic rats."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0241863:DIABETIC [Finding]
Processing 00000000.tx.139: Activation of p38 was inhibited by SB 239063, consistent with the inhibitor competing with ATP for active p38 and also binding to inactive p38 (15). 

Phrase: "Activation of p38"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1879547:Activation [Activity]

Phrase: "was"

Phrase: "inhibited by SB 239063,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C0913456:SB 239063 [Organic Chemical]
   770   C0311403:Inhibited [Qualitative Concept]

Phrase: "consistent with the inhibitor competing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   806   C0332290:Consistent with [Idea or Concept]
           Consistent

Phrase: "with ATP"

Phrase: "for active p38"

Phrase: "and"

Phrase: "also"

Phrase: "binding to inactive p38"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0205254:Inactive [Qualitative Concept]
   770   C0243122:binding [Functional Concept]
   770   C1145667:Binding [Activity]
   770   C1167622:Binding [Molecular Function]

Phrase: "(15"

Phrase: ")."
Processing 00000000.tx.140: Activation of p38 derives from diabetes, as is confirmed by the effect of insulin in normalizing levels of phospho-p38. 

Phrase: "Activation of p38"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1879547:Activation [Activity]

Phrase: "derives from diabetes,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0011847:Diabetes [Disease or Syndrome]
   790   C0011849:Diabetes [Disease or Syndrome]

Phrase: "as is"

Phrase: "confirmed by the effect of insulin"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   790   C0521093:Confirmed by [Qualitative Concept]
           confirmed
   753   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   753   C0750484:Confirmed [Idea or Concept]
   753   C1280500:Effect [Qualitative Concept]
   753   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   753   C1579433:Insulin [Pharmacologic Substance]
   753   C2348382:Effect [Qualitative Concept]
   719 E C1456348:Confirm [Qualitative Concept]

Phrase: "in normalizing levels"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0441889:Levels [Qualitative Concept]
   827 E C0456079:Level [Classification]
   827 E C1547707:Level [Geographic Area]
   827 E C2946261:Level [Pharmacologic Substance]

Phrase: "of phospho-p38."
Processing 00000000.tx.141: In none of our immunoblots did we see any systematic alteration of expression of the p38 protein itself, thus the changes in the phospho-epitope can be ascribed to real changes in the activation status (phosphorylation) of the enzyme. 

Phrase: "In none"

Phrase: "of our immunoblots"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0020985:Immunoblot [Laboratory Procedure]

Phrase: "did"

Phrase: "we"

Phrase: "see"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0042789:see [Organism Function]
  1000   C1947903:See [Activity]

Phrase: "any systematic alteration of expression of the p38 protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C1515926:Alteration [Idea or Concept]

Phrase: "itself,"

Phrase: "thus"

Phrase: "the changes in the phospho-epitope"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   773   C0025320:The change [Physiologic Function]
   753   C0392747:changes [Functional Concept]
   753   C0443172:changes [Quantitative Concept]
   719 E C1705241:Change [Quantitative Concept]

Phrase: "can"

Phrase: "be"

Phrase: "ascribed to real changes"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   770   C0237400:Real [Qualitative Concept]
   770   C0392747:changes [Functional Concept]
   770   C0443172:changes [Quantitative Concept]
   770   C3272377:REAL [Intellectual Product]
   737 E C1705241:Change [Quantitative Concept]

Phrase: "in the activation status"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0449438:Status [Qualitative Concept]

Phrase: "(phosphorylation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0031715:Phosphorylation [Molecular Function]
  1000   C1158886:Phosphorylation [Molecular Function]

Phrase: ")"

Phrase: "of the enzyme."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0014442:Enzyme [Enzyme,Organic Chemical]
   916 E C0014445:enzymes [Functional Concept]
Processing 00000000.tx.142: Immunocytochemistry showed that the changes occurred predominantly in the nucleus and that all of the different neuronal phenotypes of the DRG were involved in the diabetes-induced activation of p38. 

Phrase: "Immunocytochemistry"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0242349:Immunocytochemistry [Laboratory Procedure]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "that"

Phrase: "the changes"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0392747:changes [Functional Concept]
  1000   C0443172:changes [Quantitative Concept]
   966 E C1705241:Change [Quantitative Concept]

Phrase: "occurred"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1709305:Occurred [Activity]
   966 E C2745955:OCCUR [Temporal Concept]

Phrase: "predominantly in the nucleus"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0007610:Nucleus [Cell Component]

Phrase: "and"

Phrase: "that"

Phrase: "all of the different neuronal phenotypes of the DRG"
Meta Candidates (Total=19; Excluded=3; Pruned=0; Remaining=16)
   775   C0017070:Dorsal Root Ganglia [Body Part, Organ, or Organ Component]
           Dorsal Root
   759   C1186181:Root of ganglion [Body Part, Organ, or Organ Component]
           root ganglion
   756   C0205955:Dorsal root [Body Part, Organ, or Organ Component]
   742 E C1761610:Dorsal root ganglion [Body Part, Organ, or Organ Component]
   738   C0017067:Ganglia [Body Part, Organ, or Organ Component]
   738   C0031437:Phenotypes [Organism Attribute]
   738   C0040452:Root [Body Part, Organ, or Organ Component]
   738   C0205095:Dorsal [Spatial Concept]
   738   C0242726:Root [Plant]
   738   C0444868:All [Quantitative Concept]
   738   C0521390:Neuronal [Immunologic Factor]
   738   C1318154:Root [Body Part, Organ, or Organ Component]
   738   C1705242:Different [Qualitative Concept]
   738   C1705917:Root [Idea or Concept]
   738   C3539085:All [Idea or Concept]
   704 E C1258666:Ganglion, NOS [Acquired Abnormality,Disease or Syndrome]
   704 E C1285572:Phenotype [Laboratory Procedure]

Phrase: "were"

Phrase: "involved in the diabetes-induced activation of p38."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   744   C0011847:Diabetes [Disease or Syndrome]
   744   C0011849:Diabetes [Disease or Syndrome]
   744   C0205263:Induced [Functional Concept]
   744   C1314939:Involved [Functional Concept]
   744   C1879547:Activation [Activity]
Processing 00000000.tx.143: We made no attempt to correlate p38 immunostaining with staining to define specific neuronal phenotypes because the p38 immunoreactivity was so uniform (Fig. 2). 

Phrase: "We"

Phrase: "made"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1881534:Make [Functional Concept]

Phrase: "no attempt to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1516084:Attempt [Event]

Phrase: "correlate"

Phrase: "p38 immunostaining with staining to"

Phrase: "define"

Phrase: "specific neuronal phenotypes"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0031437:Phenotypes [Organism Attribute]
   793 E C1285572:Phenotype [Laboratory Procedure]

Phrase: "because"

Phrase: "the p38 immunoreactivity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0597879:immunoreactivity [Molecular Function]

Phrase: "was"

Phrase: "so uniform"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0205375:Uniform [Qualitative Concept]
   861   C1608508:uniform [Quantitative Concept]

Phrase: "(Fig. 2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.144: In the spinal cord of diabetic rats, p38 MAP kinase activation was seen in all motoneurons, as well as in other cell types of the gray matter. 

Phrase: "In the spinal cord"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0037925:Spinal Cord [Body Part, Organ, or Organ Component]
  1000   C1278836:Spinal cord [Body Part, Organ, or Organ Component]
   861   C0521329:Spinal [Spatial Concept]
   861   C1550235:Cord [Body Part, Organ, or Organ Component]
   861   C1552938:cord [Quantitative Concept]
   861   C1706500:Cord [Manufactured Object]

Phrase: "of diabetic rats,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0241863:DIABETIC [Finding]

Phrase: "p38 MAP kinase activation"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   861   C1819041:protein kinase activation [Cell Function]
   839   C0599177:protein activation [Genetic Function]
   799   C1879547:Activation [Activity]
   780   C1456380:p38 Mitogen Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   760 E C1120843:p38 Mitogen-Activated Protein Kinases [Amino Acid, Peptide, or Protein,Enzyme]
           p38 Protein Kinase
   734   C0752312:Mitogen-Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "was"

Phrase: "seen in all motoneurons,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   770   C0026609:motoneurons [Cell]
   770   C0205397:Seen [Qualitative Concept]
   737 E C0042789:see [Organism Function]
   737 E C1947903:See [Activity]

Phrase: "as well as in other cell types of the gray matter."
Meta Candidates (Total=14; Excluded=2; Pruned=0; Remaining=12)
   761   C0449475:Type of cell [Intellectual Product]
           Cell types
   756   C0018220:Gray matter [Tissue]
   738   C0007634:Cell [Cell]
       E   Cell Type
   738   C0205170:Well [Qualitative Concept]
   738   C0332307:Types [Qualitative Concept]
   738   C0556636:gray [Quantitative Concept]
   738   C1269647:Cell [Cell]
   738   C1269776:Gray [Qualitative Concept]
   738   C1704653:Cell [Medical Device]
   738   C1948049:Cell [Spatial Concept]
   738   C3146287:Well [Manufactured Object]
   704 E C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.145: The decreased ChAT activity in motoneuron cell bodies of diabetic rats is in accordance with old observations (3,16) of reduced axonal transport of ChAT in sciatic nerves of diabetic rats. 

Phrase: "The decreased ChAT activity"

Phrase: "in motoneuron cell bodies"
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
   867   C0599444:Cell body [Cell Component]
   867   C2752549:cell body [Cell Component]
   827   C0007634:Cell [Cell]
   827   C0242821:bodies [Human]
   827   C1269647:Cell [Cell]
   827   C1704653:Cell [Medical Device]
   827   C1948049:Cell [Spatial Concept]
   827   C1995017:Bodies [Cell Component]
   793 E C0460148:Body [Anatomical Structure]
   793 E C1268086:Body [Anatomical Structure]

Phrase: "of diabetic rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0241863:DIABETIC [Finding]

Phrase: "is in accordance with old observations"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   753   C0302523:observations [Research Activity]
   753   C0580836:Old [Temporal Concept]
   753   C0700325:observations [Health Care Activity]
   753   C3244290:observations [Functional Concept]
   719 E C1964257:Observation [Diagnostic Procedure]

Phrase: "(3,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: "16"

Phrase: ")"

Phrase: "of reduced axonal transport"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0004462:Axonal Transport [Cell Function]
   827   C0005528:Transport, NOS [Cell Function]
   827   C1317949:Transport [Manufactured Object]
   827   C3495449:transport [Medical Device]
   755   C0004461:Axon [Cell Component]

Phrase: "of ChAT"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   840   C0008407:Choline Acetyltransferase [Amino Acid, Peptide, or Protein,Enzyme]
   840   C1413376:CHOLINE ACETYLTRANSFERASE [Gene or Genome]
   804   C0001068:Acetyltransferase [Amino Acid, Peptide, or Protein,Enzyme]
   804   C0001390:Acetyltransferase [Amino Acid, Peptide, or Protein,Enzyme]
   804   C0008405:Choline [Biologically Active Substance,Organic Chemical,Pharmacologic Substance]
   804   C0332285:Of [Spatial Concept]

Phrase: "in sciatic nerves"
Meta Candidates (Total=7; Excluded=5; Pruned=0; Remaining=2)
  1000   C0036394:Sciatic Nerves [Body Part, Organ, or Organ Component]
   966 E C1278851:Sciatic nerve [Body Part, Organ, or Organ Component]
   861   C0027740:Nerves [Tissue]
   827 E C0027757:NERVE [Tissue]
   827 E C1280541:Nerve [Body Part, Organ, or Organ Component]
   789 E C0599851:Neural [Functional Concept]
   777 E C0027769:nervy [Sign or Symptom]

Phrase: "of diabetic rats."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0241863:DIABETIC [Finding]
Processing 00000000.tx.146: Indeed this observation provides an explanation for the older finding, in that there is clearly a reduction in ChAT expression in motoneuron cell bodies, which would translate to a reduced level of enzyme accumulating proximal to ligatures in the axonal transport studies. 

Phrase: "Indeed"

Phrase: "this observation"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0302523:Observation [Research Activity]
  1000   C0700325:observation [Health Care Activity]
  1000   C1964257:Observation [Diagnostic Procedure]
   928 E C1518527:OBSERVATIONAL [Research Activity]

Phrase: "provides"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0359589:provides [Food]
  1000   C1999230:Provide [Activity]

Phrase: "an explanation for the older finding,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0681841:Explanation [Intellectual Product]

Phrase: "in"

Phrase: "that there"

Phrase: "is"

Phrase: "clearly"

Phrase: "a reduction in ChAT expression"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0301630:Reduction [Natural Phenomenon or Process]
   744   C0392756:Reduction [Qualitative Concept]
   744   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "in motoneuron cell bodies,"
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
   867   C0599444:Cell body [Cell Component]
   867   C2752549:cell body [Cell Component]
   827   C0007634:Cell [Cell]
   827   C0242821:bodies [Human]
   827   C1269647:Cell [Cell]
   827   C1704653:Cell [Medical Device]
   827   C1948049:Cell [Spatial Concept]
   827   C1995017:Bodies [Cell Component]
   793 E C0460148:Body [Anatomical Structure]
   793 E C1268086:Body [Anatomical Structure]

Phrase: "which"

Phrase: "would"

Phrase: "translate to a reduced level of enzyme"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   774   C0014440:enzyme level [Laboratory Procedure]
   774   C1287349:Enzyme level [Laboratory or Test Result]
   748   C0014442:Enzyme [Enzyme,Organic Chemical]
   748   C0040710:translate [Occupational Activity]
   748   C0392756:Reduced [Qualitative Concept]
   748   C0441889:Level [Qualitative Concept]
   748   C0456079:Level [Classification]
   748   C1547707:Level [Geographic Area]
   748   C2946261:Level [Pharmacologic Substance]

Phrase: "accumulating"

Phrase: "proximal to ligatures"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0205107:Proximal [Spatial Concept]

Phrase: "in the axonal transport studies."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   827   C0947630:studies [Laboratory Procedure]
   793 E C0557651:Study [Manufactured Object]
   793 E C2603343:Study [Research Activity]
   734   C0004462:Axonal Transport [Cell Function]
Processing 00000000.tx.147: Thus, there was probably no flaw in the transport process per se, rather translocation of reduced amounts from the cell body secondary to reduced synthesis of the ChAT enzyme. 

Phrase: "Thus,"

Phrase: "there"

Phrase: "was"

Phrase: "probably"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750492:Probably [Idea or Concept]

Phrase: "no flaw in the transport process per se, rather translocation of reduced amounts"

Phrase: "from the cell body"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
  1000   C0599444:Cell body [Cell Component]
  1000   C2752549:cell body [Cell Component]
   861   C0007634:Cell [Cell]
   861   C0242821:body [Human]
   861   C0460148:Body [Anatomical Structure]
   861   C1268086:Body [Anatomical Structure]
   861   C1269647:Cell [Cell]
   861   C1704653:Cell [Medical Device]
   861   C1948049:Cell [Spatial Concept]
   777 E C1995017:Bodies [Cell Component]

Phrase: "secondary to reduced synthesis of the ChAT enzyme."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   756   C0175668:Secondary to [Temporal Concept]
           Secondary
   738   C0027627:secondary [Neoplastic Process]
   738   C0205436:Secondary [Quantitative Concept]
Processing 00000000.tx.148: Further agreement comes from our present observation that the aldose reductase inhibitor normalized expression of ChAT in the cell body, just as it normalized the amount accumulating at the ligature in the earlier studies (3,17). 

Phrase: "Further agreement"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0680240:Agreement [Social Behavior]

Phrase: "comes from our present observation"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0150312:Present [Quantitative Concept]
   760   C0302523:Observation [Research Activity]
   760   C0449450:Present [Idea or Concept]
   760   C0700325:observation [Health Care Activity]
   760   C1964257:Observation [Diagnostic Procedure]

Phrase: "that"

Phrase: "the aldose reductase inhibitor"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C2348243:Aldose Reductase Inhibitor [Pharmacologic Substance]
   901   C0002003:Aldose Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   901   C1412322:ALDOSE REDUCTASE [Gene or Genome]
   827   C0030016:Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0682934:Aldose [Carbohydrate]
   827   C1999216:Inhibitor [Qualitative Concept]

Phrase: "normalized"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882115:Normalized [Research Activity]

Phrase: "expression of ChAT"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "in the cell body,"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
  1000   C0599444:Cell body [Cell Component]
  1000   C2752549:cell body [Cell Component]
   861   C0007634:Cell [Cell]
   861   C0242821:body [Human]
   861   C0460148:Body [Anatomical Structure]
   861   C1268086:Body [Anatomical Structure]
   861   C1269647:Cell [Cell]
   861   C1704653:Cell [Medical Device]
   861   C1948049:Cell [Spatial Concept]
   777 E C1995017:Bodies [Cell Component]

Phrase: "just as it"

Phrase: "normalized"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882115:Normalized [Research Activity]

Phrase: "the amount accumulating at the ligature"

Phrase: "in the earlier studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "(3,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: "17"

Phrase: ")."
Processing 00000000.tx.149: We have shown that p38 can be activated in vitro by combined oxidative stress and elevated glucose concentration (2550 mmol/;l) (7). 

Phrase: "We"

Phrase: "have"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "that p38"

Phrase: "can"

Phrase: "be"

Phrase: "activated"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1879547:Activated [Activity]
   966 E C1515877:Activate [Functional Concept]

Phrase: "in vitro by combined oxidative stress"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0021135:In Vitro [Intellectual Product]
   790   C1533691:in vitro [Qualitative Concept]
           vitro
   790   C2827718:In Vitro [Functional Concept]

Phrase: "and"

Phrase: "elevated glucose concentration"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   901   C0427743:Glucose concentration [Laboratory Procedure]
   901   C1287281:Glucose concentration [Laboratory or Test Result]
   827   C0086045:Concentration [Mental Process]
   827   C1446561:Concentration [Quantitative Concept]
   755 E C1880165:Concentrated [Biomedical or Dental Material]

Phrase: "(2550 mmol/;l) (7"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1532563:mmol/L [Quantitative Concept]
   812   C0439190:MMOLE [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.150: This observation, plus the effect of insulin treatment seen here, strongly implicate hyperglycemia in causing activation of neuronal p38 in diabetic rats. 

Phrase: "This observation,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0302523:Observation [Research Activity]
  1000   C0700325:observation [Health Care Activity]
  1000   C1964257:Observation [Diagnostic Procedure]
   928 E C1518527:OBSERVATIONAL [Research Activity]

Phrase: "plus"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332287:Plus [Qualitative Concept]

Phrase: "the effect of insulin treatment"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   797   C1518681:Treatment Effect [Finding]
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "seen"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0205397:Seen [Qualitative Concept]
   966 E C0042789:see [Organism Function]
   966 E C1947903:See [Activity]

Phrase: "here,"

Phrase: "strongly"

Phrase: "implicate"

Phrase: "hyperglycemia in causing activation of neuronal p38"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0020456:Hyperglycaemia [Disease or Syndrome]

Phrase: "in diabetic rats."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0241863:DIABETIC [Finding]
Processing 00000000.tx.151: Furthermore, the effect of fidarestat on p38 activation strongly implicates the polyol pathway as an intermediate mechanism. 

Phrase: "Furthermore,"

Phrase: "the effect of fidarestat"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1280500:Effect [Qualitative Concept]
   770   C2348382:Effect [Qualitative Concept]

Phrase: "on p38 activation strongly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1879547:Activation [Activity]

Phrase: "implicates"

Phrase: "the polyol pathway as an intermediate mechanism."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1704259:Pathway [Molecular Function]
   748   C1705987:Pathway [Conceptual Entity]
Processing 00000000.tx.152: There may also be a direct effect of glucose itself, though such a response has not been documented. 

Phrase: "There"

Phrase: "may"

Phrase: "also"

Phrase: "be"

Phrase: "a direct effect of glucose"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   797   C1158774:glucose effect [Genetic Function]
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "itself,"

Phrase: "though"

Phrase: "such a response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0871261:Response [Organism Attribute]
  1000   C1704632:Response [Finding]
  1000   C1706817:Response [Intellectual Product]
  1000   C2911692:Response [Mental Process]

Phrase: "has"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "been"

Phrase: "documented."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C1301725:Documented [Health Care Activity]
  1000   C1609436:documented [Idea or Concept]
   966 E C1301746:document [Intellectual Product]
   966 E C1547673:Document [Intellectual Product]
Processing 00000000.tx.153: It may occur as a result of osmotic stress (1820) or of oxidative stress (2123). 

Phrase: "It"

Phrase: "may"

Phrase: "occur as a result of osmotic stress"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   778   C3661513:Osmotic Stress [Natural Phenomenon or Process]
   748   C0029391:osmotic [Natural Phenomenon or Process]
   748   C0038435:Stress [Finding]
   748   C0311417:Osmotic [Functional Concept]
   748   C1274040:Result [Functional Concept]
   748   C1546471:Result [Idea or Concept]
   748   C1709305:Occur [Activity]
   748   C2745955:OCCUR [Temporal Concept]
   748   C2825142:Result [Finding]

Phrase: "(1820"

Phrase: ")"

Phrase: "or of oxidative stress"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C0242606:Oxidative Stress [Cell or Molecular Dysfunction]
   770   C0038435:Stress [Finding]
   770   C0311404:Oxidative [Functional Concept]

Phrase: "(2123"

Phrase: ")."
Processing 00000000.tx.154: However, the elevation of nerve glucose associated with fidarestat treatment argues against a direct glucose effect on MAP kinase activation. 

Phrase: "However,"

Phrase: "the elevation of nerve glucose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0439775:Elevation [Therapeutic or Preventive Procedure]
   760   C0702240:Elevation [Spatial Concept]

Phrase: "associated with fidarestat treatment"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   770   C0039798:treatment [Functional Concept]
   770   C0087111:Treatment [Therapeutic or Preventive Procedure]
   770   C0905478:fidarestat [Organic Chemical,Pharmacologic Substance]
   770   C1522326:Treatment [Functional Concept]
   770   C1533734:Treatment [Therapeutic or Preventive Procedure]
   770   C1705169:Treatment [Conceptual Entity]
   770   C3538994:TREATMENT [Research Activity]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1706221:Associate [Professional or Occupational Group]

Phrase: "argues against a direct glucose effect"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C1158774:glucose effect [Genetic Function]
   753   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   753   C0439851:Direct [Qualitative Concept]
   753   C1280500:Effect [Qualitative Concept]
   753   C1947931:Direct [Qualitative Concept]
   753   C2348382:Effect [Qualitative Concept]

Phrase: "on MAP kinase activation."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   884   C1819041:protein kinase activation [Cell Function]
   853   C0599177:protein activation [Genetic Function]
   804   C1879547:Activation [Activity]
   771   C0752312:Mitogen-Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   717   C1979930:Mitogen-activated protein [Amino Acid, Peptide, or Protein]
Processing 00000000.tx.155: In the longer term (i.e., not mimicked by <24 h exposure to raised glucose in tissue culture) activation of receptor of advanced glycation end products receptors by glycation end products might also activate p38 MAP kinase (24,25). 

Phrase: "In the longer term"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   966   C0443252:Long-term [Temporal Concept]
   861   C1515273:Term [Temporal Concept]
   861   C1705313:Term [Idea or Concept]
   861   C2826302:TERM [Intellectual Product]
   827   C0205166:Long [Qualitative Concept]
   827   C1706317:Long [Qualitative Concept]
   777 E C1444754:Length [Quantitative Concept]
   777 E C1706316:LENGTH [Research Activity]

Phrase: "(i.e.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0683454:I-E [Diagnostic Procedure,Intellectual Product]
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "mimicked by"

Phrase: "<24 h exposure to raised glucose"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0332157:Exposure to [Clinical Attribute]
           Exposure
   753   C0274281:Exposure, NOS [Injury or Poisoning]

Phrase: "in tissue culture"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0040284:Tissue culture [Laboratory Procedure]
   861   C0010453:Culture [Idea or Concept]
   861   C0040300:Tissue [Tissue]
   861   C0220814:culture [Functional Concept]
   861   C0430400:Culture [Laboratory Procedure]
   861   C1547928:Tissue [Intellectual Product]
   861   C2242979:Culture [Laboratory Procedure]

Phrase: ")"

Phrase: "activation of receptor of advanced glycation end products receptors"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   762   C1514758:Receptor Activation [Cell Function]
   745   C0596035:activation product [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   742   C1879547:Activation [Activity]

Phrase: "by glycation end products"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   827   C0444930:End [Spatial Concept]
   827   C1514468:Products [Entity]
   827   C2746065:End [Temporal Concept]
   793 E C1704444:Product [Quantitative Concept]
   771 E C0205088:Terminal [Temporal Concept]
   771 E C1705314:Terminal [Manufactured Object]
   771 E C1705315:Terminal [Spatial Concept]

Phrase: "might"

Phrase: "also"

Phrase: "activate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515877:Activate [Functional Concept]
  1000   C1879547:Activate [Activity]

Phrase: "p38 MAP kinase"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
  1000   C1456380:p38 Mitogen Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   979 E C1120843:p38 Mitogen-Activated Protein Kinases [Amino Acid, Peptide, or Protein,Enzyme]
           p38 Protein Kinase
   937   C0752312:Mitogen-Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   884   C1979930:Mitogen-activated protein [Amino Acid, Peptide, or Protein]
   840   C0033640:PROTEIN KINASE [Amino Acid, Peptide, or Protein,Enzyme]
   804   C0018284:Mitogen [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0026249:Mitogen [Pharmacologic Substance]
   804   C0031727:Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   804   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C1879547:Activated [Activity]
   771 E C1515877:Activate [Functional Concept]

Phrase: "(24,"

Phrase: "25"

Phrase: ")."
Processing 00000000.tx.156: This latter mechanism could certainly have participated in our in vivo study. 

Phrase: "This latter mechanism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0441712:Mechanism [Functional Concept]
   861   C1706376:Mechanism [Manufactured Object]

Phrase: "could"

Phrase: "certainly"

Phrase: "have"

Phrase: "participated in our in vivo study."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   820   C0681829:in vivo study [Research Activity]
   783   C1515655:In Vivo [Spatial Concept]
           vivo
   753   C0557651:Study [Manufactured Object]
   753   C2603343:Study [Research Activity]
Processing 00000000.tx.157: As stated, a role for flux through the polyol pathway in neuronal p38 activation in diabetic rats is clear. 

Phrase: "As"

Phrase: "stated"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1301808:stated [Geographic Area]
  1000   C1442792:Stated [Functional Concept]
   966 E C3148680:State [Geographic Area]

Phrase: ","

Phrase: "a role for flux"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0035820:Role [Social Behavior]
   770   C1705810:Role [Conceptual Entity]

Phrase: "through the polyol pathway"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1704259:Pathway [Molecular Function]
   861   C1705987:Pathway [Conceptual Entity]

Phrase: "in neuronal p38 activation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1879547:Activation [Activity]

Phrase: "in diabetic rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0241863:DIABETIC [Finding]

Phrase: "is"

Phrase: "clear."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2963144:Clear [Qualitative Concept]
Processing 00000000.tx.158: This might derive from either osmotic or oxidative stress. 

Phrase: "This"

Phrase: "might"

Phrase: "derive from either osmotic"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0029391:osmotic [Natural Phenomenon or Process]
   770   C0311417:Osmotic [Functional Concept]

Phrase: "or"

Phrase: "oxidative stress."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0242606:Oxidative Stress [Cell or Molecular Dysfunction]
   861   C0038435:Stress [Finding]
   861   C0311404:Oxidative [Functional Concept]
   789 E C0231297:Stressful [Functional Concept]
Processing 00000000.tx.159: In a renal cell line, osmotic stress has been shown to both activate p38 and to induce aldose reductase expression, though the cellular signaling pathways for these two phenomena were different (26). 

Phrase: "In a renal cell line,"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   901   C0007600:Cell Line [Cell]
   901   C0553257:Renal cell [Cell]
   827   C0007634:Cell [Cell]
   827   C0205132:Line [Spatial Concept]
   827   C1269647:Cell [Cell]
   827   C1550648:Line [Substance]
   827   C1552960:Line [Quantitative Concept]
   827   C1704653:Cell [Medical Device]
   827   C1948049:Cell [Spatial Concept]

Phrase: "osmotic stress"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C3661513:Osmotic Stress [Natural Phenomenon or Process]
   861   C0038435:Stress [Finding]
   789 E C0231297:Stressful [Functional Concept]

Phrase: "has"

Phrase: "been"

Phrase: "shown to both"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   756   C1547282:Show [Intellectual Product]

Phrase: "activate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515877:Activate [Functional Concept]
  1000   C1879547:Activate [Activity]

Phrase: "p38"

Phrase: "and"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "induce"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induce [Functional Concept]

Phrase: "aldose reductase expression,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0185117:Expression [Therapeutic or Preventive Procedure]
   734   C0002003:Aldose Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   734   C1412322:ALDOSE REDUCTASE [Gene or Genome]

Phrase: "though"

Phrase: "the cellular signaling pathways for these two phenomena"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   767   C0037080:pathways signaling [Molecular Function]
   754 E C0037083:signaling pathway [Cell Function]
   754 E C0086982:Signaling Pathway [Molecular Function]
   744   C1704259:Pathways [Molecular Function]
   744   C1705987:Pathways [Conceptual Entity]

Phrase: "were"

Phrase: "different"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C1705242:Different [Qualitative Concept]
   928 E C1705241:*Difference [Quantitative Concept]
   900 E C0443199:Differential [Qualitative Concept]

Phrase: "(26"

Phrase: ")."
Processing 00000000.tx.160: This does not preclude synergy, with amplification of a direct osmotic effect on p38 by a secondary effect via the polyol pathway. 

Phrase: "This"

Phrase: "does"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "preclude"

Phrase: "synergy,"

Phrase: "with amplification"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1517480:Amplification [Molecular Biology Research Technique]
  1000   C1521871:Amplification [Phenomenon or Process]
  1000   C1705759:Amplification [Cell or Molecular Dysfunction]

Phrase: "of a direct osmotic effect"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1280500:Effect [Qualitative Concept]
   827   C2348382:Effect [Qualitative Concept]

Phrase: "on p38"

Phrase: "by a secondary effect"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1280500:Effect [Qualitative Concept]
   861   C2348382:Effect [Qualitative Concept]

Phrase: "via the polyol pathway."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1704259:Pathway [Molecular Function]
   861   C1705987:Pathway [Conceptual Entity]
Processing 00000000.tx.161: There is also good evidence for reduction of oxidative stress by inhibition of aldose reductase in peripheral nerve (27,28). 

Phrase: "There"

Phrase: "is"

Phrase: "also good evidence for reduction of oxidative stress"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   767   C0332120:Evidence of [Functional Concept]
           Evidence

Phrase: "by inhibition"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0021467:Inhibition [Mental Process]
  1000   C0021469:Inhibition [Molecular Function]
  1000   C1628982:% inhibition [Quantitative Concept]
  1000   C3463820:Inhibition [Activity]
   928 E C0311403:Inhibited [Qualitative Concept]

Phrase: "of aldose reductase"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0002003:Aldose Reductase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1412322:ALDOSE REDUCTASE [Gene or Genome]
   861   C0030016:Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0682934:Aldose [Carbohydrate]

Phrase: "in peripheral nerve"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C0031119:Peripheral nerve [Body Part, Organ, or Organ Component]
  1000   C1280200:Peripheral nerve [Body Part, Organ, or Organ Component]
   861   C0027740:Nerve [Tissue]
   861   C0027757:NERVE [Tissue]
   861   C0205100:Peripheral [Spatial Concept]
   861   C1280541:Nerve [Body Part, Organ, or Organ Component]
   805 E C0599851:Neural [Functional Concept]
   789 E C0027769:nervy [Sign or Symptom]

Phrase: "(27,"

Phrase: "28"

Phrase: ")."
Processing 00000000.tx.162: Thus, we have the potential for a funneling of different cellular stresses, derived from diabetes, through p38 MAP kinase to influence cellular phenotype and downstream function. 

Phrase: "Thus,"

Phrase: "we"

Phrase: "have"

Phrase: "the potential for a funneling of different cellular stresses,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C3245505:Potential [Qualitative Concept]

Phrase: "derived from diabetes,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0011847:Diabetes [Disease or Syndrome]
   790   C0011849:Diabetes [Disease or Syndrome]
   790   C1441547:Derived [Qualitative Concept]
   790   C3245521:derived [Idea or Concept]

Phrase: "through p38 MAP kinase to"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
   947   C1456380:p38 Mitogen Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   926 E C1120843:p38 Mitogen-Activated Protein Kinases [Amino Acid, Peptide, or Protein,Enzyme]
           p38 Protein Kinase
   901   C0752312:Mitogen-Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   861   C1979930:Mitogen-activated protein [Amino Acid, Peptide, or Protein]
   827   C0033640:PROTEIN KINASE [Amino Acid, Peptide, or Protein,Enzyme]
   799   C0018284:Mitogen [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0026249:Mitogen [Pharmacologic Substance]
   799   C0031727:Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C1879547:Activated [Activity]
   766 E C1515877:Activate [Functional Concept]

Phrase: "influence"

Phrase: "cellular phenotype"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0031437:Phenotype [Organism Attribute]
   861   C1285572:Phenotype [Laboratory Procedure]

Phrase: "and"

Phrase: "downstream function."
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   861   C0031843:function [Physiologic Function]
   861   C0542341:Function [Functional Concept]
   861   C0700205:FUNCTION [Classification]
   861   C1705273:Function [Intellectual Product]
   789 E C0205245:Functional [Functional Concept]
   789 E C2700217:Functional [Conceptual Entity]
Processing 00000000.tx.163: Although we have been able to activate neuronal p38 under tissue culture conditions (7), it was not possible to test the relationship of its activation to neurophysiological (functional) defects because a feasible time course for the development of dysfunction cannot be maintained in tissue culture without introduction of other extraneous effects. 

Phrase: "Although"

Phrase: "we"

Phrase: "have"

Phrase: "been"

Phrase: "able to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0085732:Able [Organism Attribute]
   861   C1299581:Able [Finding]

Phrase: "activate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515877:Activate [Functional Concept]
  1000   C1879547:Activate [Activity]

Phrase: "neuronal p38 under tissue culture conditions"

Phrase: "(7"

Phrase: ")"

Phrase: ","

Phrase: "it"

Phrase: "was"

Phrase: "not possible to"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0332149:Possible [Qualitative Concept]
   827   C1518422:Not [Functional Concept]
   827   C1705910:Possible [Qualitative Concept]
   827   C2362652:Possible [Qualitative Concept]

Phrase: "test"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0022885:Test [Laboratory Procedure]
  1000   C0039593:Test [Functional Concept]
  1000   C0392366:test [Intellectual Product]

Phrase: "the relationship of its activation"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0439849:Relationship [Qualitative Concept]
   760   C1705630:Relationship [Idea or Concept]
   760   C1706279:Relationship [Idea or Concept]
   760   C3540605:Relationship [Intellectual Product]

Phrase: "to neurophysiological"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   928   C0027901:Neurophysiology [Biomedical Occupation or Discipline]
   928   C0700630:neurophysiology [Physiologic Function]

Phrase: "(functional"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205245:Functional [Functional Concept]
  1000   C0542341:Functional [Functional Concept]
  1000   C2700217:Functional [Conceptual Entity]

Phrase: ")"

Phrase: "defects"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0243067:defects [Functional Concept]
   966 E C1457869:Defect [Functional Concept]
   966 E C1861101:DEFECT [Disease or Syndrome]

Phrase: "because"

Phrase: "a feasible time course for the development of dysfunction"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   764   C0449247:Time course [Temporal Concept]
   742   C0040223:Time [Temporal Concept]
   742   C0750729:Course [Temporal Concept]
   742   C3541383:Time [Temporal Concept]

Phrase: "cannot"

Phrase: "be"

Phrase: "maintained in tissue culture"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   833   C0040284:Tissue culture [Laboratory Procedure]
   770   C0010453:Culture [Idea or Concept]
   770   C0040300:Tissue [Tissue]
   770   C0220814:culture [Functional Concept]
   770   C0430400:Culture [Laboratory Procedure]
   770   C1314677:Maintained [Functional Concept]
   770   C1547928:Tissue [Intellectual Product]
   770   C2242979:Culture [Laboratory Procedure]
   737 E C0024501:Maintain [Activity]

Phrase: "without introduction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1293116:Introduction [Health Care Activity]
  1000   C1875307:INTRODUCTION [Manufactured Object]

Phrase: "of other extraneous effects."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C1280500:effects [Qualitative Concept]
   827 E C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.164: Hence, the inhibition of p38 and its effects on nerve conduction reveals important links between hyperglycemia and a classical index of nerve dysfunction in diabetic neuropathy. 

Phrase: "Hence,"

Phrase: "the inhibition of p38"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0021467:Inhibition [Mental Process]
   770   C0021469:Inhibition [Molecular Function]
   770   C1628982:% inhibition [Quantitative Concept]
   770   C3463820:Inhibition [Activity]

Phrase: "and"

Phrase: "its effects on nerve conduction"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C1280500:effects [Qualitative Concept]
   726 E C2348382:Effect [Qualitative Concept]

Phrase: "reveals"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443289:reveal [Qualitative Concept]

Phrase: "important links between hyperglycemia"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   737   C1517892:Link [Intellectual Product]
   737   C1704666:Link [Intellectual Product]

Phrase: "and"

Phrase: "a classical index of nerve dysfunction"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0918012:Index [Intellectual Product]
   753   C1552854:index [Idea or Concept]
   753   C1637833:% index [Quantitative Concept]

Phrase: "in diabetic neuropathy."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0011882:Diabetic neuropathy [Disease or Syndrome]
   861   C0241863:DIABETIC [Finding]
   861   C0442874:Neuropathy [Disease or Syndrome]
Processing 00000000.tx.165: In a previous pilot study (29), we found that a much shorter duration of treatment (enforced by the amount of compound available to us) with the same inhibitor normalized only SNCV. 

Phrase: "In a previous pilot study"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0031928:Pilot Study [Research Activity]
   827   C0473169:Pilot [Professional or Occupational Group]
   827   C0557651:Study [Manufactured Object]
   827   C1414316:PILOT [Gene or Genome]
   827   C2603343:Study [Research Activity]

Phrase: "(29"

Phrase: ")"

Phrase: ","

Phrase: "we"

Phrase: "found"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0150312:Found [Quantitative Concept]
   966 E C0243095:Find [Finding]

Phrase: "that"

Phrase: "a much shorter duration of treatment"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   833   C0444921:Duration of treatment [Temporal Concept]
           duration treatment
   773   C0439593:Short duration [Qualitative Concept]
   753   C0449238:Duration [Temporal Concept]
   753   C2926735:Duration [Pharmacologic Substance]

Phrase: "("

Phrase: "enforced by the amount of compound available"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   748   C0205198:Compound [Qualitative Concept]
   748   C0470187:Available [Functional Concept]
           Availability of
   748   C1265611:Amount [Quantitative Concept]
   748   C1706082:Compound [Chemical]

Phrase: "to us)"

Phrase: "with the same inhibitor"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1999216:Inhibitor [Qualitative Concept]

Phrase: "normalized"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882115:Normalized [Research Activity]

Phrase: "only SNCV."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C2982003:NCV [Diagnostic Procedure]
Processing 00000000.tx.166: However, the findings reported here, together with the immunocytochemistry, indicate a clear involvement of p38 activation in the motor deficit. 

Phrase: "However,"

Phrase: "the findings"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C2607943:findings [Functional Concept]
  1000   C2926606:Findings [Clinical Attribute]
  1000   C3539655:Findings [Intellectual Product]
   966 E C0037088:Finding [Sign or Symptom]
   966 E C0243095:Finding [Finding]
   966 E C2825141:Finding [Finding]

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "here,"

Phrase: "together with the immunocytochemistry,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0242349:Immunocytochemistry [Laboratory Procedure]

Phrase: "indicate"

Phrase: "a clear involvement of p38 activation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1314939:Involvement [Functional Concept]

Phrase: "in the motor deficit."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0746626:motor deficit [Pathologic Function]
   861   C0162429:Deficit, NOS [Disease or Syndrome]
   861   C2987487:Deficit [Qualitative Concept]
Processing 00000000.tx.167: This might also provide an explanation for the protection of nerve function given by aldose reductase inhibitors. 

Phrase: "This"

Phrase: "might"

Phrase: "also"

Phrase: "provide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provide [Activity]

Phrase: "an explanation for the protection of nerve function"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0681841:Explanation [Intellectual Product]

Phrase: "given by aldose reductase inhibitors."
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   828   C2348243:Aldose Reductase Inhibitor [Pharmacologic Substance]
   806   C0002003:Aldose Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   806   C1412322:ALDOSE REDUCTASE [Gene or Genome]
   760   C0030016:Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   760   C0243077:inhibitors [Chemical Viewed Functionally]
   760   C0682934:Aldose [Carbohydrate]
   760   C1442162:GIVEN [Conceptual Entity]
   760   C1550718:given [Idea or Concept]
   760   C3244317:given [Intellectual Product]
   726 E C1947971:Give [Functional Concept]
   726 E C1999216:Inhibitor [Qualitative Concept]
Processing 00000000.tx.168: Because the activation of p38 seen in the DRG was primarily a nuclear event and the known targets of p38 are transcription factors (3033), the observations reported here also suggest that the nerve conduction defects seen in diabetes derive from disordered gene expression. 

Phrase: "Because"

Phrase: "the activation of p38"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1879547:Activation [Activity]

Phrase: "seen in the DRG"
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
   833   C0017070:Dorsal Root Ganglia [Body Part, Organ, or Organ Component]
           Dorsal Root
   799 E C1761610:Dorsal root ganglion [Body Part, Organ, or Organ Component]
   790   C0205955:Dorsal root [Body Part, Organ, or Organ Component]
   773   C1186181:root ganglion [Body Part, Organ, or Organ Component]
   753   C0017067:Ganglia [Body Part, Organ, or Organ Component]
   753   C0040452:Root [Body Part, Organ, or Organ Component]
   753   C0205095:Dorsal [Spatial Concept]
   753   C0205397:Seen [Qualitative Concept]
   753   C0242726:Root [Plant]
   753   C1318154:Root [Body Part, Organ, or Organ Component]
   753   C1705917:Root [Idea or Concept]
   719 E C0042789:see [Organism Function]
   719 E C1258666:Ganglion, NOS [Acquired Abnormality,Disease or Syndrome]
   719 E C1947903:See [Activity]

Phrase: "was"

Phrase: "primarily"

Phrase: "a nuclear event"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0441471:Event [Event]

Phrase: "and"

Phrase: "the known targets of p38"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   726   C1521840:Target [Functional Concept]
   726   C2986546:TARGET [Diagnostic Procedure]

Phrase: "are"

Phrase: "transcription factors"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0040648:Transcription Factors [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0040649:Transcription [Genetic Function]
   827   C1521761:Factor [Functional Concept]
   827   C2827422:Factor [Conceptual Entity]

Phrase: "(3033"

Phrase: ")"

Phrase: ","

Phrase: "the observations"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0302523:observations [Research Activity]
  1000   C0700325:observations [Health Care Activity]
  1000   C3244290:observations [Functional Concept]
   966 E C1964257:Observation [Diagnostic Procedure]
   916 E C1518527:OBSERVATIONAL [Research Activity]

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "here also"

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "the nerve conduction defects"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   901   C0264886:Conduction defects [Disease or Syndrome]
   827   C0243067:defects [Functional Concept]
   793 E C1457869:Defect [Functional Concept]
   793 E C1861101:DEFECT [Disease or Syndrome]
   734   C0027788:Nerve Conduction [Organ or Tissue Function]

Phrase: "seen in diabetes"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   790   C0011847:Diabetes [Disease or Syndrome]
   790   C0011849:Diabetes [Disease or Syndrome]
   790   C0205397:Seen [Qualitative Concept]
   756 E C0042789:see [Organism Function]
   756 E C1947903:See [Activity]

Phrase: "derive from disordered gene expression."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C0017262:Gene Expression [Genetic Function]
   760   C0017337:Gene [Gene or Genome]
   760   C0185117:Expression [Therapeutic or Preventive Procedure]
Processing 00000000.tx.169: However, the activation of p38 MAP kinase in the sciatic nerve itself, plus the inhibition of that activation by SB 239063, does not preclude local mechanisms operating in the axon or even effects on nerve blood flow or Schwann cell function. 

Phrase: "However,"

Phrase: "the activation of p38 MAP kinase"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   793   C1819041:protein kinase activation [Cell Function]
   767   C0599177:protein activation [Genetic Function]
   744   C1879547:Activation [Activity]
   703   C1456380:p38 Mitogen Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "in the sciatic nerve"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
  1000   C0036394:Sciatic Nerve [Body Part, Organ, or Organ Component]
  1000   C1278851:Sciatic nerve [Body Part, Organ, or Organ Component]
   861   C0027740:Nerve [Tissue]
   861   C0027757:NERVE [Tissue]
   861   C1280541:Nerve [Body Part, Organ, or Organ Component]
   805 E C0599851:Neural [Functional Concept]
   789 E C0027769:nervy [Sign or Symptom]

Phrase: "itself,"

Phrase: "plus"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332287:Plus [Qualitative Concept]

Phrase: "the inhibition of"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   790   C0021467:Inhibition [Mental Process]
   790   C0021469:Inhibition [Molecular Function]
   790   C1628982:% inhibition [Quantitative Concept]
   790   C3463820:Inhibition [Activity]
   718 E C0311403:Inhibited [Qualitative Concept]

Phrase: "that activation by SB 239063,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1879547:Activation [Activity]

Phrase: "does"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "preclude"

Phrase: "local mechanisms"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0441712:Mechanisms [Functional Concept]
   827 E C1706376:Mechanism [Manufactured Object]

Phrase: "operating in the axon"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0004461:Axon [Cell Component]
   737   C3242339:operate [Functional Concept]

Phrase: "or"

Phrase: "even effects on nerve blood flow"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C1280500:effects [Qualitative Concept]
   719 E C2348382:Effect [Qualitative Concept]

Phrase: "or"

Phrase: "Schwann cell function."
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   901   C0007613:Cell Function [Cell Function]
   827   C0031843:function [Physiologic Function]
   827   C0542341:Function [Functional Concept]
   827   C0700205:FUNCTION [Classification]
   827   C1705273:Function [Intellectual Product]
   755 E C0205245:Functional [Functional Concept]
   755 E C2700217:Functional [Conceptual Entity]
   734   C0036387:Schwann cell [Cell]
Processing 00000000.tx.170: Further studies will clarify these possibilities. 

Phrase: "Further studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "will"

Phrase: "clarify"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2986669:Clarify [Activity]

Phrase: "these possibilities."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   916   C0332149:Possible [Qualitative Concept]
   916   C1705910:Possible [Qualitative Concept]
   916   C2362652:Possible [Qualitative Concept]
Processing 00000000.tx.171: Whatever the mechanism, this study clearly implicates p38 MAP kinase in the development of nerve conduction deficits. 

Phrase: "Whatever"

Phrase: "the mechanism,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0441712:Mechanism [Functional Concept]
  1000   C1706376:Mechanism [Manufactured Object]

Phrase: "this study clearly"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0557651:Study [Manufactured Object]
   861   C2603343:Study [Research Activity]

Phrase: "implicates"

Phrase: "p38 MAP kinase in the development of nerve conduction deficits."
Meta Candidates (Total=13; Excluded=2; Pruned=0; Remaining=11)
   810   C1456380:p38 Mitogen Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   804 E C1120843:mitogen-activated protein kinase p38 [Amino Acid, Peptide, or Protein,Enzyme]
           p38 Protein Kinase
   790   C0752312:Mitogen-Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   770   C1979930:Mitogen-activated protein [Amino Acid, Peptide, or Protein]
   753   C0033640:PROTEIN KINASE [Amino Acid, Peptide, or Protein,Enzyme]
   751   C0027759:nerve protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   736   C0018284:Mitogen [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   736   C0026249:Mitogen [Pharmacologic Substance]
   736   C0031727:Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   736   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   736   C1879547:Activated [Activity]
   703 E C1515877:Activate [Functional Concept]
Processing 00000000.tx.172: Further studies will also seek the substrate downstream of p38 MAP kinase. 

Phrase: "Further studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "will"

Phrase: "also"

Phrase: "seek"

Phrase: "the substrate downstream of p38 MAP kinase."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C1710236:Substrate [Manufactured Object]
Processing 00000000.tx.173: So far we have examined activation of both activating transcription factor-2 and c-Jun, but the former was unaffected by diabetes and the latter unaffected by the inhibitor (data not shown). 

Phrase: "So far"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0037640:SO [Geographic Area]
   861   C0205108:far [Spatial Concept]

Phrase: "we"

Phrase: "have"

Phrase: "examined activation of both activating transcription factor-2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   767   C0162493:Transcription Activation [Genetic Function]
   744   C1879547:Activation [Activity]

Phrase: "and"

Phrase: "c-Jun,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0162508:c-Jun [Gene or Genome]
   861   C3536909:JUN [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "but"

Phrase: "the former"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205156:Former [Temporal Concept]
  1000   C0750523:FORMER [Idea or Concept]

Phrase: "was"

Phrase: "unaffected by diabetes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C2986417:Unaffected [Conceptual Entity]

Phrase: "and"

Phrase: "the latter"

Phrase: "unaffected by the inhibitor"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C2986417:Unaffected [Conceptual Entity]

Phrase: "(data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.174: In any case, both of these substrates are activated by other upstream events, such as phosphorylation of c-Jun NH2-terminal kinase, which is also increased in diabetes (7). 

Phrase: "In any case,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0868928:Case [Functional Concept]
  1000   C1706255:CASE [Medical Device]
  1000   C1706256:Case [Conceptual Entity]

Phrase: "both of these substrates"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0238767:Both [Spatial Concept]
   770   C1706086:Both [Qualitative Concept]
   737   C1710236:Substrate [Manufactured Object]

Phrase: "are"

Phrase: "activated by other upstream events,"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   760   C0441471:Events [Event]
   760   C0522505:Upstream [Spatial Concept]
   760   C1879547:Activated [Activity]
   760   C3541888:Events [Classification]
   726 E C1515877:Activate [Functional Concept]

Phrase: "such as phosphorylation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0031715:Phosphorylation [Molecular Function]
  1000   C1158886:Phosphorylation [Molecular Function]

Phrase: "of c-Jun NH2-terminal kinase,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   937   C0248813:jun-NH2-Terminal Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   911   C0872123:c JUN kinase [Amino Acid, Peptide, or Protein,Enzyme]
   875   C0872053:JUN kinase [Amino Acid, Peptide, or Protein,Enzyme]
   875   C1334482:Jun kinase [Gene or Genome]
   875   C1367019:Jun Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   804   C0031727:Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   708   C1707271:C-Terminal [Amino Acid Sequence]

Phrase: "which"

Phrase: "is"

Phrase: "also"

Phrase: "increased in diabetes"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   790   C0011847:Diabetes [Disease or Syndrome]
   790   C0011849:Diabetes [Disease or Syndrome]
   790   C0205217:Increased [Quantitative Concept]
   790   C0442805:Increased [Functional Concept]
   718 E C1517378:Gain [Quantitative Concept]

Phrase: "(7"

Phrase: ")."
Processing 00000000.tx.175: In conclusion, the present study provides a possible mechanism to explain the causation of nerve conduction deficits by exaggerated flux through the polyol pathway, namely activation of MAP kinase p38. 

Phrase: "In conclusion,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707478:Conclusion [Idea or Concept]

Phrase: "the present study"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0150312:Present [Quantitative Concept]
   861   C0449450:Present [Idea or Concept]
   861   C0557651:Study [Manufactured Object]
   861   C2603343:Study [Research Activity]

Phrase: "provides"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0359589:provides [Food]
  1000   C1999230:Provide [Activity]

Phrase: "a possible mechanism to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0441712:Mechanism [Functional Concept]
   827   C1706376:Mechanism [Manufactured Object]

Phrase: "explain"

Phrase: "the causation of nerve conduction deficits"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0085978:Causation [Idea or Concept]
   753   C1524003:Causation [Conceptual Entity]

Phrase: "by exaggerated flux"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2348693:Flux [Natural Phenomenon or Process]

Phrase: "through the polyol pathway,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1704259:Pathway [Molecular Function]
   861   C1705987:Pathway [Conceptual Entity]

Phrase: "namely activation of MAP kinase p38."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   793   C1819041:protein kinase activation [Cell Function]
   767   C0599177:protein activation [Genetic Function]
   744   C1879547:Activation [Activity]
   703   C1120843:mitogen-activated protein kinase p38 [Amino Acid, Peptide, or Protein,Enzyme]
Processing 00000000.tx.176: We suggest that this phosphorylates transcription factors, leading to reduced expression of proteins critical to the propagation of the nerve action potential. 

Phrase: "We"

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "this"

Phrase: "phosphorylates"

Phrase: "transcription factors,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0040648:Transcription Factors [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0040649:Transcription [Genetic Function]
   827   C1521761:Factor [Functional Concept]
   827   C2827422:Factor [Conceptual Entity]

Phrase: "leading to reduced expression of proteins"
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
   767   C1171362:expression protein [Genetic Function]
   753   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   753   C0185117:Expression [Therapeutic or Preventive Procedure]
   753   C0332152:Leading [Temporal Concept]
   753   C0392756:Reduced [Qualitative Concept]
   753   C1522538:Leading [Functional Concept]
   719 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   719 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   719 E C2348269:Lead [Element, Ion, or Isotope]
   719 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "critical to the propagation of the nerve action potential."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C1511545:Critical [Qualitative Concept]
Processing 00000000.tx.177: Given that p38 could be activated by a combination of osmotic and oxidative stressesboth attributable to and independent of the polyol pathwayplus the action of advanced glycation end products via receptor of advanced glycation end products receptors, it may act as a synergy funnel, whereby different biochemical anomalies affect a single function.  

Phrase: "Given"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C1442162:GIVEN [Conceptual Entity]
  1000   C1550718:given [Idea or Concept]
  1000   C3244317:given [Intellectual Product]
   966 E C1947971:Give [Functional Concept]

Phrase: "that p38"

Phrase: "could"

Phrase: "be"

Phrase: "activated by a combination of osmotic"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   753   C0029391:osmotic [Natural Phenomenon or Process]
   753   C0205195:Combination [Qualitative Concept]
   753   C0311417:Osmotic [Functional Concept]
   753   C1879547:Activated [Activity]
   753   C1947911:Combination [Physical Object]
   719 E C1515877:Activate [Functional Concept]

Phrase: "and"

Phrase: "oxidative stressesboth"

Phrase: "attributable to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   833   C0596130:Attributable [Mental Process]

Phrase: "and independent of the polyol pathwayplus"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C0332291:Independent of [Functional Concept]
   753   C0071629:polyol [Organic Chemical]
   753   C0085862:Independent [Idea or Concept]
   753   C1299583:Independent [Finding]
   753   C1515981:And [Idea or Concept]

Phrase: "the action of advanced glycation end products"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0441472:Action [Functional Concept]
   748   C3266814:Action [Activity]

Phrase: "via receptor"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "of advanced glycation end products receptors,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   804   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   771   C0162574:Glycation End Products, Advanced [Biologically Active Substance,Organic Chemical]

Phrase: "it"

Phrase: "may"

Phrase: "act as a synergy funnel,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0079613:ACT [Therapeutic or Preventive Procedure]

Phrase: "whereby different biochemical anomalies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   812   C0000769:anomalies [Functional Concept]
   779 E C1704258:Anomaly [Finding]
   729 E C3277934:Anomalous [Finding]

Phrase: "affect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001721:Affect [Mental Process]

Phrase: "a single function."
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   861   C0031843:function [Physiologic Function]
   861   C0542341:Function [Functional Concept]
   861   C0700205:FUNCTION [Classification]
   861   C1705273:Function [Intellectual Product]
   789 E C0205245:Functional [Functional Concept]
   789 E C2700217:Functional [Conceptual Entity]
Processing 00000000.tx.178: ACKNOWLEDGMENTS  S.A. was in receipt of a scholarship from the government of Thailand. 

Phrase: "ACKNOWLEDGMENTS  S.A."

Phrase: "was in receipt of a scholarship"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0036365:scholarship [Idea or Concept]
   753   C0043194:WAS [Disease or Syndrome]
   753   C0258432:WAS [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   753   C1421478:WAS [Gene or Genome]

Phrase: "from the government"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0018104:Government [Organization]

Phrase: "of Thailand."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0039725:Thailand [Geographic Area]
Processing 00000000.tx.179: Financial support from the Medical Research Council of the U.K. 

Phrase: "Financial support from the Medical Research Council of the U.K."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   770   C1568415:Support of Research [Intellectual Product]
   756   C0016118:Financial Support [Idea or Concept]
   754   C0035176:Research Support [Quantitative Concept]
   738   C0183683:Support [Medical Device]
   738   C0376243:financial [Quantitative Concept]
   738   C1521721:Support [Conceptual Entity]
   738   C2350008:Financial [Qualitative Concept]
Processing 00000000.tx.180: (to D.R.T. and supporting S.A.P.) is gratefully acknowledged. 

Phrase: "("

Phrase: "to D.R.T."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   901   C0232024:R T [Clinical Attribute]

Phrase: "and"

Phrase: "supporting S.A.P.)"

Phrase: "is"

Phrase: "gratefully"

Phrase: "acknowledged."
Processing 00000000.tx.181: We thank Sanwa (fidarestat) and GlaxoSmithKline (SB 239063) for gifts of drugs. 

Phrase: "We"

Phrase: "thank"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2986676:THANK [Gene or Genome]

Phrase: "Sanwa"

Phrase: "(fidarestat"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0905478:fidarestat [Organic Chemical,Pharmacologic Substance]

Phrase: ")"

Phrase: "and"

Phrase: "GlaxoSmithKline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1546895:GlaxoSmithKline [Health Care Related Organization]

Phrase: "(SB 239063"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0913456:SB 239063 [Organic Chemical]

Phrase: ")"

Phrase: "for gifts"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1136188:Gifts [Entity]
   916 E C0423899:Gifted [Finding]

Phrase: "of drugs."
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
  1000   C0013227:Drugs [Pharmacologic Substance]
   966 E C1254351:Drug [Pharmacologic Substance]
   928 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   928 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   900 E C0456386:Medicament [Pharmacologic Substance]
Processing 00000000.tx.182: Address correspondence and reprint requests to Professor David Tomlinson, Division of Neuroscience, School of Biological Sciences, University of Manchester, Stopford Building 1.124, Oxford Road, Manchester M13 9PT, U.K. 

Phrase: "Address correspondence"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0282413:Correspondence [Intellectual Product]

Phrase: "and"

Phrase: "reprint"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3273171:Reprint [Intellectual Product]

Phrase: "requests to Professor David Tomlinson,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0599518:Professor [Professional or Occupational Group]
   760   C0686900:request [Functional Concept]
   760   C1272683:Request [Functional Concept]
   760   C1522634:Request [Intellectual Product]

Phrase: "Division of Neuroscience,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C1293097:Division [Therapeutic or Preventive Procedure]
   790   C2919030:Division [Organization]
   790   C2919031:Division [Activity]

Phrase: "School of Biological Sciences,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0036375:School [Manufactured Object,Organization]

Phrase: "University of Manchester,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0041740:University [Manufactured Object,Organization]

Phrase: "Stopford"

Phrase: "Building"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1547706:Building [Functional Concept]
  1000   C1999269:Building [Manufactured Object]
   966 E C1707059:Build [Conceptual Entity]

Phrase: "1.124,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C2827734:1+ [Quantitative Concept]
   861   C2981698:1+ [Classification]

Phrase: "Oxford Road,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0442650:Road [Manufactured Object]

Phrase: "Manchester M13 9PT,"

Phrase: "U.K."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]
Processing 00000000.tx.183: E-mail: david.tomlinson{at}man.ac.uk Received for publication April 4, 2003 and accepted in revised form April 19, 2004 ChAT, choline acetyltransferase; 

Phrase: "E-mail"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0013849:E-Mail [Intellectual Product]
  1000   C1705961:E-mail [Intellectual Product]
   861   C0024492:Mail [Manufactured Object]
   861   C1538057:MAIL [Gene or Genome]
   861   C1547565:Mail [Idea or Concept]

Phrase: ":"

Phrase: "david.tomlinson{at}man.ac.uk"

Phrase: "Received for publication April 4,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0034036:Publication [Intellectual Product,Manufactured Object]
   760   C0034037:Publication [Occupational Activity]
   760   C1514756:Received [Qualitative Concept]
   760   C1704324:Publication [Intellectual Product]

Phrase: "2003"

Phrase: "and"

Phrase: "accepted in revised form April 19,"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   753   C0348078:Form [Qualitative Concept]
   753   C0376315:Form [Manufactured Object]
   753   C1272684:Accepted [Qualitative Concept]
   753   C1522492:Form [Functional Concept]
   753   C1527075:Revised [Therapeutic or Preventive Procedure]
   753   C1548435:Accepted [Idea or Concept]
   719 E C1548601:Accept [Idea or Concept]

Phrase: "2004 ChAT,"

Phrase: "choline acetyltransferase"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0008407:Choline Acetyltransferase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1413376:CHOLINE ACETYLTRANSFERASE [Gene or Genome]
   861   C0001068:Acetyltransferase [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0001390:Acetyltransferase [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0008405:Choline [Biologically Active Substance,Organic Chemical,Pharmacologic Substance]

Phrase: ";"
Processing 00000000.tx.184: DRG, dorsal root ganglia; 

Phrase: "DRG,"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
  1000   C0017070:Dorsal Root Ganglia [Body Part, Organ, or Organ Component]
           Dorsal Root
   966 E C1761610:Dorsal root ganglion [Body Part, Organ, or Organ Component]
   901   C0205955:Dorsal root [Body Part, Organ, or Organ Component]
   884   C1186181:root ganglion [Body Part, Organ, or Organ Component]
   827   C0017067:Ganglia [Body Part, Organ, or Organ Component]
   827   C0040452:Root [Body Part, Organ, or Organ Component]
   827   C0205095:Dorsal [Spatial Concept]
   827   C0242726:Root [Plant]
   827   C1318154:Root [Body Part, Organ, or Organ Component]
   827   C1705917:Root [Idea or Concept]
   793 E C1258666:Ganglion, NOS [Acquired Abnormality,Disease or Syndrome]

Phrase: "dorsal root ganglia"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
  1000   C0017070:Dorsal Root Ganglia [Body Part, Organ, or Organ Component]
           Dorsal Root
   966 E C1761610:Dorsal root ganglion [Body Part, Organ, or Organ Component]
   901   C0205955:Dorsal root [Body Part, Organ, or Organ Component]
   884   C1186181:root ganglion [Body Part, Organ, or Organ Component]
   827   C0017067:Ganglia [Body Part, Organ, or Organ Component]
   827   C0040452:Root [Body Part, Organ, or Organ Component]
   827   C0205095:Dorsal [Spatial Concept]
   827   C0242726:Root [Plant]
   827   C1318154:Root [Body Part, Organ, or Organ Component]
   827   C1705917:Root [Idea or Concept]
   793 E C1258666:Ganglion, NOS [Acquired Abnormality,Disease or Syndrome]

Phrase: ";"
Processing 00000000.tx.185: MAP, mitogen-activated protein; 

Phrase: "MAP,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1979930:Mitogen-activated protein [Amino Acid, Peptide, or Protein]
   827   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "mitogen-activated protein"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1979930:Mitogen-activated protein [Amino Acid, Peptide, or Protein]
   827   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: ";"
Processing 00000000.tx.186: MNCV, motor nerve conduction velocity; 

Phrase: "MNCV,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2982003:NCV [Diagnostic Procedure]

Phrase: "motor nerve conduction velocity"
Meta Candidates (Total=17; Excluded=2; Pruned=0; Remaining=15)
  1000   C0457379:Motor nerve conduction velocity [Finding]
   923   C0429381:Nerve conduction velocity [Finding]
   923   C2982003:Nerve Conduction Velocity [Diagnostic Procedure]
   861   C0027788:Nerve Conduction [Organ or Tissue Function]
   861   C0234084:Conduction velocity [Organ or Tissue Function]
   861   C0501384:Motor nerve [Body Part, Organ, or Organ Component]
   812   C0027740:Nerve [Tissue]
   812   C0027757:NERVE [Tissue]
   812   C0232217:Conduction [Organ or Tissue Function]
   812   C0439830:Velocity [Quantitative Concept]
   812   C0457405:Conduction [Natural Phenomenon or Process]
   812   C1280541:Nerve [Body Part, Organ, or Organ Component]
   812   C1513492:Motor [Functional Concept]
   812   C1547053:*Velocity [Quantitative Concept]
   812   C1705994:Motor [Manufactured Object]
   756 E C0599851:Neural [Functional Concept]
   741 E C0027769:nervy [Sign or Symptom]

Phrase: ";"
Processing 00000000.tx.187: NCV, nerve conduction velocity; 

Phrase: "NCV,"
Meta Candidates (Total=13; Excluded=2; Pruned=0; Remaining=11)
  1000   C0429381:Nerve conduction velocity [Finding]
  1000   C2982003:Nerve Conduction Velocity [Diagnostic Procedure]
   901   C0027788:Nerve Conduction [Organ or Tissue Function]
   901   C0234084:Conduction velocity [Organ or Tissue Function]
   827   C0027740:Nerve [Tissue]
   827   C0027757:NERVE [Tissue]
   827   C0232217:Conduction [Organ or Tissue Function]
   827   C0439830:Velocity [Quantitative Concept]
   827   C0457405:Conduction [Natural Phenomenon or Process]
   827   C1280541:Nerve [Body Part, Organ, or Organ Component]
   827   C1547053:*Velocity [Quantitative Concept]
   771 E C0599851:Neural [Functional Concept]
   755 E C0027769:nervy [Sign or Symptom]

Phrase: "nerve conduction velocity"
Meta Candidates (Total=13; Excluded=2; Pruned=0; Remaining=11)
  1000   C0429381:Nerve conduction velocity [Finding]
  1000   C2982003:Nerve Conduction Velocity [Diagnostic Procedure]
   901   C0027788:Nerve Conduction [Organ or Tissue Function]
   901   C0234084:Conduction velocity [Organ or Tissue Function]
   827   C0027740:Nerve [Tissue]
   827   C0027757:NERVE [Tissue]
   827   C0232217:Conduction [Organ or Tissue Function]
   827   C0439830:Velocity [Quantitative Concept]
   827   C0457405:Conduction [Natural Phenomenon or Process]
   827   C1280541:Nerve [Body Part, Organ, or Organ Component]
   827   C1547053:*Velocity [Quantitative Concept]
   771 E C0599851:Neural [Functional Concept]
   755 E C0027769:nervy [Sign or Symptom]

Phrase: ";"
Processing 00000000.tx.188: SNCV, sensory NCV; 

Phrase: "SNCV,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2982003:NCV [Diagnostic Procedure]

Phrase: "sensory NCV"
Meta Candidates (Total=16; Excluded=2; Pruned=0; Remaining=14)
  1000   C0457378:Sensory nerve conduction velocity [Finding]
   923   C0429381:Nerve conduction velocity [Finding]
   923   C2982003:Nerve Conduction Velocity [Diagnostic Procedure]
   861   C0027788:Nerve Conduction [Organ or Tissue Function]
   861   C0234084:Conduction velocity [Organ or Tissue Function]
   861   C0501385:Sensory nerve [Body Part, Organ, or Organ Component]
   812   C0027740:Nerve [Tissue]
   812   C0027757:NERVE [Tissue]
   812   C0232217:Conduction [Organ or Tissue Function]
   812   C0439830:Velocity [Quantitative Concept]
   812   C0445254:Sensory [Qualitative Concept]
   812   C0457405:Conduction [Natural Phenomenon or Process]
   812   C1280541:Nerve [Body Part, Organ, or Organ Component]
   812   C1547053:*Velocity [Quantitative Concept]
   756 E C0599851:Neural [Functional Concept]
   741 E C0027769:nervy [Sign or Symptom]

Phrase: ";"
Processing 00000000.tx.189: STZ, streptozocin  REFERENCES TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES  Lawrence DG, Locke S: Motor nerve conduction velocity in diabetes. 

Phrase: "STZ,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0038432:STZ [Antibiotic,Carbohydrate]
  1000   C1539862:STZ [Gene or Genome]

Phrase: "streptozocin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0038432:Streptozocin [Antibiotic,Carbohydrate]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "TOP ABSTRACT RESEARCH DESIGN"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0035171:Research Design [Research Activity]
   812   C0035168:research [Research Activity]
   812   C0242481:Research [Research Activity]
   812   C1707689:Design [Activity]
   812   C2983265:DESIGN [Intellectual Product]

Phrase: "AND"

Phrase: "METHODS RESULTS DISCUSSION"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Lawrence DG,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1275573:dg [Quantitative Concept]

Phrase: "Locke S"

Phrase: ":"

Phrase: "Motor nerve conduction velocity in diabetes."
Meta Candidates (Total=15; Excluded=0; Pruned=0; Remaining=15)
   882   C0457379:Motor nerve conduction velocity [Finding]
   833   C0429381:Nerve conduction velocity [Finding]
   833   C2982003:Nerve Conduction Velocity [Diagnostic Procedure]
   790   C0027788:Nerve Conduction [Organ or Tissue Function]
   790   C0234084:Conduction velocity [Organ or Tissue Function]
   790   C0501384:Motor nerve [Body Part, Organ, or Organ Component]
   753   C0027740:Nerve [Tissue]
   753   C0027757:NERVE [Tissue]
   753   C0232217:Conduction [Organ or Tissue Function]
   753   C0439830:Velocity [Quantitative Concept]
   753   C0457405:Conduction [Natural Phenomenon or Process]
   753   C1280541:Nerve [Body Part, Organ, or Organ Component]
   753   C1513492:Motor [Functional Concept]
   753   C1547053:*Velocity [Quantitative Concept]
   753   C1705994:Motor [Manufactured Object]
Processing 00000000.tx.190: Arch Neurol5 :483 490,1961[Medline] Eliasson SG: Nerve conduction changes in experimental diabetes. 

Phrase: "Arch Neurol5"

Phrase: ":"

Phrase: "483 490,"

Phrase: "1961"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Eliasson SG"

Phrase: ":"

Phrase: "Nerve conduction"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C0027788:Nerve Conduction [Organ or Tissue Function]
   861   C0027740:Nerve [Tissue]
   861   C0027757:NERVE [Tissue]
   861   C0232217:Conduction [Organ or Tissue Function]
   861   C0457405:Conduction [Natural Phenomenon or Process]
   861   C1280541:Nerve [Body Part, Organ, or Organ Component]
   805 E C0599851:Neural [Functional Concept]
   789 E C0027769:nervy [Sign or Symptom]

Phrase: "changes in experimental diabetes."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C0011847:Diabetes [Disease or Syndrome]
   770   C0011849:Diabetes [Disease or Syndrome]
   770   C0392747:Change [Functional Concept]
   770   C0443172:change [Quantitative Concept]
   770   C1517586:Experimental [Qualitative Concept]
   770   C1705241:Change [Quantitative Concept]
Processing 00000000.tx.191: J Clin Invest43 :2353 2358,1964[Medline] Tomlinson DR, Holmes PR, Mayer JH: Reversal, by treatment with an aldose reductase inhibitor, of impaired axonal transport and motor nerve conduction velocity in experimental diabetes mellitus. 

Phrase: "J Clin Invest43"

Phrase: ":"

Phrase: "2353 2358,"

Phrase: "1964"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Tomlinson DR,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0031831:DR [Professional or Occupational Group]
   861   C1707664:DR [Biomedical or Dental Material]
   861   C2348314:Dr. [Conceptual Entity]
   861   C3540849:DR [Idea or Concept]

Phrase: "Holmes PR,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0279759:PR+ [Laboratory or Test Result]
   861   C0279766:PR- [Laboratory or Test Result]
   861   C1418864:PR@ [Gene or Genome]
   861   C3538934:PR [Intellectual Product]
   861   C3538935:PR [Idea or Concept]

Phrase: "Mayer JH"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0268060:JH [Disease or Syndrome]
   861   C1415529:JH [Gene or Genome]

Phrase: ":"

Phrase: "Reversal,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443290:Reversal [Functional Concept]

Phrase: "by treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "with an aldose reductase inhibitor,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C2348243:Aldose Reductase Inhibitor [Pharmacologic Substance]
   901   C0002003:Aldose Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   901   C1412322:ALDOSE REDUCTASE [Gene or Genome]
   827   C0030016:Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0682934:Aldose [Carbohydrate]
   827   C1999216:Inhibitor [Qualitative Concept]

Phrase: "of impaired axonal transport"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0004462:Axonal Transport [Cell Function]
   827   C0005528:Transport, NOS [Cell Function]
   827   C1317949:Transport [Manufactured Object]
   827   C3495449:transport [Medical Device]
   755   C0004461:Axon [Cell Component]

Phrase: "and"

Phrase: "motor nerve conduction velocity in experimental diabetes mellitus."
Meta Candidates (Total=15; Excluded=0; Pruned=0; Remaining=15)
   833   C0457379:Motor nerve conduction velocity [Finding]
   800   C0429381:Nerve conduction velocity [Finding]
   800   C2982003:Nerve Conduction Velocity [Diagnostic Procedure]
   770   C0027788:Nerve Conduction [Organ or Tissue Function]
   770   C0234084:Conduction velocity [Organ or Tissue Function]
   770   C0501384:Motor nerve [Body Part, Organ, or Organ Component]
   744   C0027740:Nerve [Tissue]
   744   C0027757:NERVE [Tissue]
   744   C0232217:Conduction [Organ or Tissue Function]
   744   C0439830:Velocity [Quantitative Concept]
   744   C0457405:Conduction [Natural Phenomenon or Process]
   744   C1280541:Nerve [Body Part, Organ, or Organ Component]
   744   C1513492:Motor [Functional Concept]
   744   C1547053:*Velocity [Quantitative Concept]
   744   C1705994:Motor [Manufactured Object]
Processing 00000000.tx.192: Neurosci Lett31 :189 193,1982[Medline] Judzewitsch RG, Jaspan JB, Polonsky KS, Weinberg CR, Halter JB, Halar E, Pfeifer MA, Vukadinovic C, Bernstein L, Schneider M, Liang K-Y, Gabbay KH, Rubenstein AH, Porte D Jr: Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. 

Phrase: "Neurosci Lett31"

Phrase: ":"

Phrase: "189 193,"

Phrase: "1982"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Judzewitsch RG,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1412999:RG [Gene or Genome]

Phrase: "Jaspan JB,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1550751:JB [Temporal Concept]

Phrase: "Polonsky KS,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3541894:ks [Quantitative Concept]

Phrase: "Weinberg CR,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0201975:Cr [Laboratory Procedure]
   861   C3539604:CR [Gene or Genome]

Phrase: "Halter JB,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1550751:JB [Temporal Concept]

Phrase: "Halar E,"

Phrase: "Pfeifer MA,"

Phrase: "Vukadinovic C,"

Phrase: "Bernstein L,"

Phrase: "Schneider M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Liang K-Y,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   827   C1708601:K' [Quantitative Concept]

Phrase: "Gabbay KH,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0006797:KH [Geographic Area]

Phrase: "Rubenstein AH,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1836672:AH [Disease or Syndrome]

Phrase: "Porte D Jr"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1708595:Jr [Idea or Concept]
   827   C3280986:JR [Disease or Syndrome]

Phrase: ":"

Phrase: "Aldose reductase inhibition"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   827   C0021467:Inhibition [Mental Process]
   827   C0021469:Inhibition [Molecular Function]
   827   C1628982:% inhibition [Quantitative Concept]
   827   C3463820:Inhibition [Activity]
   755 E C0311403:Inhibited [Qualitative Concept]
   734   C0002003:Aldose Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   734   C1412322:ALDOSE REDUCTASE [Gene or Genome]

Phrase: "improves"

Phrase: "nerve conduction velocity in diabetic patients."
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   833   C0429381:Nerve conduction velocity [Finding]
   833   C2982003:Nerve Conduction Velocity [Diagnostic Procedure]
   790   C0027788:Nerve Conduction [Organ or Tissue Function]
   790   C0234084:Conduction velocity [Organ or Tissue Function]
   753   C0027740:Nerve [Tissue]
   753   C0027757:NERVE [Tissue]
   753   C0232217:Conduction [Organ or Tissue Function]
   753   C0439830:Velocity [Quantitative Concept]
   753   C0457405:Conduction [Natural Phenomenon or Process]
   753   C1280541:Nerve [Body Part, Organ, or Organ Component]
   753   C1547053:*Velocity [Quantitative Concept]
Processing 00000000.tx.193: N Engl J Med308 :119 125,1983[Abstract] Santiago JV, Snksen PH, Boulton AJ, Macleod A, Beg M, Bochenek W, Graepel GJ, Gonen B: Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function: the Tolrestat Study Group. 

Phrase: "N Engl J Med308"

Phrase: ":"

Phrase: "119 125,"

Phrase: "1983"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Santiago JV,"

Phrase: "Snksen PH,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0020283:[pH] [Quantitative Concept]
   861   C0450407:ph+ [Finding]
   861   C0450408:ph++ [Finding]
   861   C0450409:ph+++ [Finding]

Phrase: "Boulton AJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0230613:AJ [Cell Component]

Phrase: "Macleod A,"

Phrase: "Beg"

Phrase: "M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]

Phrase: "Bochenek W,"

Phrase: "Graepel GJ,"

Phrase: "Gonen B"

Phrase: ":"

Phrase: "Withdrawal of the aldose reductase inhibitor tolrestat"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C2349954:Withdrawal [Activity]
   748   C2825032:Withdrawal [Mental or Behavioral Dysfunction]

Phrase: "in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "with diabetic neuropathy"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0011882:Diabetic neuropathy [Disease or Syndrome]
   861   C0241863:DIABETIC [Finding]
   861   C0442874:Neuropathy [Disease or Syndrome]

Phrase: ":"

Phrase: "effect on nerve function"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1280500:Effect [Qualitative Concept]
   770   C2348382:Effect [Qualitative Concept]

Phrase: ":"

Phrase: "the Tolrestat Study Group."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   827   C0441833:Group [Idea or Concept]
   827   C0557651:Study [Manufactured Object]
   827   C0687744:group [Population Group]
   827   C1257890:Group [Population Group]
   827   C1552516:Group [Health Care Related Organization]
   827   C1705428:Group [Conceptual Entity]
   827   C1705429:Group [Population Group]
   827   C2603343:Study [Research Activity]
Processing 00000000.tx.194: J Diabet Complications7 :170 178,1993 Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. 

Phrase: "J Diabet Complications7"

Phrase: ":"

Phrase: "170 178,"

Phrase: "1993 Diabetes Control and Complications Trial Research Group"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   864   C0009932:Control Group [Group]
   793   C0441833:Group [Idea or Concept]
   793   C0687744:group [Population Group]
   793   C1257890:Group [Population Group]
   793   C1552516:Group [Health Care Related Organization]
   793   C1705428:Group [Conceptual Entity]
   793   C1705429:Group [Population Group]

Phrase: ":"

Phrase: "The effect of intensive treatment of diabetes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   774   C1518681:Treatment Effect [Finding]
   748   C1280500:Effect [Qualitative Concept]
   748   C2348382:Effect [Qualitative Concept]

Phrase: "on the development"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0243107:development [Physiologic Function]
  1000   C0678723:Development [Organism Function]
  1000   C1527148:Development [Functional Concept]
   928 E C0458003:Developmental [Qualitative Concept]

Phrase: "and"

Phrase: "progression of long-term complications"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0242656:progression [Pathologic Function]
   760   C0449258:Progression [Functional Concept]

Phrase: "in insulin-dependent diabetes mellitus."
Meta Candidates (Total=13; Excluded=2; Pruned=0; Remaining=11)
  1000   C0011854:Diabetes Mellitus, Insulin-Dependent [Disease or Syndrome]
           Insulin Dependent Diabetes
   861   C0011849:Diabetes Mellitus [Disease or Syndrome]
           Diabetes
   812   C0011847:Diabetes [Disease or Syndrome]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0851827:Dependent [Qualitative Concept]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   812   C1701901:Dependent [Qualitative Concept]
   812   C3244310:dependent [Functional Concept]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.195: N Engl J Med329 :977 986,1993[Abstract/Free FullText] Purves TD, Middlemas A, Agthong S, Jude EB, Boulton AJM, Fernyhough P, Tomlinson DR: A role for mitogen-activated protein kinases in the aetiology of diabetic neuropathy. 

Phrase: "N Engl J Med329"

Phrase: ":"

Phrase: "977 986,"

Phrase: "1993"

Phrase: "[Abstract/Free FullText"

Phrase: "] Purves TD,"

Phrase: "Middlemas A,"

Phrase: "Agthong S,"

Phrase: "Jude EB,"

Phrase: "Boulton AJM,"

Phrase: "Fernyhough P,"

Phrase: "Tomlinson DR"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0031831:DR [Professional or Occupational Group]
   861   C1707664:DR [Biomedical or Dental Material]
   861   C2348314:Dr. [Conceptual Entity]
   861   C3540849:DR [Idea or Concept]

Phrase: ":"

Phrase: "A role for mitogen-activated protein kinases"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0035820:Role [Social Behavior]
   748   C1705810:Role [Conceptual Entity]

Phrase: "in the aetiology"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0015127:aetiology [Functional Concept]
  1000   C1314792:Aetiology [Functional Concept]
  1000   C1524003:Etiology [Conceptual Entity]

Phrase: "of diabetic neuropathy."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0011882:Diabetic neuropathy [Disease or Syndrome]
   861   C0241863:DIABETIC [Finding]
   861   C0442874:Neuropathy [Disease or Syndrome]
Processing 00000000.tx.196: FASEB J15 :2508 2514,2001[Abstract/Free FullText] Jiang Y, Gram H, Zhao M, New L, Gu J, Feng L, Di-Padova F, Ulevitch RJ, Han J: Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38delta. 

Phrase: "FASEB J15"

Phrase: ":"

Phrase: "2508 2514,"

Phrase: "2001"

Phrase: "[Abstract/Free FullText"

Phrase: "] Jiang Y,"

Phrase: "Gram H,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0560020:gram/h [Quantitative Concept]
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Zhao M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "New L,"

Phrase: "Gu J,"

Phrase: "Feng L,"

Phrase: "Di-Padova F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   827   C0439133:(f) [Intellectual Product]
   827   C1553038:[f] [Quantitative Concept]

Phrase: "Ulevitch RJ,"

Phrase: "Han J"

Phrase: ":"

Phrase: "Characterization of the structure"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1880022:Characterization [Activity]

Phrase: "and"

Phrase: "function of the fourth member of p38 group mitogen-activated protein kinases,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   751   C0815043:function protein [Amino Acid, Peptide, or Protein]
   751   C1527118:Protein Function [Molecular Function]
   736   C0031843:function [Physiologic Function]
   736   C0542341:Function [Functional Concept]
   736   C0700205:FUNCTION [Classification]
   736   C1705273:Function [Intellectual Product]
   715   C0598132:functional group [Chemical Viewed Functionally]

Phrase: "p38delta."
Processing 00000000.tx.197: J Biol Chem272 :30122 30128,1997[Abstract/Free FullText] Underwood DC, Osborn RR, Kotzer CJ, Adams JL, Lee JC, Webb EF, Carpenter DC, Bochnowicz S, Thomas HC, Hay DW, Griswold DE: SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. 

Phrase: "J Biol Chem272"

Phrase: ":"

Phrase: "30122 30128,"

Phrase: "1997"

Phrase: "[Abstract/Free FullText"

Phrase: "] Underwood DC,"

Phrase: "Osborn RR,"

Phrase: "Kotzer CJ,"

Phrase: "Adams JL,"

Phrase: "Lee JC,"

Phrase: "Webb EF,"

Phrase: "Carpenter DC,"

Phrase: "Bochnowicz S,"

Phrase: "Thomas HC,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0020268:HC [Hormone,Pharmacologic Substance,Steroid]
   861   C1413512:Hc [Gene or Genome]

Phrase: "Hay DW,"

Phrase: "Griswold DE"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0011198:DE [Geographic Area]
   861   C0017480:DE [Geographic Area]
   861   C3541240:DE [Idea or Concept]

Phrase: ":"

Phrase: "SB 239063,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0913456:SB 239063 [Organic Chemical]

Phrase: "a potent p38 MAP kinase inhibitor,"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   913   C1513344:Mitogen-Activated Protein Kinase Inhibitor [Pharmacologic Substance]
   845   C1449702:Protein kinase inhibitor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   818   C1171350:Kinase Inhibitor [Pharmacologic Substance]
   818   C3537023:kinase inhibitor [Molecular Function]
   818   C3537035:kinase inhibitor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   795   C1999216:Inhibitor [Qualitative Concept]
   747   C1456380:p38 Mitogen Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   726 E C1120843:p38 Mitogen-Activated Protein Kinases [Amino Acid, Peptide, or Protein,Enzyme]
           p38 Protein Kinase
   710   C0752312:Mitogen-Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "reduces"

Phrase: "inflammatory cytokine production,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C1327413:cytokine production [Organism Function]
   827   C0033268:production [Occupational Activity]

Phrase: "airways eosinophil infiltration,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   865   C0333390:Eosinophilic infiltration [Pathologic Function]
   827   C0332448:Infiltration [Pathologic Function]
   827   C0702249:Infiltration [Therapeutic or Preventive Procedure]
   827   C1523986:Infiltration [Functional Concept]

Phrase: "and"

Phrase: "persistence."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0546816:Persistence [Mental Process]
   928 E C0205322:Persistent [Temporal Concept]
Processing 00000000.tx.198: J Pharmacol Exp Ther293 :281 288,2000[Abstract/Free FullText] Stevens EJ, Carrington AL, Tomlinson DR: Nerve ischaemia in diabetic rats: time-course of development, effect of insulin treatment plus comparison of streptozotocin and BB models. 

Phrase: "J Pharmacol Exp Ther293"

Phrase: ":"

Phrase: "281 288,"

Phrase: "2000"

Phrase: "[Abstract/Free FullText"

Phrase: "] Stevens EJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1718783:Ej [Immunologic Factor]

Phrase: "Carrington AL,"

Phrase: "Tomlinson DR"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0031831:DR [Professional or Occupational Group]
   861   C1707664:DR [Biomedical or Dental Material]
   861   C2348314:Dr. [Conceptual Entity]
   861   C3540849:DR [Idea or Concept]

Phrase: ":"

Phrase: "Nerve ischaemia in diabetic rats"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0022116:Ischaemia [Disease or Syndrome]

Phrase: ":"

Phrase: "time-course of development,"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   833   C0449247:Time course [Temporal Concept]
   770   C0040223:Time [Temporal Concept]
   770   C0750729:Course [Temporal Concept]
   770   C3541383:Time [Temporal Concept]
   715 E C0442043:Temporal [Spatial Concept]
   715 E C2362314:Temporal [Temporal Concept]

Phrase: "effect of insulin treatment plus comparison of streptozotocin"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   767   C1518681:Treatment Effect [Finding]
   744   C1280500:Effect [Qualitative Concept]
   744   C2348382:Effect [Qualitative Concept]

Phrase: "and"

Phrase: "BB models."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3161035:Models [Intellectual Product]
Processing 00000000.tx.199: Diabetologia37 :43 48,1994[Medline] Patel J, Tomlinson DR: Nerve conduction impairment in experimental diabetes: proximodistal gradient of severity. 

Phrase: "Diabetologia37"

Phrase: ":"

Phrase: "43 48,"

Phrase: "1994"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Patel J,"

Phrase: "Tomlinson DR"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0031831:DR [Professional or Occupational Group]
   861   C1707664:DR [Biomedical or Dental Material]
   861   C2348314:Dr. [Conceptual Entity]
   861   C3540849:DR [Idea or Concept]

Phrase: ":"

Phrase: "Nerve conduction impairment in experimental diabetes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0684336:Impairment [Pathologic Function]

Phrase: ":"

Phrase: "proximodistal gradient of severity."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0439182:% gradient [Quantitative Concept]
   770   C0812409:Gradient [Quantitative Concept]
Processing 00000000.tx.200: Muscle Nerve22 :1403 1411,1999[Medline] Lambourne JE, Brown AM, Calcutt NA, Tomlinson DR, Willars GB: Adenosine triphosphatase in nerves and ganglia of rats with streptozotocin-induced diabetes or galactosaemia: effects of aldose reductase inhibition. 

Phrase: "Muscle Nerve22"

Phrase: ":"

Phrase: "1403 1411,"

Phrase: "1999"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Lambourne JE,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0454673:JE [Geographic Area]
   861   C1550752:JE [Temporal Concept]

Phrase: "Brown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0678579:Brown [Natural Phenomenon or Process]

Phrase: "AM"

Phrase: ","

Phrase: "Calcutt NA,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597484:Na+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1272460:{NA} [Qualitative Concept]

Phrase: "Tomlinson DR,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0031831:DR [Professional or Occupational Group]
   861   C1707664:DR [Biomedical or Dental Material]
   861   C2348314:Dr. [Conceptual Entity]
   861   C3540849:DR [Idea or Concept]

Phrase: "Willars GB"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0041700:GB [Geographic Area]
   861   C1551090:Gb [Quantitative Concept]

Phrase: ":"

Phrase: "Adenosine triphosphatase in nerves"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C0001473:Adenosine Triphosphatase [Amino Acid, Peptide, or Protein,Enzyme]
   833   C1706373:Adenosine Triphosphatase [Amino Acid, Peptide, or Protein,Enzyme]
   770   C0001443:Adenosine [Nucleic Acid, Nucleoside, or Nucleotide,Neuroreactive Substance or Biogenic Amine,Pharmacologic Substance]
   770   C0312235:Triphosphatase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "and"

Phrase: "ganglia of rats"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C0017067:Ganglia [Body Part, Organ, or Organ Component]
   756 E C1258666:Ganglion, NOS [Acquired Abnormality,Disease or Syndrome]

Phrase: "with streptozotocin-induced diabetes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   913   C0038433:Streptozotocin Diabetes [Experimental Model of Disease]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]

Phrase: "or"

Phrase: "galactosaemia"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0016952:Galactosaemia [Disease or Syndrome]
  1000   C0268151:GALACTOSEMIA [Disease or Syndrome]

Phrase: ":"

Phrase: "effects of aldose reductase inhibition."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C1280500:effects [Qualitative Concept]
   726 E C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.201: Diabetologia31 :379 384,1988[Medline] Fernyhough P, Gallagher A, Averill SA, Priestley JV, Hounsom L, Patel J, Tomlinson DR: Aberrant neurofilament phosphorylation in sensory neurons of rats with diabetic neuropathy. 

Phrase: "Diabetologia31"

Phrase: ":"

Phrase: "379 384,"

Phrase: "1988"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Fernyhough P,"

Phrase: "Gallagher A,"

Phrase: "Averill SA,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0036243:SA [Geographic Area]
   861   C1539696:SA [Gene or Genome]
   861   C1825840:SA [Gene or Genome]
   861   C3539736:Sa [Spatial Concept]

Phrase: "Priestley JV,"

Phrase: "Hounsom L,"

Phrase: "Patel J,"

Phrase: "Tomlinson DR"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0031831:DR [Professional or Occupational Group]
   861   C1707664:DR [Biomedical or Dental Material]
   861   C2348314:Dr. [Conceptual Entity]
   861   C3540849:DR [Idea or Concept]

Phrase: ":"

Phrase: "Aberrant neurofilament phosphorylation in sensory neurons of rats"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0031715:Phosphorylation [Molecular Function]
   744   C1158886:Phosphorylation [Molecular Function]

Phrase: "with diabetic neuropathy."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0011882:Diabetic neuropathy [Disease or Syndrome]
   861   C0241863:DIABETIC [Finding]
   861   C0442874:Neuropathy [Disease or Syndrome]
Processing 00000000.tx.202: Diabetes48 :881 889,1999[Abstract] Barone FC, Irving EA, May AM, Lee JC, Kassis S, Kumar S, Badger AM, White RF, McVey MJ, Legos JJ, Erhardt JA, Nelson AH, Ohlstein EH, Hunter AJ, Ward K, Smith BR, Adams JL, Parsons AA: SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. 

Phrase: "Diabetes48"

Phrase: ":"

Phrase: "881 889,"

Phrase: "1999"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Barone FC,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2983605:FC [Activity]

Phrase: "Irving EA,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0014963:EA [Organic Chemical,Pharmacologic Substance]
   861   C1457900:EA [Quantitative Concept]

Phrase: "May"

Phrase: "AM"

Phrase: ","

Phrase: "Lee JC,"

Phrase: "Kassis S,"

Phrase: "Kumar S,"

Phrase: "Badger"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0325051:Badger [Mammal]

Phrase: "AM"

Phrase: ","

Phrase: "White RF,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0035448:RF [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0201660:RF [Laboratory Procedure]
   861   C0748398:RF [Finding]

Phrase: "McVey MJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439254:MJ [Medical Device]

Phrase: "Legos JJ,"

Phrase: "Erhardt JA,"

Phrase: "Nelson AH,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1836672:AH [Disease or Syndrome]

Phrase: "Ohlstein EH,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1520135:EH [Geographic Area]

Phrase: "Hunter AJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0230613:AJ [Cell Component]

Phrase: "Ward K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Smith BR,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1704648:Br. [Conceptual Entity]

Phrase: "Adams JL,"

Phrase: "Parsons AA"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1235746:Aa [Plant]
   861   C1882141:aa [Qualitative Concept]

Phrase: ":"

Phrase: "SB 239063,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0913456:SB 239063 [Organic Chemical]

Phrase: "a second-generation p38 mitogen-activated protein kinase inhibitor,"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   890   C1513344:Mitogen-Activated Protein Kinase Inhibitor [Pharmacologic Substance]
   835   C1449702:Protein kinase inhibitor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   812   C1171350:Kinase Inhibitor [Pharmacologic Substance]
   812   C3537023:kinase inhibitor [Molecular Function]
   812   C3537035:kinase inhibitor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   793   C1999216:Inhibitor [Qualitative Concept]
   723   C1456380:p38 Mitogen Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   703 E C1120843:p38 Mitogen-Activated Protein Kinases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "reduces"

Phrase: "brain injury"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0270611:Brain Injury [Injury or Poisoning]
   861   C3263722:Injury [Injury or Poisoning]
   861   C3263723:Injury [Injury or Poisoning]

Phrase: "and"

Phrase: "neurological deficits in cerebral focal ischemia."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   773   C0521654:Neurological deficit [Finding]
   753   C2987487:deficits [Qualitative Concept]
   719 E C0162429:Deficit, NOS [Disease or Syndrome]
Processing 00000000.tx.203: J Pharmacol Exp Ther296 :312 321,2001[Abstract/Free FullText] Frantz B, Klatt T, Pang M, Parsons J, Rolando A, Williams H, Tocci MJ, OKeefe SJ, ONeill EA: The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. 

Phrase: "J Pharmacol Exp Ther296"

Phrase: ":"

Phrase: "312 321,"

Phrase: "2001"

Phrase: "[Abstract/Free FullText"

Phrase: "] Frantz B,"

Phrase: "Klatt T,"

Phrase: "Pang"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1413561:PANG [Gene or Genome]

Phrase: "M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]

Phrase: "Parsons J,"

Phrase: "Rolando A,"

Phrase: "Williams H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Tocci MJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439254:MJ [Medical Device]

Phrase: "OKeefe SJ,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1515101:SJ [Geographic Area]
   861   C2986905:SJ [Idea or Concept]

Phrase: "ONeill EA"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0014963:EA [Organic Chemical,Pharmacologic Substance]
   861   C1457900:EA [Quantitative Concept]

Phrase: ":"

Phrase: "The activation state of p38 mitogen-activated protein kinase"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   784   C1819041:protein kinase activation [Cell Function]
   762   C0599177:protein activation [Genetic Function]
   742   C1301808:State [Geographic Area]
   742   C1442792:State [Functional Concept]
   742   C1879547:Activation [Activity]
   742   C3148680:State [Geographic Area]

Phrase: "determines"

Phrase: "the efficiency of ATP competition"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0013682:Efficiency [Quantitative Concept]

Phrase: "for pyridinylimidazole inhibitor binding."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0243122:binding [Functional Concept]
   827   C1145667:Binding [Activity]
   827   C1167622:Binding [Molecular Function]
Processing 00000000.tx.204: Biochemistry37 :13846 13853,1998[Medline] Schmidt RE, Matschinsky FM, Godfrey DA, Williams AD, McDougal DB Jr: Fast and slow axoplasmic flow in sciatic nerve of diabetic rats. 

Phrase: "Biochemistry37"

Phrase: ":"

Phrase: "13846 13853,"

Phrase: "1998"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Schmidt RE,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2986904:RE [Idea or Concept]

Phrase: "Matschinsky FM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540627:FM [Gene or Genome]

Phrase: "Godfrey DA,"

Phrase: "Williams AD,"

Phrase: "McDougal DB Jr"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1708595:Jr [Idea or Concept]
   827   C3280986:JR [Disease or Syndrome]

Phrase: ":"

Phrase: "Fast"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0015663:Fast [Finding]
  1000   C0456962:Fast [Qualitative Concept]

Phrase: "and"

Phrase: "slow axoplasmic flow in sciatic nerve of diabetic rats."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   764   C0282067:Axoplasmic Flow [Cell Function]
   742   C0806140:Flow [Natural Phenomenon or Process]
Processing 00000000.tx.205: Diabetes24 :1081 1085,1975[Abstract] Mayer JH, Tomlinson DR: Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats. 

Phrase: "Diabetes24"

Phrase: ":"

Phrase: "1081 1085,"

Phrase: "1975"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Mayer JH,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0268060:JH [Disease or Syndrome]
   861   C1415529:JH [Gene or Genome]

Phrase: "Tomlinson DR"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0031831:DR [Professional or Occupational Group]
   861   C1707664:DR [Biomedical or Dental Material]
   861   C2348314:Dr. [Conceptual Entity]
   861   C3540849:DR [Idea or Concept]

Phrase: ":"

Phrase: "Prevention of defects of axonal transport"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0199176:Prevention [Therapeutic or Preventive Procedure]
   753   C1706420:PREVENTION [Research Activity]
   753   C2700409:prevention [Qualitative Concept]

Phrase: "and"

Phrase: "nerve conduction velocity by oral administration of myo-inositol"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   790   C0429381:Nerve conduction velocity [Finding]
   790   C2982003:Nerve Conduction Velocity [Diagnostic Procedure]
   764   C0027788:Nerve Conduction [Organ or Tissue Function]
   764   C0234084:Conduction velocity [Organ or Tissue Function]
   742   C0027740:Nerve [Tissue]
   742   C0027757:NERVE [Tissue]
   742   C0232217:Conduction [Organ or Tissue Function]
   742   C0439830:Velocity [Quantitative Concept]
   742   C0457405:Conduction [Natural Phenomenon or Process]
   742   C1280541:Nerve [Body Part, Organ, or Organ Component]
   742   C1547053:*Velocity [Quantitative Concept]

Phrase: "or"

Phrase: "an aldose reductase inhibitor in streptozotocin-diabetic rats."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   800   C2348243:Aldose Reductase Inhibitor [Pharmacologic Substance]
   770   C0002003:Aldose Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   770   C1412322:ALDOSE REDUCTASE [Gene or Genome]
   744   C0030016:Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   744   C0682934:Aldose [Carbohydrate]
   744   C1999216:Inhibitor [Qualitative Concept]
Processing 00000000.tx.206: Diabetologia25 :433 438,1983[Medline] Han J, Lee JD, Bibbs L, Ulevitch RJ: A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. 

Phrase: "Diabetologia25"

Phrase: ":"

Phrase: "433 438,"

Phrase: "1983"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Han J,"

Phrase: "Lee JD,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1549972:JD [Intellectual Product]

Phrase: "Bibbs L,"

Phrase: "Ulevitch RJ"

Phrase: ":"

Phrase: "A MAP kinase"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
  1000   C0752312:Mitogen-Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   923   C1979930:Mitogen-activated protein [Amino Acid, Peptide, or Protein]
   861   C0033640:PROTEIN KINASE [Amino Acid, Peptide, or Protein,Enzyme]
   812   C0018284:Mitogen [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   812   C0026249:Mitogen [Pharmacologic Substance]
   812   C0031727:Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   812   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   812   C1879547:Activated [Activity]
   779 E C1515877:Activate [Functional Concept]

Phrase: "targeted by endotoxin"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0014264:Endotoxin [Carbohydrate,Hazardous or Poisonous Substance,Lipid]
   790   C1521840:Targeted [Functional Concept]
   756 E C2986546:TARGET [Diagnostic Procedure]

Phrase: "and"

Phrase: "hyperosmolarity in mammalian cells."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0259752:Hyperosmolarity [Finding]
Processing 00000000.tx.207: Science265 :808 811,1994[Medline] Berl T, Siriwardana G, Ao L, Butterfield LM, Heasley LE: Multiple mitogen-activated protein kinases are regulated by hyperosmolality in mouse IMCD cells. 

Phrase: "Science265"

Phrase: ":"

Phrase: "808 811,"

Phrase: "1994"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Berl T,"

Phrase: "Siriwardana G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Ao L,"

Phrase: "Butterfield LM,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1261082:LM [Body Part, Organ, or Organ Component]
   861   C1551056:lm [Quantitative Concept]
   861   C2981682:LM [Quantitative Concept]

Phrase: "Heasley LE"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439090:LE [Idea or Concept]
   861   C1423767:LE [Gene or Genome]

Phrase: ":"

Phrase: "Multiple mitogen-activated protein kinases"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   937   C0752312:Mitogen-Activated Protein Kinases [Amino Acid, Peptide, or Protein,Enzyme]
   884   C1979930:Mitogen-activated protein [Amino Acid, Peptide, or Protein]
   840   C0033640:Protein Kinases [Amino Acid, Peptide, or Protein,Enzyme]
   804   C0018284:Mitogen [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0026249:Mitogen [Pharmacologic Substance]
   804   C0031727:Kinases [Amino Acid, Peptide, or Protein,Enzyme]
   804   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C1879547:Activated [Activity]
   771 E C1515877:Activate [Functional Concept]

Phrase: "are"

Phrase: "regulated by hyperosmolality"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0268009:Hyperosmolality [Disease or Syndrome]
   790   C0851285:Regulated [Governmental or Regulatory Activity]

Phrase: "in mouse IMCD cells."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.208: Am J Physiol272 :F305 F311,1997 Obata T, Brown GE, Yaffe MB: MAP kinase pathways activated by stress: the p38 MAPK pathway. 

Phrase: "Am"

Phrase: "J Physiol272"

Phrase: ":"

Phrase: "F305 F311,"

Phrase: "1997 Obata T,"

Phrase: "Brown GE,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3538705:GE [Gene or Genome]

Phrase: "Yaffe MB"

Phrase: ":"

Phrase: "MAP kinase pathways"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C1704259:Pathways [Molecular Function]
   804   C1705987:Pathways [Conceptual Entity]
   771   C0752312:Mitogen-Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   717   C1979930:Mitogen-activated protein [Amino Acid, Peptide, or Protein]

Phrase: "activated by stress"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C0038435:Stress [Finding]
   790   C1879547:Activated [Activity]
   756 E C1515877:Activate [Functional Concept]
   718 E C0231297:Stressful [Functional Concept]

Phrase: ":"

Phrase: "the p38 MAPK pathway."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1704259:Pathway [Molecular Function]
   827   C1705987:Pathway [Conceptual Entity]
   734   C1120843:MAPK, p38 [Amino Acid, Peptide, or Protein,Enzyme]
Processing 00000000.tx.209: Crit Care Med28 :N67 N77,2000[Medline] Kyriakis JM, Avruch J: Protein kinase cascades activated by stress and inflammatory cytokines. 

Phrase: "Crit Care Med28"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1537682:MED28 [Gene or Genome]

Phrase: ":"

Phrase: "N67 N77,"

Phrase: "2000"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Kyriakis JM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022337:JM [Geographic Area]

Phrase: "Avruch J"

Phrase: ":"

Phrase: "Protein kinase cascades"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   983   C1155502:protein kinase cascade [Molecular Function]
   793   C1707310:Cascade [Manufactured Object]
   734   C0033640:PROTEIN KINASE [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "activated by stress"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C0038435:Stress [Finding]
   790   C1879547:Activated [Activity]
   756 E C1515877:Activate [Functional Concept]
   718 E C0231297:Stressful [Functional Concept]

Phrase: "and"

Phrase: "inflammatory cytokines."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0079189:Cytokines [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C1524094:Cytokines [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
Processing 00000000.tx.210: BioEssays18 :567 577,1996[Medline] Zhang L, Jope RS: Oxidative stress differentially modulates phosphorylation of ERK, p38 and CREB induced by NGF or EGF in PC12 cells. 

Phrase: "BioEssays18"

Phrase: ":"

Phrase: "567 577,"

Phrase: "1996"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Zhang L,"

Phrase: "Jope RS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3539879:RS [Idea or Concept]

Phrase: ":"

Phrase: "Oxidative stress differentially"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   901   C0242606:Oxidative Stress [Cell or Molecular Dysfunction]
   827   C0038435:Stress [Finding]
   827   C0311404:Oxidative [Functional Concept]
   755 E C0231297:Stressful [Functional Concept]

Phrase: "modulates"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443264:modulate [Spatial Concept]

Phrase: "phosphorylation of ERK,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0031715:Phosphorylation [Molecular Function]
   790   C1158886:Phosphorylation [Molecular Function]

Phrase: "p38"

Phrase: "and"

Phrase: "CREB"

Phrase: "induced by NGF"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0205263:Induced [Functional Concept]
   790   C1417719:NGF [Gene or Genome]

Phrase: "or"

Phrase: "EGF in PC12 cells."
Processing 00000000.tx.211: Neurobiol Aging20 :271 278,1999[Medline] Kurata S: Selective activation of p38 MAPK cascade and mitotic arrest caused by low level oxidative stress. 

Phrase: "Neurobiol Aging20"

Phrase: ":"

Phrase: "271 278,"

Phrase: "1999"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Kurata S"

Phrase: ":"

Phrase: "Selective activation of p38 MAPK cascade"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   938   C3545718:activation of p38MAPK cascade [Organism Function]
   938   C3547944:activation of p38 MAPK cascade [Organism Function]
           activation of p38 cascade
   858   C3271939:activation of MAPK cascade [Molecular Function]
   783   C1155551:MAPK activation [Molecular Function]
   753   C1879547:Activation [Activity]

Phrase: "and"

Phrase: "mitotic arrest"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0544888:Mitotic arrest [Cell Function]
   861   C0237477:Arrest [Temporal Concept]
   861   C0392351:arrest [Governmental or Regulatory Activity]

Phrase: "caused by low level oxidative stress."
Meta Candidates (Total=13; Excluded=0; Pruned=0; Remaining=13)
   790   C0242606:Oxidative Stress [Cell or Molecular Dysfunction]
   783   C1319127:Stress level [Finding]
   753   C0038435:Stress [Finding]
   753   C0205251:low [Qualitative Concept]
   753   C0311404:Oxidative [Functional Concept]
   753   C0441889:Level [Qualitative Concept]
   753   C0456079:Level [Classification]
   753   C1299352:Low [Qualitative Concept]
   753   C1547707:Level [Geographic Area]
   753   C1550472:low [Idea or Concept]
   753   C2946261:Level [Pharmacologic Substance]
   719   C0015127:cause [Functional Concept]
   719   C1524003:Cause [Conceptual Entity]
Processing 00000000.tx.212: J Biol Chem275 :23413 23416,2000[Abstract/Free FullText] Yeh CH, Sturgis L, Haidacher J, Zhang XN, Sherwood SJ, Bjercke RJ, Juhasz O, Crow MT, Tilton RG, Denner L: Requirement for p38 and p44/;p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-B transcriptional activation and cytokine secretion. 

Phrase: "J Biol Chem275"

Phrase: ":"

Phrase: "23413 23416,"

Phrase: "2000"

Phrase: "[Abstract/Free FullText"

Phrase: "] Yeh CH,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0558269:Ch. [Professional or Occupational Group]
   861   C1552984:[Ch] [Quantitative Concept]

Phrase: "Sturgis L,"

Phrase: "Haidacher J,"

Phrase: "Zhang XN,"

Phrase: "Sherwood SJ,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1515101:SJ [Geographic Area]
   861   C2986905:SJ [Idea or Concept]

Phrase: "Bjercke RJ,"

Phrase: "Juhasz O,"

Phrase: "Crow MT,"

Phrase: "Tilton RG,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1412999:RG [Gene or Genome]

Phrase: "Denner L"

Phrase: ":"

Phrase: "Requirement for p38"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1514873:Requirement [Functional Concept]

Phrase: "and"

Phrase: "p44/"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0082529:p44 [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1415344:p44 [Gene or Genome]
  1000   C1424650:p44 [Gene or Genome]
  1000   C1823841:p44 [Gene or Genome]

Phrase: ";p42 mitogen-activated protein kinases"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   937   C0752312:Mitogen-Activated Protein Kinases [Amino Acid, Peptide, or Protein,Enzyme]
   884   C1979930:Mitogen-activated protein [Amino Acid, Peptide, or Protein]
   840   C0033640:Protein Kinases [Amino Acid, Peptide, or Protein,Enzyme]
   804   C0018284:Mitogen [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0026249:Mitogen [Pharmacologic Substance]
   804   C0031727:Kinases [Amino Acid, Peptide, or Protein,Enzyme]
   804   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C1879547:Activated [Activity]
   771 E C1515877:Activate [Functional Concept]

Phrase: "in RAGE-mediated nuclear factor-B transcriptional activation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   818   C0162493:Transcriptional Activation [Genetic Function]
   795   C1879547:Activation [Activity]

Phrase: "and"

Phrase: "cytokine secretion."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1327414:cytokine secretion [Cell Function]
   861   C0036536:secretion [Biologic Function]
   861   C0036537:Secretion [Body Substance]
Processing 00000000.tx.213: Diabetes50 :1495 1504,2001[Abstract/Free FullText] Zill H, Bek S, Hofmann T, Huber J, Frank O, Lindenmeier M, Weigle B, Erbersdobler HF, Scheidler S, Busch AE, Faist V: RAGE-mediated MAPK activation by food-derived AGE and non-AGE products. 

Phrase: "Diabetes50"

Phrase: ":"

Phrase: "1495 1504,"

Phrase: "2001"

Phrase: "[Abstract/Free FullText"

Phrase: "] Zill H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Bek S,"

Phrase: "Hofmann T,"

Phrase: "Huber J,"

Phrase: "Frank O,"

Phrase: "Lindenmeier M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Weigle B,"

Phrase: "Erbersdobler HF,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0018488:Hf [Element, Ion, or Isotope]
   861   C1538440:HF [Gene or Genome]
   861   C3273279:HF [Gene or Genome]

Phrase: "Scheidler S,"

Phrase: "Busch AE,"

Phrase: "Faist V"

Phrase: ":"

Phrase: "RAGE-mediated MAPK activation by food-derived AGE"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1155551:MAPK activation [Molecular Function]
   744   C1879547:Activation [Activity]

Phrase: "and"

Phrase: "non-AGE products."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C1514468:Products [Entity]
   793 E C1704444:Product [Quantitative Concept]
Processing 00000000.tx.214: Biochem Biophys Res Commun300 :311 315,2003[Medline] Kultz D, Garcia-Perez A, Ferraris JD, Burg MB: Distinct regulation of osmoprotective genes in yeast and mammals: aldose reductase osmotic response element is induced independent of p38 and stress-activated protein kinase/;Jun N-terminal kinase in rabbit kidney cells. 

Phrase: "Biochem Biophys Res Commun300"

Phrase: ":"

Phrase: "311 315,"

Phrase: "2003"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Kultz D,"

Phrase: "Garcia-Perez A,"

Phrase: "Ferraris JD,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1549972:JD [Intellectual Product]

Phrase: "Burg MB"

Phrase: ":"

Phrase: "Distinct regulation of osmoprotective genes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   797   C0017263:genes regulation [Genetic Function]
   760   C0851285:Regulation [Governmental or Regulatory Activity]
   760   C1327622:Regulation [Biologic Function]

Phrase: "in yeast"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0036025:yeast [Fungus]
  1000   C0043392:Yeast [Food]
  1000   C0043393:Yeast [Fungus]
  1000   C0717551:YEAST [Immunologic Factor,Pharmacologic Substance]

Phrase: "and"

Phrase: "mammals"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0024660:Mammals [Mammal]

Phrase: ":"

Phrase: "aldose reductase osmotic response element"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   840   C0600508:Response Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   840   C1510659:osmotic response [Cell Function]
   804   C0013879:Element [Element, Ion, or Isotope]
   804   C0029391:osmotic [Natural Phenomenon or Process]
   804   C0311417:Osmotic [Functional Concept]
   804   C0871261:Response [Organism Attribute]
   804   C1704632:Response [Finding]
   804   C1705248:Element [Conceptual Entity]
   804   C1706817:Response [Intellectual Product]
   804   C2911692:Response [Mental Process]

Phrase: "is"

Phrase: "induced independent of p38"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C0332291:Independent of [Functional Concept]
   770   C0085862:Independent [Idea or Concept]
   770   C0205263:Induced [Functional Concept]
   770   C1299583:Independent [Finding]

Phrase: "and"

Phrase: "stress-activated protein kinase/"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
  1000   C0872280:stress activated protein kinase [Amino Acid, Peptide, or Protein,Enzyme]
   875   C0018850:stress protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0033640:PROTEIN KINASE [Amino Acid, Peptide, or Protein,Enzyme]
   812   C0031727:Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   812   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   812   C0038435:Stress [Finding]
   812   C1879547:Activated [Activity]
   779 E C1515877:Activate [Functional Concept]
   741 E C0231297:Stressful [Functional Concept]

Phrase: ";Jun N-terminal kinase in rabbit kidney cells."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   833   C1367731:JUN N-terminal kinase [Gene or Genome]
   767   C0872053:JUN kinase [Amino Acid, Peptide, or Protein,Enzyme]
   767   C1334482:Jun kinase [Gene or Genome]
   767   C1367019:Jun Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   744   C0031727:Kinase [Amino Acid, Peptide, or Protein,Enzyme]
Processing 00000000.tx.215: J Biol Chem272 :13165 13170,1997[Abstract/Free FullText] Obrosova IG: How does glucose generate oxidative stress in peripheral nerve? 

Phrase: "J Biol Chem272"

Phrase: ":"

Phrase: "13165 13170,"

Phrase: "1997"

Phrase: "[Abstract/Free FullText"

Phrase: "] Obrosova IG"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0021027:Ig [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0305052:IG [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0360506:IG [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C3541296:IG [Idea or Concept]

Phrase: ":"

Phrase: "How"

Phrase: "does"

Phrase: "glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "generate"

Phrase: "oxidative stress in peripheral nerve?"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C0242606:Oxidative Stress [Cell or Molecular Dysfunction]
   760   C0038435:Stress [Finding]
   760   C0311404:Oxidative [Functional Concept]
Processing 00000000.tx.216: Int Rev Neurobiol50 :3 35,2002[Medline] Obrosova IG, Van Huysen C, Fathallah L, Cao XC, Greene DA, Stevens MJ: An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. 

Phrase: "Int Rev Neurobiol50"

Phrase: ":"

Phrase: "3 35,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0439086:<3 [Quantitative Concept]
   861   C2827736:3+ [Quantitative Concept]
   861   C2981702:3+ [Classification]

Phrase: "2002"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Obrosova IG,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0021027:Ig [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0305052:IG [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0360506:IG [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C3541296:IG [Idea or Concept]

Phrase: "Van Huysen C,"

Phrase: "Fathallah L,"

Phrase: "Cao XC,"

Phrase: "Greene DA,"

Phrase: "Stevens MJ"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439254:MJ [Medical Device]

Phrase: ":"

Phrase: "An aldose reductase inhibitor"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C2348243:Aldose Reductase Inhibitor [Pharmacologic Substance]
   901   C0002003:Aldose Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   901   C1412322:ALDOSE REDUCTASE [Gene or Genome]
   827   C0030016:Reductase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0682934:Aldose [Carbohydrate]
   827   C1999216:Inhibitor [Qualitative Concept]

Phrase: "reverses"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1555029:Reverse [Idea or Concept]

Phrase: "early diabetes-induced changes in peripheral nerve function,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   744   C0392747:changes [Functional Concept]
   744   C0443172:changes [Quantitative Concept]
   711 E C1705241:Change [Quantitative Concept]

Phrase: "metabolism,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0025519:Metabolism [Organism Function]
  1000   C0025520:metabolism [Functional Concept]

Phrase: "and"

Phrase: "antioxidative defense."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1880266:Defense [Conceptual Entity]
Processing 00000000.tx.217: FASEB J16 :123 125,2002[Abstract/Free FullText] Agthong S, Tomlinson DR: Inhibition of p38 MAP kinase corrects biochemical and neurological deficits in experimental diabetic neuropathy. 

Phrase: "FASEB J16"

Phrase: ":"

Phrase: "123 125,"

Phrase: "2002"

Phrase: "[Abstract/Free FullText"

Phrase: "] Agthong S,"

Phrase: "Tomlinson DR"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0031831:DR [Professional or Occupational Group]
   861   C1707664:DR [Biomedical or Dental Material]
   861   C2348314:Dr. [Conceptual Entity]
   861   C3540849:DR [Idea or Concept]

Phrase: ":"

Phrase: "Inhibition of p38 MAP kinase"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   748   C0021467:Inhibition [Mental Process]
   748   C0021469:Inhibition [Molecular Function]
   748   C1628982:% inhibition [Quantitative Concept]
   748   C3463820:Inhibition [Activity]
   731   C1456380:p38 Mitogen Activated Protein Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   713 E C1120843:mitogen-activated protein kinase p38 [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "corrects"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2349182:Correct [Qualitative Concept]

Phrase: "biochemical"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205474:Biochemical [Functional Concept]

Phrase: "and"

Phrase: "neurological deficits in experimental diabetic neuropathy."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   773   C0521654:Neurological deficit [Finding]
   753   C2987487:deficits [Qualitative Concept]
   719 E C0162429:Deficit, NOS [Disease or Syndrome]
Processing 00000000.tx.218: Ann N Y Acad Sci973 :359 362,2002[Abstract/Free FullText] Harper SJ, LoGrasso P: Signalling for survival and death in neurones: the role of stress-activated kinases, JNK and p38. 

Phrase: "Ann N Y Acad Sci973"

Phrase: ":"

Phrase: "359 362,"

Phrase: "2002"

Phrase: "[Abstract/Free FullText"

Phrase: "] Harper SJ,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1515101:SJ [Geographic Area]
   861   C2986905:SJ [Idea or Concept]

Phrase: "LoGrasso P"

Phrase: ":"

Phrase: "Signalling for survival"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0038952:Survival [Activity]
   790   C0220921:survival [Functional Concept]
   790   C3537152:signalling [Biologic Function]
   756 E C1710082:Signal [Phenomenon or Process]

Phrase: "and"

Phrase: "death in neurones"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0011065:Death [Organism Function]
   790   C1306577:Death, NOS [Finding]

Phrase: ":"

Phrase: "the role of stress-activated kinases,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0035820:Role [Social Behavior]
   753   C1705810:Role [Conceptual Entity]

Phrase: "JNK"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1150587:JNK [Molecular Function]
  1000   C1367731:JNK [Gene or Genome]
  1000   C1705632:JNK [Gene or Genome]

Phrase: "and"

Phrase: "p38."
Processing 00000000.tx.219: Cell Signal13 :299 310,2001[Medline] Mielke K, Herdegen T: JNK and p38 stresskinases: degenerative effectors of signal-transduction-cascades in the nervous system. 

Phrase: "Cell Signal13"

Phrase: ":"

Phrase: "299 310,"

Phrase: "2001"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Mielke K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Herdegen T"

Phrase: ":"

Phrase: "JNK"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1150587:JNK [Molecular Function]
  1000   C1367731:JNK [Gene or Genome]
  1000   C1705632:JNK [Gene or Genome]

Phrase: "and"

Phrase: "p38 stresskinases"

Phrase: ":"

Phrase: "degenerative effectors of signal-transduction-cascades"

Phrase: "in the nervous system."
Meta Candidates (Total=15; Excluded=7; Pruned=0; Remaining=8)
  1000   C0027763:Nervous System [Body System]
  1000   C0422837:NERVOUS SYSTEM [Finding]
  1000   C1269560:Nervous system [Body System]
   944 E C0205494:Neurologic [Qualitative Concept]
   907 E C0027855:Neurology [Biomedical Occupation or Discipline]
   888 E C2707261:Neurological [Clinical Attribute]
   861   C0027769:Nervous [Sign or Symptom]
   861   C0449913:System [Functional Concept]
   861   C0599851:Nervous [Functional Concept]
   861   C1553451:System [Manufactured Object]
   861   C1704459:System [Medical Device]
   789 E C0205373:Systemic [Functional Concept]
   745 E C0027740:Nerve [Tissue]
   745 E C0027757:NERVE [Tissue]
   745 E C1280541:Nerve [Body Part, Organ, or Organ Component]
Processing 00000000.tx.220: Prog Neurobiol61 :45 60,2000[Medline] Ono K, Han JH: The p38 signal transduction pathway: activation and function. 

Phrase: "Prog Neurobiol61"

Phrase: ":"

Phrase: "45 60,"

Phrase: "2000"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Ono K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Han JH"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0268060:JH [Disease or Syndrome]
   861   C1415529:JH [Gene or Genome]

Phrase: ":"

Phrase: "The p38 signal transduction pathway"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   923   C0086982:Signal Transduction Pathway [Molecular Function]
   875   C0037080:Signal Pathway [Molecular Function]
   861   C0037083:Signal Transduction [Cell Function]
   812   C1160185:transduction [Organism Function]
   812   C1704259:Pathway [Molecular Function]
   812   C1705987:Pathway [Conceptual Entity]
   812   C1710082:Signal [Phenomenon or Process]

Phrase: ":"

Phrase: "activation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1879547:Activation [Activity]

Phrase: "and"

Phrase: "function."
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
  1000   C0031843:function [Physiologic Function]
  1000   C0542341:Function [Functional Concept]
  1000   C0700205:FUNCTION [Classification]
  1000   C1705273:Function [Intellectual Product]
   928 E C0205245:Functional [Functional Concept]
   928 E C2700217:Functional [Conceptual Entity]
Processing 00000000.tx.221: Cell Signal12 :1 13,2000[Medline] Zhu T, Lobie PE: Janus kinase 2-dependent activation of p38 mitogen-activated protein kinase by growth hormone: resultant transcriptional, activation of ATF-2 and chop, cytoskeletal re-organization and mitogenesis. 

Phrase: "Cell Signal12"

Phrase: ":"

Phrase: "1 13,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C2827734:1+ [Quantitative Concept]
   861   C2981698:1+ [Classification]

Phrase: "2000"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Zhu T,"

Phrase: "Lobie PE"

Phrase: ":"

Phrase: "Janus kinase 2-dependent activation of p38 mitogen-activated protein kinase"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   772   C1819041:protein kinase activation [Cell Function]
   754   C0599177:protein activation [Genetic Function]
   738   C1879547:Activation [Activity]

Phrase: "by growth hormone"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
  1000   C0037663:Growth Hormone [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C0169964:Growth hormone [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0018270:'growth' NOS [Organism Function]
   861   C0019932:Hormone [Hormone]
   861   C0220844:growth [Physiologic Function]
   861   C1621966:Growth [Organ or Tissue Function]
   861   C2911660:Growth [Activity]
   789 E C0458083:Hormonal [Qualitative Concept]

Phrase: ":"

Phrase: "resultant transcriptional, activation of ATF-2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0162493:Transcriptional Activation [Genetic Function]
   753   C1879547:Activation [Activity]

Phrase: "and"

Phrase: "chop,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2945739:chop [Activity]

Phrase: "cytoskeletal re-organization"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   913   C1511632:Cytoskeletal Organization [Cell Function]
   827   C0029237:Organisation [Physiologic Function]
   827   C0029246:Organization [Organization]
   827   C0220885:organization [Qualitative Concept]
   827   C1300196:Organization [Functional Concept]
   827   C1522486:Organization [Professional or Occupational Group]
   827   C2986904:RE [Idea or Concept]

Phrase: "and"

Phrase: "mitogenesis."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1156237:Mitogenesis [Cell Function]
Processing 00000000.tx.222: J Biol Chem275 :2103 2114,2000[Abstract/Free FullText]

Phrase: "J Biol Chem275"

Phrase: ":"

Phrase: "2103 2114,"

Phrase: "2000"

Phrase: "[Abstract/Free FullText"

Phrase: "]"

